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INTRODUCTION
Urinary tract infections are a common cause of morbidity in 
the community. They are a frequent source of symptoms leading to 
consultations with general practitioners and may often result in 
hospitalisation of the individual concerned. They may occur in 
all age groups and are particularly prevalent in the young adult 
female.
The renewed interest in urinary tract infections observed in the 
last decade has been due in part to the development of quantitative 
bacteriological techniques for examining urine specimens (Kass 1956) 
and in part to the development of regular dialysis therapy and renal 
transplantation.
With this increased interest has come the realisation that the 
relationship between symptomatic urinary tract infection on the one 
hand and chronic pyelonephritis on the other is considerably more 
complicated than was originally thought. In particular the studies 
of Kimmelstiel et al (1961) and of Angell et al (1968) indicate that 
a history of recurrent symptomatic urinary tract infection is relatively 
uncommon in patients with non-obstructive chronic pyelonephritis. More­
over, Leonard and his colleagues (1969) showed that bacteriuria was a 
common accompaniment of renal disorders irrespective of the aetiology. 
Thus the interrelationships between clinically apparent urinary tract 
Infection, bacteriuria and impaired renal function are far from clear- 
cut and are currently receiving considerable attention.
2Although patients with symptomatic urinary tract infections may 
rarely go on to develop frank renal failure, once renal failure from 
any cause has occurred, urinary tract infections are common 
(Montgomerie et al 1968). Thus to treat adequately all patients with 
urinary tract infection, requires an extensive knowledge both of the 
effects of antimicrobial agents on the kidney and of the effects of 
renal impairment on the body handling of these drugs.
Recently it has been suggested that there is a relationship between 
long-term analgesic use and the development of renal impairment (for 
extensive reviews of this topic see Shelley 1967; Abel 1971). The 
nature of this relationship is currently under investigation; however, 
it is possible either that analgesics are taken to relieve symptoms of 
an underlying chronic pyelonephritis or that these drugs may predispose 
each individual consuming them to chronic renal failure as a result of 
a direct nephrotoxic action or finally that there is a group of indi­
viduals with an enhanced susceptibility to renal damage caused by 
analgesic preparations.
Thus the management of patients with urinary tract infection can 
be considered under various headings :
(a) Prevention if possible, particularly in a selected population 
(e.g., pregnant patients).
(b) Management of the acute symptomatic episode when this 
occurs.
3(c) Management of recurrent attacks in patients who have 
previously responded to therapy.
(d) Management of patients with moderate or severe renal 
failure complicated by, or associated with, urinary 
tract infection.
(e) Assessment of the general and nephrotoxic adverse effects 
of antibiotic therapy required by these patients.
(f) The investigation of possible complicating factors in 
relation to the episode of urinary tract infection.
The purpose of this thesis is to investigate certain aspects of the 
management of patients with urinary tract infections. The investigations 
undertaken were:
1. An epidemiologic survey of the benefits of routinely screening all 
pregnant patients for the presence of asymptomatic bacteriuria in 
the first trimester of pregnancy (Chapters 1 and 2).
2. A series of investigations into the efficacy of antibacterial therapy 
in the treatment of ambulatory patients with urinary tract infection 
(Chapters 3 and 4).
3. A search for possible relationships between recurrent urinary tract 
infection and latent diabetes mellitus (Chapter 5) and between 
prolonged analgesic consumption and impaired renal function (Chapter 6)
44. An assessment of the frequency of adverse reactions attributed by 
physicians to twenty commonly prescribed antibacterial agents 
(Chapter 7).
5. A study of the frequency with which tetracycline is associated 
with clinically significant rises in blood urea nitrogen levels 
(Chapter 8).
6. A series of investigations into the nephrotoxicity of a number of 
antibiotics in animals (Chapters 9 and 10).
7. A study of the pharmacokinetics of several antibiotics in patients
with impaired renal function, together with a review of the current 
bibliography concerning antibacterial therapy in patients with
impaired renal function (Chapters 11 and 12).
The major part of the work for this thesis was performed in Glasgow. 
However, the data discussed in Chapters 6, 7 and 8, were obtained and 
analysed during a visit to the Boston Collaborative Drug Surveillance 
Program of the Department of Medicine, Boston University, Massachusetts, 
U.S.A. In order to simplify the description of the methods used in 
these chapters, a detailed review of the aims, methods and techniques of 
this program follows.
5BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM
The Boston Collaborative Drug Surveillance Program (B.C.D.S.P.) is 
the largest drug monitoring scheme in operation. Since 1966, it has 
monitored over 10,000 patients admitted to the medical wards of nine 
hospitals in three countries. A detailed description of the aims and 
methods of the program has been given by Jick et al (1970) and will 
be only briefly mentioned here.
The main aims of this program are:
1. To quantitate clinical drug usage.
2. Evaluate known or suspected drug effects.
3. Detect unsuspected drug effects,
4. Characterise groups of patients at particular risk 
of developing adverse drug reactions.
In order to fulfil these aims, nurse monitors are employed and, 
after training, are assigned to medical wards where they record data on 
consecutive admissions. The data recorded include routine demographic 
information, e.g., age, sex, race, height, weight, parity, marital 
status, etc., together with the results of certain laboratory tests, 
e.g., blood urea nitrogen (BUN) level on admission, serum protein, 
haptoglobin titre, and a detailed genetic grouping.
All drug starting and stopping dates are recorded on special forms 
by the monitor who also obtains, by interview with the attending physician.
6the reasons for starting and stopping the drugs. At this time, the 
physician is also asked whether any adverse drug effects developed 
during therapy. Finally, his opinion on the efficacy of the drug 
is solicited. If an adverse event is reported, a more detailed review 
of the circumstances is undertaken and a judgment is made concerning 
the existence of a connection between the drug and the adverse reaction 
(—  in terms of "definite," "probable," "doubtful" or "don’t know").
At the time of discharge, the physician is again interviewed to obtain 
information on the o-currence of certain adverse events, irrespective 
of whether or not they have been attributed to a specific drug. The 
data are then reviewed for accuracy and entered onto computer files.
At regular intervals these are brought up to date and subjected to a 
variety of routine analyses. Detailed analyses can be undertaken 
depending on the nature of the problem under study.
For. a more detailed reivew of the nature of the program and the 
type of information which can be obtained, see Jick et al (1970) and 
Lawson et al (1972),
While such a system can be readily used to quantify both clinical 
drug usage and known or suspected adverse reactions to drugs, the 
detection of previously unsuspected "reactions" or "events" presents 
considerable problems. Undoubtedly the most satisfactory method for 
accomplishing the latter aim would be to adopt the approach advocated 
by Finney (1965). In essence, this consists of collecting information 
on all "events" occurring in an individual patient during his stay in
7hospital, together with data on diagnosis, drug exposure, routine 
demographic data and so on. Finally when the time comes to analyse 
the results, it is likely that a large number of "events" will be found 
to be related temporally with drug exposure and hence to be possibly 
"drug-related." However, this type of system, while admirable in 
theory, would be likely to produce "significant" results only after 
an enormous amount of data had been collected. In addition, the 
handling of such data would be difficult and extremely costly. As 
yet, no one has embarked on such a project in large scale, although 
the program organised by the Kaiser-Permanente Foundation in California 
has in part adhered to this scheme (Friedman et al 1971).
While this method is likely to be more conclusive and to receive 
more widespread acceptance in the medical community, its costs are 
likely to be prohibitively greater than the alternative approach adopted 
by the Boston Collaborative Drug Surveillance Program. Furthermore, the 
latter program has been in progress for six years and has already 
accumulated vast quantities of data. For these reasons the approach of 
this group to the detection of unsuspected events is of interest.
Detection of Unsuspected Adverse Effects of a Drug, In the data collected 
by the B.C.D.S.P., only events deemed to be drug-related are recorded.
Thus if a patient develops an arrhythmia following a myocardial infarction, 
that event "arrhythmia" will only be recorded within the data if the 
attending physician felt that it was drug-related, as would happen, for 
example, if the arrhythmia was thought to be the result of digitalisation.
8To look for unsuspected events then one has to look within 
that set of events deemed to be drug-attributed. For example, if 
drug X was recently released on to the market and if, unknown to 
manufacturers or to physicians, this drug was a potent cause of 
arrhythmias, this would be detected in the data by looking at the 
frequency of exposure to drug X in patients who developed digoxin- 
attributed arrhythmias and comparing this to the frequency of exposure 
to drug X in patients who did not develop drug-attributed arrhythmias.
If a significantly greater proportion of patients in the digoxin- 
attributed arrhythmia group had received drug X as compared to those 
who did not have digoxin-attributed arrhythmia, then it could be 
concluded that either drug X alone or drug X in combination with 
digoxin may be the cause of the arrhythmias.
An example of the type of unsuspected drug reaction uncovered by 
this technique is the relation between ethacrynic acid given intra­
venously and the development of clinically significant gastro-intestinal 
bleeding (Slone et al 1969). Thus with economy of effort and minimised 
cost, unsuspected events may be detected by using a monitoring scheme 
based primarily on recording suspected events. This technique, however, 
has drawbacks, firstly due to the considerable difficulties involved in 
interpretation of the data, and secondly, due to the imprecise nature of 
the conclusions, that is, the difficulty of separating a primary unsus­
pected effect from that of an unsuspected interaction. It is likely 
that this distinction will not be made successfully with any regularity
9by the B.C.D.S.P., but rather the initial results will require to be 
further rested in prospective trials.
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CHAPTER 1
Screening for Bacteriuria in Pregnancy:
A Pilot Study
12
Asymptomatic bacteriuria in pregnancy has been widely studied 
since the observation by Kass (1959) that a large proportion of 
patients with bacteriuria in early pregnancy develop symptoms of 
acute urinary tract infection (U.T.I.) later in the pregnancy. In 
subsequent publications, he recorded a high prevalence of prematurity 
and foetal loss in bacteriuric patients and suggested that these 
complications could be reduced by treating the, bacteriuria early in 
pregnancy (Kass, 1960, 1962; Norden and Kass 1968),
Little (1965) supported Kass in regarding urinary tract infection 
in pregnancy as a preventible disease indicating that detection and 
treatment of asymptomatic bacteriuria in early pregnancy leads to a 
drastic reduction in the subsequent incidence of this complication.
Kincaid-Sraith and Bullen (1965) reported an increased frequency 
of acute pyelonephritis, prematurity, pre-eclampsia and perinatal loss 
in a series of 240 bacteriuric patients. Successful treatment of a group 
of these bacteriuric individuals reduced the incidence of acute urinary 
tract infection but not of the other complications of pregnancy. However, 
even urinary tract infection in pregnancy was not eradicated by treatment. 
These workers indicated that underlying renal disease was the cause both 
of the bacteriuria and of the increased incidence of prematurity, foetal 
loss and pre-eclampsia. As evidence for this they recorded a prevalence 
of radiological abnormalities of 51.4% in 148 bacteriuric patients, the 
majority of the radiographs being taken within six weeks of the end of 
pregnancy.
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Other workers have remained unconvinced of the magnitude of the 
link between asymptomatic bacteriuria in early pregnancy and the 
subsequent appearance of these complications (Pinkerton et al 1965;
Dixon and Brant 1967). In particular, Dixon and Brant noted that, in 
their series of 1309 patients, only 31,8% of those developing an acute 
urinary tract infection had bacteriuria on first screening.
In a recent extensive review of the topic, Whalley (1967) tabulated 
the results available to that date. The frequency of urinary tract infection 
in bacteriuric individuals varied from 4*5% to 63% and similarly the fre­
quency in non-bacteriurics varied from 0 to 14%. Of particular interest 
was the wide variation in the frequency of this complication in non- 
bacteriuric individuals —  due, no doubt, at least in part to differences 
in the criteria: used to assign an individual to such a group.
Kass (1962) considered significant bacteriuria to be present when 
over 10^ organisms per ml of urine were present in at least two consecutive 
clean-catch mid-stream specimens of urine, and indicated that the reliability 
of the test increased with increasing numbers of samples taken. Unfortunately, 
the collection of so many specimens at a busy ante-natal clinic and the 
subsequent bacterial counting impose considerable burdens on both clinical 
and laboratory staff. For this reason, it was decided to carry out a 
preliminary survey of possible benefits to be obtained by routinely 
screening all pregnant patients appearing at the ante-natal clinics of the 
Queen Mother's Hospital in Glasgow. This survey was commenced in 1967.
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PATIENTS AND METHODS
Patients admitted to the survey were all attending hospital for
their first visit to the ante-natal clinic in that pregnancy. All were
questioned regarding their age,parity, previous medical history including
/
hypertensive episodes during pregnancy and any incident of urethral 
catheterisation. All were examined for pre-existing disease such as 
diabetes and, in addition, a record was made of their blood pressure. 
Patients with blood pressures exceeding 140/80 mm. of mercury after five 
minutes' rest were said to be hypertensive.
Following the history, a sample of urine was obtained by a standard 
technique. The vulva was cleaned with sterile water and a clean-catch 
mid-stream specimen was collected in a sterile honey-pot. This sample 
was divided into two and the aliquot to be cultured was stored at 4°C 
until plating, which took place within three hours of collection. A 
modified Addis count (McGeachie and Kennedy 1963) was performed on the 
other sample of urine. The collection of all specimens was under the 
direct supervision of one nurse throughout the study.
A standard loop of urine was spread on nutrient agar and on MacConkey's 
agar and incubated overnight at 37°C. Specimens containing more than 10^ 
organisms per ml were regarded as positive and colony counts were performed 
on specimens containing organisms in concentrations less than 10^ per ml of 
urine. The antibiotic sensitivity of the organisms was determined using 
Oxoid Multodiscs.
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The patients were divided into three groups on the basis of the 
findings on urine culture:
Group A - "Bacteriurics" - patients whose urine culture yielded
bacteria in concentrations exceeding 10^ organisms per ml.
Group B - "Doubtfuls" - patients whose urine culture yielded
bacteria- in concentrations between 10^ and 10^ organisms 
per ml.
Group C - "Non-bacteriurics" - patients whose urine culture yielded 
bacteria in concentrations of less than 10^ organisms 
per ml.
All patients were followed in a routine manner, being treated by the 
obstetricians who were unaware of the results of the patients’ urine 
culture. Patients were instructed where possible to return to the clinic 
should symptoms referable to the urinary tract develop.
After parturition, all patients were seen and all their records 
examined by Dr. A.W.F. Miller. A detailed history was taken of all 
complications arising during pregnancy, of the presence of symptoms of 
urinary tract infection (frequency, nocturia, pyrexia and loin pain) and of 
any foetal abnormalities which occurred. The resulting data was then 
transferred to punch-cards and detailed analyses carried out.
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RESULTS
A total of 1160 patients were studied. Of these 54 (4.6%) had 
asymptomatic bacteriuria on screening and a further 89 (7.7%) had 
bacterial counts in the doubtful range. The remaining 1017 patients 
were non-bacteriuric.
Urinary tract infection (U»T,I,). The frequency of U.T.I. in the 
comparison groups is shovm in Table 1.1, T'Jhen this complication was 
defined clinically as the occurrence of frequency, dysuria, loin pain 
and pyrexia, 27.7% of Group A, 10.1% of Group B, and 6.9% of Group C 
developed U.T.I. If the definition was further restricted to include 
only those patients with such symptoms who also had bacteriuria detected 
at that time (i.e. over 10^ organisms per ml of urine) there were 47 such 
individuals —  16.6% of Group.A, 6.7% of Group B, and 3.1% of Group C.
The relationship between the initial screening test and the subsequent 
development of urinary tract infection is emphasised in Table 1,2. The 
sensitivity of the screening test in predicting U.T.I. was 15.9% when 
this complication was defined clinically, and 19.1% when it was restricted 
to those cases with clinical and bacteriological evidence of infection.
In addition, under these conditions the specificity of the test was 95.4% 
-and 91.3%, respectively. [The sensitivity of the test was calculated 
as the percentage of patients with U.T.I. who had an initially positive 
screening test and the specificity as the percentage of patients without 
U.T.I. who had an initially negative screening test.]
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Bacterial counts and hypertension. There were no significant 
differences between Groups A, B, and C, with respect to the history 
of previous hypertension or pre-eclampsia (Table 1,3). Elevation 
of blood pressure at the first clinic visit was commoner in Group A 
patients (15 of 54 = 27.8%) than in the other groups (16 of 89 = 18% 
and 162 of 1017 = 15.9%, respectively). However, the results fall 
short of statistical significance (x^ = 3.43, p > 0,05 when comparing 
frequency in Group A with that of Group C). Similarly, hypertensive 
disorders of late pregnancy were commoner in patients in Group A (20.4%) 
than in the other Groups (15.7% and 11.1%, respectively), although again 
the results are not statistically significant.
Addis count and hypertension. Modified Addis counts were available 
for 966 patients (83%). The distribution of patients with recorded counts 
was similar in Groups A, B and C (46 of 54 = 85%; 74 of 89 = 83%; and 
846 of 1017 = 83%, respectively).
Of the 966 patients, 90 (9.3%) had positive Addis counts (as defined 
by McGeachie and Kennedy 1963). The proportion of patients with positive 
counts was greatest in Group A (28 of 46 = 61%) and lower in Group B 
(16 of 74 = 22%) and Group C (46 of 846 = 5.5%).
The frequency of recorded hypertension at the first clinic visit was 
similar in those with a positive Addis count and those without (15.5% and 
16.0%, respectively). However, a past history of hypertensive disorders of 
pregnancy was significantly commoner (y^ = 3.92, p < 0.05) amongst those 
presenting with a positive Addis count (15 of 90 = 16.6%) than amongst 
those with a negative count (87 of 876 = 10%). Similarly, hypertensive
1 8
disorders occurred more frequently during the pregnancy in those with 
initially positive counts (20 of 90 = 22%) than in those with initially
negative counts (119 of 876 = 13.7%) = 4.94, p < 0.05 —  Table 1.4.
Other complications. Premature labour, stillbirth, abortion, foetal 
abnormalities and maternal anaemia were rare in the present series and 
were not related to bacteriuria or to abnormal Addis counts.
Bacteriuria and previous catheterisation. Of the 1160 patients 
studied, 434 (37%) gave a history of urethral catheterisation. Of 
these 305 (70%) had been catheterised once, 81 (19%) twice and 48 (11%) 
more than twice. The distribution of the cases by initial bacterial
counts was similar to control subjects who had not been catheterised
(Table 1.5).
DISCUSSION
The results of the present survey are in substantial agreement with 
many of the previously published series (for review see Whalley 1967).
Using a single specimen of urine for test purposes, the prevalence of 
bacteriuria in the studied population was 4.6%, and some 27.7% of these 
patients went on to develop urinary tract infection during the pregnancy.
One disadvantage of using the single test for screening purposes was that 
the number of patients whose test yielded doubtful results was greater than 
would have been the case had multiple samples of urine been tested. However, 
this disadvantage was outweighed by the convenience and reduction in work 
load involved.
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Nevertheless in one important area the pilot study results 
disagree with many previously published data. The current data show 
that some 3.1% to 6.9% of patieats with initially negative screening 
tests developed urinary tract infection during pregnancy. This figure 
is considerably higher than that reported by Kass (1959), Little (1966), 
and Kincaid-Smith and Bullen (1965). However, the magnitude of this 
proportion is critical when assessing the value of routine screening 
for bacteriuria in the prevention of urinary tract infection in later 
pregnancy. The reasons for this will be explored in greater depth in 
Chapter 2. For the present, it should be emphasised that the discrepancy 
between the results found in the present survey and those of many previous 
workers is not due to the nature of the screening test employed, since 
the relevant patients all had negative screening tests on their first 
visit. The most likely cause for the observed discrepancy is that most 
workers in the field have failed to follow-up alt patients who had an 
initially negative screening test. The commonest study plan has been to 
investigate all patients with proven bacteriuria together with an 
approximately equal number of "controls," (For example see Kincaid-Smith 
and Bullen 1965; McFadyen and Eykyn 1971), This plan is unsatisfactory 
since the proportion of controls expected to develop urinary tract infection 
is so small (0-6%) that with a total control group of 100 to 300 individuals, 
the accuracy of the observed proportion is low. That is, the 95% confidence 
limits around the observed frequency reported by these workers are very 
large. To reduce the size of these confidence limits many more "controls" 
than "cases" are required.
20
One of the critical factors in assessing the value of a screening 
test for bacteriuria of pregnancy is the sensitivity of the test in 
predicting the development of urinary tract infection. The sensitivity 
of the test used in this study was 15.9% to 19.1% depending upon the 
criteria used to define urinary tract infection. Comparable figures 
from some other series are 31.8% (Dixon and Brant 1967) 44% (Pinkerton 
et al 1965), 59% (Kincaid-Smith and Bullen 1965) and 57% (Little 1965).
Thus at first sight there are wide discrepancies in the sensitivity of 
these tests for predicting urinary tract infection. This is partly 
explained by differences in definitions of bacteriuria and urinary 
tract infection, partly by the use of insufficiently large control 
groups and partly by using different follow-up techniques for "cases" 
(bacteriuric patients) and "controls" (non-bacteriurics). When these 
differences are taken into account it would appear that the sensitivity 
of this screening test is likely to lie between 15% and 35%, rather 
than 50% to 75%. Thus the conclusion reached by Beard and Roberts (1968) 
that acute pyelonephritis is unlikely to be eliminated as a disease of 
pregnancy by the detection and treatment of bacteriuria in early pregnancy, 
seems amply justified. For this reason, the pilot study was concluded 
after the 1160th patient had been investigated.
Certain other aspects of the study deserve mention. Kass (1962), 
Stuart et al (1965) and Kincaid-Smith and Bullen (1965) reported a higher 
prevalence of hypertension in bacteriuric patients than in controls.
Others have failed to confirm this (Little 1966; Dixon and Brant 1967)
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and the present study provides equivocal results. However this study 
revealed a positive association between hypertensive disorders of pregnancy 
and an abnormal modified Addis count. This finding supports that of 
Cross and Leather (1965) who recorded a high frequency of abnormal urinary 
white-cell excretion rates in 31 patients with hypertension in pregnancy. 
Since there is a correlation between urinary white-cell excretion rates 
and bacteriuria of pregnancy (Little 1966) the present observation may 
account for some of the variability in the observed results of other 
workers who have searched for a relationship between hypertension and 
bacteriuria while frequently omitting mention of the urinary white-cell 
excretion rate.
The present data provide evidence against the value of using a 
single, carefully collected mid-stream specimen of urine as an indicator of 
patients at high risk of developing urinary tract infection in pregnancy, 
and thereby hoping to eradicate this condition as a disease of pregnancy 
by prophylactic therapy of all those with a positive screening test.
Laboratory resources could be better employed following those 
patients who develop urinary tract infection in pregnancy once this infection 
has been successfully treated, .since it is known that these patients are 
prone to sustain recurrences of infection during the pregnancy (Little and 
deWardener 1966).
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CHAPTER 2
Screening for Bacteriuria:
A Cr it ic a l  Reappraisal
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In the past ten years, a considerable amount of time and effort has 
been spent investigating both the frequency of occurrence and the outcome 
of asymptomatic bacteriuria in pregnancy. This topic has been reviewed 
on many occasions, notably by Whalley (1967) and by Beard and Roberts 
(1968). Initial reports suggested that the detection and treatment of 
asymptomatic bacteriuria could lead to the virtual eradication of urinary 
tract infection in pregnancy (Kass 1960; Little 1965). This claim has 
been challenged by several groups who have noted that less than 50% of 
patients developing urinary tract infection in pregnancy are detected 
by the initial screening procedure. (Pinkerton et al 1965; Dixon and 
Brant 1967; Lawson and Miller 1971). The main arguments against routinely 
screening all pregnant patients for asymptomatic bacteriuria revolve 
around the practical problems of collecting and analysing the large numbers 
of specimens obtained and around the value of the resulting data.
It is therefore apparent that some reassessment of the procedure is 
necessary before its use becomes widespread. In order.to do so the answers 
to several questions must be considered: Firstly, how accurate are the
tests used to detect bacteriuria in pregnant patients? Secondly, with 
what frequency do positive tests for bacteriuria occur in pregnancy?
Thirdly, what proportion of patients with untreated bacteria go on to 
develop complications in that pregnancy; and fourthly, what proportion of 
patients without bacteriuria go on to develop the same complications?
Knowing the answers to these questions leads to a further group of questions 
For example: How "expensive" is the test in terms of time, personnel and 
materials involved? How serious is the main complication (urinary tract
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infection) both in terms of maternal and fetal outcome? How difficult 
is the complication to treat successfully once it has arisen, and finally, 
is bacteriuria an indication of basic underlying renal disease? The 
answers to most of these questions are well known but are worth reconsidering 
here.
Aocuraoy of Soreening Tests. Kass (1962) clearly demonstrated that the 
accuracy of determining the presence or absence of bacteriuria in a given 
patient depends upon the method of collecting the urine sample and the 
particular tests applied to it. Under ideal collection circumstances, 
with rapid and efficient bacteriological services, if the results of two 
consecutive specimens are in agreement, the accuracy of the screening 
test is 96%, That is to say, when a patient has bacteriuria the test 
will be positive 96 out of 100 times. With less stringent methods of 
collection and processing of the samples, the accuracy of the test may 
fall to 80% or less— particularly if the results are based only on a single 
sample of urine (Norden and Kass 1968). Chemical tests are considerably 
less accurate. Williams et al (1965) stated that the T.T.C. test was 87% 
accurate, however this was when it was compared to the conventional test.
Thus if a single routine culture procedure is 80% reliable in detecting 
bacteriuria, the T.T.C. Test is 0.8 x 0.87 = approximately 0.70 or 70% 
reliable and as will be shown later, this is insufficient to be of value 
as a test for predicting the development of urinary tract infection in 
later pregnancy.
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Bacteriuria and Urinary Tract Infection. Using the standard microbiological 
methods the frequency of a positive test for bacteriuria in the pregnant 
population in the first trimester of pregnancy varies in most series, between 
3.6% and 7% (Beard and Roberts 1968). The frequency with which untreated 
bacteriuric patients develop urinary tract infection varies from 20% to 30%. 
However, the important fact when considering the accuracy of screening tests 
in predicting urinary tract infection in pregnancy is the frequency with 
which patients without demonstrable bacteriuria in the first trimester of 
pregnancy subsequently develop urinary tract infection. This frequency 
varies widely according to the series consulted (see Whalley 1967) and 
obviously depends upon differences in techniques, definitions of bacteriuria 
and urinary tract infection between the series, figures varying from 0 to 14% 
being reported.
Relationships between Screening Tests^ Bacteriuria and Urinary Tract 
Infection. Knowing the accuracy of a screening test and the frequency of 
bacteriuria in a population, it is a simple matter to produce tables showing 
the distribution of cases of bacteriuria according to the results of the 
screening test. This can be done by multiplying together the probabilities 
of the two events (positive screeningtest and bacteriuria) happening on 
their own. Furthermore, knowing the rate at which patients with and patients 
without bacteriuria independently develop any complication of pregnancy, the 
numbers in each group can readily be calculated. An example of such a 
calculation is shown in Figure 2.1. The numbers in this figure are those 
expected, following the screening of 1,000 consecutive pregnant patients.
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The screening test used, has a reliability of 95% and the frequency of 
positive tests in the populace under survey is 4.6%. The basis of the 
calculation for the development of urinary tract infection depends upon 
the assumption that 25% of untreated bacteriuric patients go on to develop 
urinary tract infection, whereas only 1% of nonbacteriuric patients do so 
(Savage et al 1967). It can be seen that the overall proportion of 
patients developing urinary tract infection is 3.2% of the population at 
risk (31.8 out of 1,000 patients). Further consideration of this table 
shows that if all patients with a positive screening test are treated, and 
assuming that all treated patients will not develop urinary tract infection 
in pregnancy, the reduction in numbers of patients developing urinary tract 
infection will be only one third (31,8 to 20.9). In practice even this 
reduction will not be attained since it is widely recognised that a pro­
portion of patients with treated asymptomatic bacteriuria will nevertheless 
develop urinary tract infection during pregnancy (Sleigh et al 1964 ;
Condie et al 1968). Furthermore, since three quarters of the patients with 
a positive screening test will not go on to develop urinary tract infection, 
they will have been exposed needlessly to the dangers of antibacterial therapy 
and in some instances, to the emergence of bacterial strains resistant to the
therapeutic agent used (Williams and Smith 1970),
Tables similar to Figure 2.1 can be produced for a wide variety of
variables. For example, the accuracy of the screening test may vary from 80%
to 97.5%, the frequency of bacteriuria in the populace from 3.6% to 8%, and 
the occurrence of urinary tract infection in bacteriuric and non-bacteriuric 
patients may also vary widely. The results of several such calculations are 
shown in summary form in Tables 2.1 and 2.2.
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The terms "sensitivity" and "specificity" used in these tables 
require careful definition. The sensitivity of a screening test in, for 
example, predicting urinary tract infection is obtained by calculating that 
percentage of all patients developing urinary tract infection, who had an 
initially positive screening test. Likewise, the specificity of a screening 
test in predicting urinary tract infection is obtained by calculating 
that percentage of patients not deveveloping urinary tract infection who 
had an initially negative screening test. A more detailed account of these 
terms and their applicability is given by Cochrane and Holland (1971) who 
observed that "sensitivity is inversely related to specificity, that is, 
few false positives = many false negatives." The reverse also holds 
true and this is particularly germane to the present issue, since the 
specificity of the screening test is high (Tables 2.1 and 2.2).
The relationship between the accuracy of the screening test and 
the prediction of subsequent urinary tract infection in pregnancy is 
shown in Figure 2.2, where it can be seen that the sensitivity increases 
as the accuracy of the test increases. This figure also emphasises that 
for a given degree of test accuracy, the sensitivity of the test increases 
as the proportion of persons with a negative screening test who develop 
urinary tract infection decreases. However, even under the most ideal 
conditions, the test sensitivity is only 54%— that is, out of every 
one hundred patients developing urinary tract infection, only 54 will have 
been predicted by the screening test, and of those, only three quarters 
(40 to 41 patients) are likely to have the infection prevented by treatment 
of the patient at the time of the initial screen (Condie et al 1968).
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Given such figures, it is obvious that unless the condition under 
investigation is a serious one, this procedure does not justify the 
effort involved in its execution. In the case of urinary tract infection 
in pregnancy the condition is virtually always amenable to appropriate 
therapy and appears to be for all practical purposes without risk to the 
mother or child. In a survey of the annual reports of several maternity 
units in the west of Scotland over a period of five years, no reference 
to pyelonephritis or urinary tract infection in pregnancy was made—  
evidence that in practical terms this condition appears to be a benign 
one, at least during the course of the pregnancy.
Bacteriuria and Radiological Abnormalities, Although the above-stated 
calculations have been orientated to a consideration of urinary tract 
infection in pregnancy, it has been suggested that asymptomatic bacteriuria 
is an indication of basic underlying renal disease (Monzon et al 1963;
Low et al 1964). Kincaid-Smith and Bullen (1965) demonstrated a 30% 
prevalence of major abnormalities of the intravenous pyelogram of bacteri­
uric patients some six weeks post-partum and suggested that, for this reason 
alone, screening for bacteriuria is indicated. This policy has been 
supported by Pinkerton et al (1971). However, the same arguments which 
apply to the prediciion of urinary tract infection by the screening test 
must also apply to this indication with the additional constraints, firstly, 
that in none of the reported surveys has a control study been undertaken, and 
secondly, that the investigation of any underlying renal disease cannot be 
carried out until after completion of the pregnancy.
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The situation has arisen that, on the basis of uncontrolled 
observations on the frequency of radiological changes in pregnant 
patients with bacteriuria, screening for bacteriuria is being advocated 
for all pregnant patients. This could only be justified after control 
studies are made. If the finding is shown to be real (i.e. if less than, 
say, 0.2% of non—bacteriuric women have major radiological abnormalities 
on intravenous pyelography) it has further to be shown that treatment of 
the bacteriuria is of value to the patient. Finally, were this the case, 
the question would then arise as to the reason for excluding persons not 
choosing to become pregnant, since the renal changes shown in bacteriuric 
patients are widely held to pre-date the pregnancy (Beard and Roberts 1968; 
Kincaid-Smith and Bullen 1965; Sidaway 1968).
In the best study of radiological changes in patients with bacteriuria 
yet reported, Gower et al (1968) noted a frequency of major radiological 
abnormalities in a series of 164 patients of only 11.6% and recorded that 
treatment of the bacteriuria during pregnancy appeared to have no effect 
upon the subsequent occurrence of radiological changes.
Long-term FotZow-up of Baoteriurios, In the longest follow-up of patients 
with bacteriuria in pregnancy yet reported, Zinner and Kass (1971) observed 
that 38% (51 out of 134) of patients with bacteriuria during pregnancy were 
also bacteriuric when examined 14 years later, regardless of treatment at 
the time of pregnancy, The frequency of pyelographic changes of pyelo­
nephritis in the previously bacteriuric patients was 29% (12 out of 41).
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The only evidence of impaired renal function in this group of patients 
was a significantly lower mean urine osmolality in those who were 
bacteriuric at follow-up when compared to those who were not.
CONCLUSIONS
Beard and Roberts (1968) concluded that screening was justified on 
the grounds that it could lead to the prevention of about two thirds of 
the cases of acute pyelonephritis in pregnancy, that it could alert the 
obstetrician to the presence of surgically remediable renal lesions and 
finally, that it could identify those patients at risk from developing 
chronic pyelonephritis. The evidence presented here suggests that in 
the case of acute pyelonephritis of pregnancy the proportion of cases 
prevented will be considerably less than 66%. The evidence for a high 
proportion of patients with surgically remediable lesions being detected 
by the procedure has yet to be conclusively produced. Finally, as yet no 
one has demonstrated that patients with persistent bacteriuria go on to 
develop chronic pyelonephritis or even have significant deterioration in 
renal function. For these reasons, it seems that the case for routine 
screening of all pregnant patients for the presence of bacteriuria is not 
proven. Before costly, large scale epidemiologic surveys of pregnant 
women are undertaken, a test which has both a specificity and a sensitivity 
of over 90% is required.
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Pending such a test it would seem reasonable to investigate those 
patients generally thought to constitute a "high risk" group, for 
example: firstly, those with previous histories of urinary tract 
infection in pregnancy; secondly, those with co-existing disease, e.g. 
diabetes; and thirdly, those with known renal abnormalities.
Finally, where any patient develops urinary tract infection 
during pregnancy, it would seem advisable to investigate such a patient 
after completion of pregnancy. Should persistent bacteriuria be detected, 
then intravenous pyelography and other urological examinations may be 
indicated some months later. However, it should be emphasised that the 
connection between symptomatic urinary tract infection and chronic, non­
obstructive pyelonephritis, is as yet a tenuous one, since there are 
considerable difficulties in correctly diagnosing the latter condition 
(Heptinstall 1967). In a recent survey of 173 patients considered for 
regular dialysis therapy, Schecter et al (1971) stated that they were 
"unable to find a single case of unequivocal non-obstructive chronic 
pyelonephritis (excluding patients with uretero-vesical reflex) which 
progressed to end-stage renal failure in young or middle-aged patients."
Thus they provide more evidence in support of the findings of Kimmelstiel 
et al (1961), who recorded .only five cases of uraemic non-obstructive 
chronic pyelonephritis in a study of over 3,300 autopsies. In the survey 
cited above, Schecter et al concluded that their findings "suggested but 
did not prove that mass screening programs for the detection of asymptomatic 
bacteriuria may have little impact on the reduction of end-stage renal
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disease in the young and middle-aged population." Taken in association 
with these findings, the results of the calculations presented here, 
strongly question the value of screening for bacteriuria in pregnancy.
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CHAPTER 3
Urinary Tract Symptomatology in
General Practice
39
Considerable controversy exists as to the nature and outcome of 
the lesion in patients with acute urinary tract symptomatology. Several 
clinical studies have been undertaken to elucidate this problem, notably 
those of Fry et al (1962), Mond et al (1965) and Steensberg et al (1969). 
However, the issue remains in doubt.
Angell et al (1968) observed that many patients found at autopsy to 
have "active non-obstructive chronic pyelonephritis" had denied previous 
symptoms of urinary tract infection during life. It may be therefore that 
the current view of aVl cases of urinary tract infection as potentially 
serious conditions which might become established and later present as 
chronic pyelonephritis is incorrect (Editorial, Lancet 1968).
Waters (1969a) has advocated a detailed cohort study of such patients 
as one way to solve the problem. However, such a study will, of necessity, 
be a long-term undertaking. To assess the practical problems likely to 
be encountered in such a large study, a small pilot survey of two group 
practices in the Glasgow area was carried out. The present report deals 
with the findings on initial examination together with the results of a 
follow-up analysis on a group of patients admitted in the initial phase 
of the study.
PATIENTS AND METHODS
Patients selected for the survey were those who complained directly 
or on questioning of symptoms which led their practitioners to diagnose 
the presence of "urinary tract infection" (U.T.I.). Female patients
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between the ages of 15 and 55 years were investigated from both 
practices and a separate group aged over 55 years were included from 
one. All pregnant patients, patients with diabetes mellitus and all 
males were excluded from the survey.
Following admission by the practitioner, each patient was inter­
viewed by a trained nurse who collected certain demographic data on 
a standard form (Figure 3.1) and thereafter obtained a specimen of 
urine by a standard technique. The vulva was cleansed with sterile 
water and a clean-catch, mid-stream specimen of urine collected 
directly into a sterile honey-pot. Where the patient was unable to 
produce a specimen, she was instructed to return within a short period 
when a further attempt was made to collect the specimen. When a sample 
was obtained, it was divided into two, and placed in a refrigerated container 
in which it was transported to the laboratory within four hours.
At the outset of the trial a further sample collected at the 
beginning of micturition was studied, but this was subsequently dis­
continued.
When a satisfactory sample was obtained, the patient was then 
allocated randomly to one of three treatment groups, supplied by the 
nurse with the appropriate tablets and instructed in their use. The 
treatment groups were;
1. Sulphadimidine 1 g six-hourly for seven days.
2. Ampicillin 500 mg six hourly for seven days.
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3. Sulphadimidine 1 g six-hourly for four days, after which 
the therapy could be changed, if necessary, to the drug 
indicated by the bacterial sensitivities reported to the pract­
itioner. Ifhere the patient was symptom-free the sulphadimidine 
was continued to a total of seven days.
Patients were given a full course of treatment even if the urine 
culture was sterile and irrespective of the sensitivity pattern of the 
organisms discovered except where indicated for those patients in Group 3.
All patients were seen again at 14 days after admission to the survey 
and a repeat sample obtained. They were instructed to return to the clinic 
if symptoms recurred and a group were reviewed at a period of one year after 
therapy commenced. All patients who failed to respond to therapy or who 
developed more than two recurrences within 18 months of admission to the 
study were referred to hospital for detailed investigation.
■'ÜT'ine Sanîptes. One specimen was taken for culture in the laboratory where 
one of two technicians plated the samples using the technique described by 
McGeachie and Kennedy (1963) and also tested the sensitivities of the 
organisms to various antibacterial drugs using a U2 Oxoid Multodisc.
The second sample was centrifuged and a modified Addis count performed 
using the method of McGeachie and Kennedy (1963).
On the basis of the laboratory findings patients were allocated 
to one of four groups:
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(A) Urine culture > 10^ organisms/ml; Addis count > 10 white cells 
per counted field.
(B) Urine culture > 10^ organisms/ml; Addis count < 10 white cells
*
per counted field.
(C) Urine, culture < 10^ organisms/ml; Addis count > 10 white cells 
per counted field.
(D) Urine culture < 10^ organisms/ml; Addis count < 10 white cells 
per counted field.
No attempt was made to estimate blood urea or serum creatinine levels, 
or to perform intravenous pyelography since it was felt that such procedures 
could lead to a substantial number of patients failing to return for follow- 
up examinations.
Patients were admitted to the study during an 18-month period commencing 
1st October 1967 and a random sample was interviewed one year after admission.
RESULTS
A total of 343 patients were admitted to the survey. Of these, 201 
were from practice R and 142 from practice S. The mean age of the 134 
patients agend 15-55 years from practice R was 34.7 (SEM 0.6) years, that 
of the 67 patients aged over 55 years was 65.0 (SEM 0.4) years, and that 
of the 142 patients from practice S was 34.5 (SEM 0.6) years. Of the 
343 patients, 79% were married, 15% single and 6% widowed. A total of 53.3% 
had one child or less, 27.6% had 2-3 children, and 19.1% had four or more 
children.
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VTvne anaZyses, The findings on initial examination of the urine are 
shown in Table 3.1, together with the therapy group to which the patients 
were allocated. There were no significant differences between the practices 
with respect to the findings on initial urine examination, nor was there an 
association between the number of children and the findings on urine 
examination.
Symptoms, The symptoms recorded on presentation are shown in Table 3.2. 
There were no significant differences between any of the groups with respect 
to these symptoms considered individually. In addition when combinations 
of two symptoms were considered together (loin pain and pyrexia; stress and 
nocturia; loin pain and dysuria) no significant differences were observed.
In particular, patients in Group A could not be differentiated from the 
others by consideration of symptoms alone.
Social and past histories. Patients were compared with respect to social 
status, parity and a history of previous urinary tract symptomatology.
There was no evidence that any of these factors considered alone played 
a significant role in determining the urinary findings on presentation. 
Previous symptoms of U.T.I. occurred in 49.3, 57.5, 47.7 and 43.1% of 
patients in Groups A to D, respectively.
Bacteriological' findings, Bacteria isolated in concentrations of over 10^ 
organisms per ml of urine are shoxm in Table 3.3, together with a comparison 
of organisms isolated from the two practices. There were no significant 
differences between the practices with respect to the types of organisms 
isolated (x^ = 4.1, p > 0.1). Micrococci were isolated in 12% of cases 
(14 • out of 118 positive cultures).
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Urine microscopy, Patients were assigned to Groups A to D on the 
basis of a modified Addis count performed on a mid-stream specimen 
of urine together with the bacterial count. In addition, in 75 patients 
the results of the mid-stream specimen Addis count were compared with 
an early-stream specimen Addis count. This comparison revealed that, 
apart from a greater proportion of squames in the latter group, there ' 
were no significant differences between the two samples (Table 3.4).
This procedure was therefore abandoned.
Effect of therapy, (Table 3.5) At the return visit 14 days after admission 
to the survey, 296 patients were interviewed (86.8%). The remaining 
patients were either lost to follow-up (33 patients) or were unable to 
attend for other reasons (14 patients). Of the 296, 50 (16.8%) either 
had persistent symptoms (37 patients) or persistent urinary abnormalities 
(32 patients). The distribution of patients with abnormal urine was 
“28% Group A; 16% Group B; 20% Group C and 36% Group D. Comparable figures 
for the entire series were 21%, 14%, 13%, and 52%, respectively. Nhen 
these patients were given a course of therapy appropriate to the infecting 
organism, all responded satisfactorily.
The initial therapy was therefore successful in 246 patients (83.2%)
The three treatment regimes appeared equally effective in relieving symptoms 
and in rendering the urine free of abnormalities. In particular, only 
nine patients (15%) of those allocated‘to treatment Group 3 were changed 
to another drug after four days (two received ampicillin and seven 
nitrofurantoin).
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Reported recurrences, (Table 3.6) Of the original 343 patients, 310 
(90%) were available for follow-up during the 18 months of the study 
currently under evaluation. The mean follow-up period was 11 months.
The overall recurrence rate amongst these patients was 11.3% (35 individuals) 
Recurrences were reported significantly more often from patients in Group A 
than from those in the other groups (x^ = 8.46, p < 0.01). There were no 
significant differences between Groups B, C and D in this respect, nor 
were there differences between patients in the two practices.
Recurrences on questioning, A group of 137 patients were reviewed at 
one year after admission to the survey. At the time of interview, 
seventeen patients (12.4%) had reported recurrence of symptoms to their 
practitioner. On questioning 38 patients admitted recurrences (27.7%)—  
a significantly greater number than spontaneously reported them (x^ = 6.70, 
p < 0.05). Further analysis of this group revealed that patients between
the ages of 15 and 55 years reported about one third of the recurrences
■(eight out of 25 = 32%) and those over 55 years about two-thirds (nine out 
of 13 = 69%).
Of the 38 patients with recurrences, 21 (55%) had experienced 
epi'sodes of U.T.I. in the past whereas of the 99 without recurrences, 
nineteen (19.2%) had such episodes —  ~ 15.6, p < 0.001.
Analgesic consumption. The regular consumption of analgesic preparations
was common; 15.3% (21 out of 137) of patients admitted regular consumption
of over 10 analgesic tablets or powders per week and 8.7% (12 out of 137)
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of patients gave histories of consuming analgesics in excess of 1 kg 
of salicylates or phenacetin or codeine in their life-time. The drugs 
most commonly taken were aspirin (in various proprietary preparations), 
Askit powders, compound codeine tablets and paracetamol. Of the 21 regular 
analgesic consumers, 14 had no abnormality in the initial urine sample, and 
the remainder had abnormal Addis counts and infected urine.
Referral to hospital. Only eight of the 343 patients in the study were 
referred to hospital (2.7%). Details of these patients are appended (Case 
Reports 3i - 3viii), Of the eight patients, three had persistent frank 
U.T.I. (Group A), two had persistently negative urine examination (Group D)
and the remaining patients had chronic cystitis (1 patient), malabsorption
syndrome (1 patient), systemic lupus erythematosus (1 patient).
Comparison of practioes. The observed incidence of urinary tract symptoms 
was over twice as great in one practice than in the other— a finding which
was consistent at all ages other than the 20 to 29 year- old group, where
the difference was not so marked (Table 3.7).
When incidence rates were calculated per 1000 patients at risk per
annum, the differences between the two practices become quite apparent, 
the overall incidence rate being 35.1 per 1000 patients per annum in
practice R and 76.2 per 1000 patients per annum in practice S (Table 3.8).
Because of this disparity in the incidence rates between the practices 
several other (potentially confounding) factors were investigated. In 
particular the social grading of the patients in the two practices was
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investigated and found to be similar to each other (Table 3.9).
Moreover, when this social grading was compared with that of the 
general female population of Glasgow city in 1961 (the most recent 
full census figures available) there was a tendency for the patients 
to aggregate in the lower social grades.
DISCUSSION
Pyelonephritis is a term which has come to be applied loosely to a 
wide variety of apparently different conditions (Jackson et al 1962) and 
so much confusion has been caused by failure to define the exact terms 
used when describing patients with urinary tract symptomatology (Editorial 
Lancet 1968). For this reason, no rigid definitions have been applied to 
patients in this study.
In British general practice some 12 to 13 consultations per 1,000 
concern patients with urinary tract symptoms and bacteriuria (Fry et al 
1962; Milne et al 1969). In Denmark some 34 consultations per 1,000 
concern patients with urninary tract symptoms alone, irrespective of the 
presence or absence of bacteriuria (Steensberg et al 1969). In the 
present study 33 patients per 1,000 consulted their practitioners on 
account of urinary tract symptoms from one practice and 82 per 1,000 from 
the other. This highly significant difference (p < 0.001) between the 
two practices could be due to:
(a) failure to report about half of the cases in practice R - 
an unlikely event.
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(b) overenthusiastic reporting of cases from practice S - an 
equally unlikely event since under those circumstances a preference 
for certain symptoms should have been observed from this group.
(c) a true difference between the practices. Several possible 
differences were considered and two seem likely to be significant. 
Practice R serves an area of considerably higher social status than 
practice S, yet the social grading of patients was similar in the two 
groups of patients considered here. Unfortunately, the exact social 
grading of patients in both practices was not available, however, it 
is the impression of both practitioners and myself that the social 
grading of patients in this study was similar to the overall grading 
of practice S and distinctly lower than that of practice R. T'/hile 
this data is merely "impressionistic" it raises the possibility of 
either a higher prevalence of U.T.I. in the lower social classes or
a greater tendency to report such symptoms by these groups. Finally, 
the physicians in practice R were all male and those in practice S 
all female, a possible source of variability in the proportion of 
symptomatic patients who were willing to discuss their symptoms with 
their practitioners.
Although the prevalence of urinary tract symptomatology is higher 
than that previously reported in Britain, Waters et al (1970) recorded 
that 48% of an asymptomatic group of females dra\m randomly from a 
general population, gave a history of dysuria. In this study some 22% 
of those interviewed had experienced dysuria in the year preceeding the
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survey (Waters 1969b). Other workers have suggested that only some 
40% of patients with urinary tract symptoms actually consult their 
practitioners about them (Danish National Morbidity Survey 1960), It 
would therefore seem that previous general practitioner surveys have 
underestimated the size of the problem of urinary tract symptomatology 
usually be excluding from analysis (or analysing separately) the 30-50% 
of patients who do not have bacteriuria at the time of the symptoms 
(Fry et al 1962; Gallacher et al 1965).
The present study confirms the findings of Mond et al (1965) and 
Steensberg et al (1969) that the analysis of presenting symptoms does 
not help to select those with bacteriuria from those without. However, 
the use of a modified Addis count together with a bacterial count has 
proven.of value in detecting patients with the highest risk of recurrences.
This may be of help if the data presented by Little and deWardener (1966) 
is considered. These workers suggested that all patients with a history 
of acute loin pain, pyrexia and infected urine should be examined at 
short (undefined) intervals to detect and treat recurrences early. However, 
the majority of patients with recurrences in the present study were apyrexial 
on presentation and most of those who were pyrexial did not have recurrences 
during the study.
Moore et al (1965) claimed to be able to differentiate patients with 
lower urethral disease from those with infection occurring at or above the 
bladder, by means of a differential urethro-vesical count. Using a modification 
of their technique, the present investigation failed to lend support to 
this observation.
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Organisms other than E, ooti can cause U.T.I. (Mitchell 1964;
Stamey et al 1965; Kincald-Smith 1965; McGeachie 1966; McFayden and 
Eykyn 1968; Mabeck 1969; McAllister et al 1971). In the present 
study 64% of bacteria isolated from the urines were E, coVl^ the 
remainder being staph albus, proteus mirabilis and micrococci. This 
data confirms the observation by Mabeck (1969) of a high prevalence 
of staphylococcal U.T.I.
The proportion of patients with micrococci in high concentrations 
(12%) is an index of the inherent error of accepting the result of a 
single mid-stream specimen before treatment. It is likely that these 
are "faise-positives" which would have been sterile on culturing a second 
specimen, however it is impractical for a practitioner to repeat cultures 
before commencing therapy and so such patients have been classified in 
Groups Â-B in this study.
The clinical effectiveness of sulphadimidine was striking. This 
drug was as effective as ampicillin in therapy of such patients. Sixteen 
patients received sulphadimidine despite a later bacteriology report of 
sulphadimidine resistance. Only four of these patients had recurrences 
on questioning— a rate similar to the overall rate in the study. This 
supports the observation of Harper and Cowston (1945) that sulphonamide 
sensitivities are of little value unless steps are taken to avoid 
antagonists in the medium and the true mean inhibitory concentration of 
drug to the organism is reported.
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This study confirms the observations by Brocklehurst et al (1968) 
and McMillan and Linton (1968) that the prevalence of U.T.I. is approxi­
mately constant in the over 55-year olds. The condition did not appear 
more difficult to treat initially in these patients, but the recurrence 
rate was higher than in the younger age groups.
The prevalence of analgesic abuse in the present patients is high. 
McMillan et al (1968) reported that 14.2% of patients attending a renal 
clinic with chronic pyelonephritis abused analgesics and Murray et al (1970) 
observed that 8.8% of a group of psychiatric patients did so. However, 
until the true prevalence of analgesic consumption in the community from 
which these patients were drawn is known, the relevance of these figures 
must remain in doubt. Nevertheless, it would seem prudent to question all 
patients with urinary tract symptoms regarding their consumption of analgesics 
since there is some evidence that these drugs may be associated with impaired 
renal function which can be readily halted if analgesic intake ceases (Bell 
et al 1969; Murray et al 1971).
These data suggest that it is reasonable to perform routine bacteriology 
and Addis counts on all patients with symptoms of U.T.I. presenting to a 
generar practitioner in order to select a group at particular risk of 
developing recurrences after therapy. This, however, is the only indication 
for these examinations since some 90% respond adequately to the initial 
therapy and of those who do not, the majority continue to have symptoms of 
U.T.I. Thus the taking of an initial M.S.U. and Addis count from patients 
with urinary tract symptomatology has value mainly in predicting recurrence 
rates and will not materially affect the outcome of the presenting episode.
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CHAPTER 4
E)crENDED Therapy in  the Treatment of
Established Urinary Tract I nfection
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In the past decade increasing interest has been sho\m in the 
management of urinary tract infections. Despite this, controversy 
still exists as to the value of prolonged therapy in preventing 
occurrence of these infections once they become established. Orsten 
(1962) reported a beneficial effect with long-term therapy as did 
Murdoch et al (1968), but others notably Turck et al (1962), Campanacci 
et al (1963), Little and deWardener (1966) and Bengtsson et al (1967) 
have failed to confirm this finding.
The present investigation was undertaken to assess the benefits of 
a three-month course of therapy given to patients with established urinary 
tract infection. Treatment was undertaken as an outpatient and the patients 
were given a three-month course of the antibacterial agent to which the 
organism responsible for the urinary tract infection was sensitive. Patients 
who failed to respond to therapy or whose infection returned after treat­
ment were treated with a further three-month course of the trimethoprim- 
sulphonamide combination "Septrin" (Burroughs-Wellcome). This combination 
is known to attain both therapeutic tissue levels and a high urine con­
centration, It is effective against all gram-negative organisms occurring 
in the urine except pseudomonads (Darrell et al 1968; Bushby 1969). The 
minimum inhibitory concentration of the drug is considerably lower than that 
of sulphonamides alone and the effect is bactericidal rather than bacterio­
static.
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PATIENTS AND METHODS
All patients were referred to the Renal Clinic by their practitioners 
because of recurrent urinary tract symptoms which had either failed to 
respond to short courses of antibiotics or relapsed after therapy was 
stopped. Mid-stream speimens of urine were collected from the patients 
weekly for three weeks, using the method cited by Kincaid-Smith and 
Fairley (1967). A quantitative bacterial count with a modified Addis 
count (McGeachie and Kennedy 1963) was performed on each specimen. The 
patient was said to have a urinary tract infection if on each of the 
three visits the same bacteriae were present in concentrations exceeding 
10^ organisms per ml of urine and the modified Addis count was positive.
At the same time the in-vitro drug sensitivity of each organism was 
obtained using a standard disc technique.
Blood urea estimations were carried out on all patients and an 
intravenous pyelogram (I.V.P.) was performed where no contra-indications 
were present. The latter investigation was undertaken after the acute 
infection had settled.
All patients were given a three-month course of the antibacterial 
agent indicated by the sensitivity tests. The drugs used were sulphadimidine, 
nitrofurantoin, nalidixic acid and ampicillin.
If the patient failed to respond to the first drug given or if 
infection returned after stopping treatment, the therapy was recorded as a 
failure and the patient was reassessed prior to entering into the second 
part of the investigation.
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In the first stage of the investigation no attempt was made to 
check regularly that the patients were in fact taking the prescribed 
drugs. During the second stage, that is if a patient failed to respond 
to the initial three months of therapy or if the infection returned, the 
discrepancy count method of Porter (1969) was adopted as a simple check 
on consumption of tablets.
Patients proceeding to the second part of the investigation were 
given a three-month course of the trimethoprim-sulphamethoxazole 
combination (Septrin— Burroughs Wellcome) in a dose of two tablets 
twice daily. (One tablet contains 80 mg trimethoprim and 400 mg sulpha- 
methoxazole).
All patients were followed at regular intervals during therapy and 
for a prolonged period after therapy ceased,
RESULTS
Initial therapy, A total of 66 patients were studied for periods ranging 
from 12 to 72 months (mean follow-up - 26 months). The mean age of the 
patients was 46 years (range 17 to 79 years), and the female to male ratio 
was 4.5:1. The mean age of males was 45 years and of females 47 years. 
Patients were seen on average once every eight weeks.
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On the basis of presenting I.V.P. and blood urea estimations they 
were divided into four groups :
(A) Normal I.V.P. and blood urea below 40 mg/100 ml - 27 patients
(B) Abnormal I.V.P, and blood urea below 40 mg/100 ml - 12 patients
(C) Abnormal I.V.P. and blood urea above 40 mg/100 ml - 15 patients
(no history of excessive analgesic intake)
(D) Abnormal I.V.P. and blood urea above 40 mg/100 ml - 12 patients
1 (history of excessive analgesic intake)
Groups C and D included three and two individuals, respectively, whose 
renal function did not permit intravenous pyelography. Excessive analgesic 
intake was defined arbitrarily as the ingestion of more than one kilogram 
salicylates or phenacetin in a life time (MacMillan et al 1968). The 
abnormalities noted on I.V.P. included calyceal clubbing - 28 patients, 
cortical scarring - 36 patients, dilated pelvic-calyceal system - 3 patients, 
and urinary calculi - 6 patients.
The reason for referral to the renal clinic is shox'jn in Table 4.1 —  
fifty-eight patients had recurrent urinary tract infections and the remaining 
eight were found to have recurrent infection although they had been referred 
because of other conditions. Nineteen patients had mixed infections, the 
most common organism being Escherichia coli (Table 4.2),
The overall effect of therapy is shown in Table 4.3. Three months 
after stopping therapy, 18 patients (27%) had infected urine and by six 
months after stopping therapy 25 patients (38%) had had further significant
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bacteriuria. By 24 months, 37 patients (56%) had developed bacteriuria 
once again. Only one third of the patients followed up for 30 months 
had sterile urine throughout this period.
When the results were analysed by groups, the recurrence rate at 
twenty-four months in patients with normal I.V.P.s (Group A) was signifi­
cantly lower —  11 out of 27 patients = 41% —  than in patients with 
abnormal I.V.P.s (Groups B, C, D) —  26 out of 39 patients = 66% —
(x^ = 4.33, p < 0.05). The recurrence rates in Groups B, C, and D did 
not differ significantly one from the other, however, there was a 
tendency for patients in Groups B and D to fare better than those in Group C 
Further studies will be required to adequately quantitate this difference 
between the groups.
Effect of trtmethopr'Cm-sutph'isoxa^ole mixture. A total of 32 patients 
were admitted to this phase of the study - three males and 29 females.
Their mean'age was 44 years (range 17 to 78 years). The causative 
organisms were Escherichia coli 26 cases, proteus spp. in four cases and
klebseillae in two cases. Two patients defaulted from the study, the
remainder were seen monthly for six months after completion of therapy.
On the basis of the I.V.P., patients were divided into two groups;
Group E - normal I.V.P. - 15 patients
Group F - abnormal I.V.P. - 15 patients
(Table 4.4)
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The abnormalities noted on I.V.P. were clubbed calyces - 10 patients 
(including eight with cortical scarring); renal calculi - 2 patients ; 
hydronephrosis - 2 patients; and previous nephrectomy - 1 patient. Of the 
fifteen patients in Group E all had blood urea levels below 40 mg/100 ml 
and of the 15 in Group F, 12 had blood urea levels above 50 mg/100 ml.
Treatment had to be discontinued in the first week of the trial in 
eight patients out of the 30 studied —  26.6% (95% confidence limits 10.8 - 
42.4%). In four patients this was due to skin sensitivity and in four to 
severe gastrointestinal upset.
Six months after completing the three-month course of therapy, nine 
patients out of the remaining 22 (41%) had experienced a further episode of 
symptomatic urinary tract infection in association with bacteriuria. There 
was no evidence of a significant difference in recurrence rates between 
Groups E and F. Finally, the overall recurrence rate of 41% was similar 
to that found at the same time interval after therapy in the initial study 
(38%) .
DISCUSSION
There is widespread pessimism about the results of prolonged anti­
bacterial therapy in patients with urinary tract infection. Kennedy et 
al (1969) studying a group of female patients found to have urinary tract 
infection in hospital reported a recurrence rate of 53% at six months 
in 28 patients who had- received short courses of appropriate therapy (five 
to ten days). Half of their patients were asymptomatic at the time of
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initial therapy. Only three of their patients had elevated blood urea 
levels and the failure rate observed is somewhat higher than that noted 
in patients in Group A of the present study (the most comparable group).
Petersdorf and Turck (1967) reported a 75% failure rate in 48 patients 
who were known to suffer from chronic bacteriuria and who were given one to 
two week courses of ampicillin. This rate is considerably higher than 
that reported either in the present study or by Kennedy et al (1969).
Murdoch and his co-workers (1968) reported a 35% failure rate in 
forty-six patients who had previously failed to respond to short-term 
therapy. This group of patients is comparable to the present series 
and the recurrence rate is similar to that reported in Group A, Murdoch 
gave his patients 500 mg ampicillin nightly for one to two years and 
failure of therapy occurred in all cases during the time when the patients 
were presumed to be taking the antibacterial agent.
In a recent trial of a single daily dose of nitrofurantoin given at 
night to a group of patients with recurrent urinary tract infection,
Bailey et al (1971) reported a significant reduction in the frequency of 
recurrences in the treated group when compared to control subjects. This 
study was reported after completion of the present investigation and its 
results apply only to patients with normal renal function since nitrofurantoin 
should be avoided in patients with even mild renal impairment.
Gower (1968) studied 81 patients with chronic renal infection and 
found the bacteriological relapse rate to be constant irrespectice of the 
length of therapy, whereas there was evidence of symptomatic improvement 
during continuous treatment. In addition, he found no evidence of progressive
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impairment of renal function with succeeding episodes of infection.
Turck et al (1967) suggested that patients with recurrent urinary 
tract infections be grouped into those with relapsing infections (probably 
due to renal involvement) and those with reinfections (probably only bladder 
involvement), They felt that the former might respond to long-term therapy 
whereas the latter rarely does. This work has subsequently been confirmed 
by several independent groups of investigators. However, to discover if 
a patient is suffering from relapse or reinfection requires careful urine 
examination including full serological identification of the infecting 
organism. This is a time consuming task not suitable for use in a district 
hospital or laboratory. Moreover, it requires the patient to attend clinics 
regularly for periods of up to two to three months before a definite decision 
can be made regarding the nature of the recurrence (Turck and Petersdorf 
1968).
Although no sero-typing could be undertaken in the present study, it 
is possible that the response to a three-month course of treatment is, in 
itself, a diagnostic as well as a therapeutic procedure. If this is so 
it may prove to be more economical to select patients who should be closely 
investigated by using their response to three-months therapy as a diagnostic 
criterion rather than deny such patients therapy during the initial three- 
month period.
Bengtsson C1967) reported that patients who have renal disease as a 
result of analgesic abuse tend to fare badly when suffering from superimposed 
urinary tract infections. In her series most patients had experienced
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episodes of renal papillary necrosis. In the present study, there was 
no evidence of a difference between patients with impaired renal function 
with or without a history of excessive analgesic intake (Groups D and C, 
respectively).
To date several investigations into the effect of trimethoprim- 
sulphonamide combinations on urinary tract infection have been reported 
(Gruneberg and Kolbe 1969; Reeves et al 1969; Allison et al 1969; 0'Grady
I
et al 1969). However in the majority of cases, the follow-up period has 
been short (six weeks or less). Such a brief period is unsatisfactory as 
an indicator of the efficacy of a new drug in the treatment of established 
urinary tract infection since it has been sho^m frequently that almost any 
antibacterial agent to which the causative organism is sensitive will 
result in an initial period of relief of symptoms and sterilisation of 
urine. The results of the present investigation into the long-term efficacy 
of this combination are disappointing. One quarter of the patients had to 
stop the drug because of unwanted side effects, all of which developed in 
the first week of therapy. This is a considerably higher frequency than 
expected from previous studies (Allison et al 1969; Czonka and Knight 1967; 
Drew et al 1967) and it may not reflect the true rate, being rather a chance 
finding since the 95% confidence limits around the observed frequency varied 
from 10% to 42%. The recurrence rate in those who completed therapy was not 
significantly different from that observed to occur with other antibacterial 
agents.
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Despite previously reported cases of leucopenia and thrombocyto­
penia after administration of trimethoprim in doses of 500 mg to 1500 mg 
per day (Drew et al 1967; Sourander and Werner 1967) no such adverse 
reactions were observed in the present study where the trimethoprim 
dosage was 320 mg per day. Similar negative findings have been reported 
by Allison et al (1969).
The present study of a large group of patients suffering from 
recurrent urinary tract infection which was refractory to previous short 
courses of antibacterial therapy indicates that the recurrence rate after 
a three month course of therapy with the indicated antibacterial agent 
is 38% at six months, and 61% at two years. This recurrence rate is 
somewhat lower than reported from other centres but the comparability 
of these series in terms of the type of patient included, the degree of 
renal damage involved, and many other factors is difficult to assess.
The response to a three month-course of therapy was significantly better 
in those patients with normal intravenous pyelograms than in patients with 
abnormal pyelograms (most of whom also had elevated blood urea levels),
There was no evidence of a significantly better response to therapy 
with a trimethoprim-sulphonamide mixture than with ampicillin, sulphonamide 
or nitrofurantoin. The observed adverse reaction rate to the trimethoprim 
sulphonamide mixture was high-26.6%-although the 95% conficence limits of 
this observation were wide (10% to 42%).
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In patients who do not experience adverse reactions to the drug, this 
mixture may have some advantages over conventional antibacterial therapy 
on the grounds of cost and convenience (twice daily administration).
These advantages however may be outweighed by the fact that in renal 
failure the renal handling of the two constituents of this mixture are 
different (for detailed discussion see Chapter 12).
Finally, these results indicate the need for a large (and therefore
multicentre) study into the effect of various treatment schedules in
patients with recurrent urinary tract infection. All of the studies
reported to date involve relatively small numbers of patients (usually
less than 100) and therefore are of insufficient size to fully assess
the effect of such variables as patient age, renal structural and functional
abnormalities and previous history of childhood or pregnancy bacteriuria
upon the outcome of treatment. In addition, because of interstudy
variability in inclusion material, comparability of results has not been
attained. In view of the impressive results claimed for a nightly tablet
of nitrofurantoin (Bailey et al 1971), such a multicentre study might
compare the effects of nightly nitrofurantoin, nalidixic acid, and sulpha-
dimidine, with short and long-term courses of standard antimicrobial therapy
and with, if possible, a placebo control group. Pending the results of such
a trial, the present evidence suggest that patients with established urinary
tract infection should be given 50 mg nitrofurantoin nightly if renal function 
is normal (as judged by blood urea, levels below 40 mg/100 ml) and a three-
month course of continuous sulphadiraidine or other suitable antibacterial
agent if renal function is abnormal.
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CHAPTER 5
Glucose Tolerance in  Patients with
Established Urinary Tract I nfection
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Urinary tract infection is a common condition in the community.
Some 30 to 40 per 1,000 consultations with general practitioners are 
a result of symptoms due to this condition (see Chapter 3). Nevertheless 
its true prevalence is unknown, although it is commoner in women of 
childbearing age than in any other group.
Urinary tract infection is a frequent and often severe complication 
of diabetes mellitus. While it has been stated that such infections are 
more common in diabetics than in non-diabetics (Sharkey and Root 1935;
Kass 1960), this may be a reflection of the increased frequency of 
catheterisation, of hospitalisation, or of physician awareness rather 
than a true increase in its prevalence in diabetics. Both Huvos and 
Rocha (1959) and Rengarts (1960) recorded similar rates of.bacteriuria 
among hospitalised diabetic and non-diabetic patients. Moreover,
Oseasohn et al (1962) found a low prevalence of bacteriuria in a group 
of post-partum diabetics. Nevertheless, the true frequency of bacteriuria 
and of urinary tract infection in the diabetic population at large is 
unknown.
Diabetes mellitus itself is a common condition. Several large 
population surveys have reported a prevalence of known diabetics in the 
community of 0.64% and of undiagnosed diabetics of 0.69%, giving a 
combined prevalence of 1.33% (Pyke 1968),
Thus, both diabetes and urinary tract infection frequently occur in 
the community. Unfortunately the exact relationship between them is 
ill-defined.
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The present investigation was conducted to test the hypothesis 
that latent diabetes mellitus is commonly associated with recurrent 
urinary tract infection occurring in the absence of other "risk" factors 
such as analgesic consumption, obstruction to the urinary tract or 
vesico-ureteric reflex,
PATIENTS AND METHODS
A group of female patients referred to the Renal Clinic, Western 
Infirmary Glasgow, by their general practitioners for the investigation 
and treatment of recurrent episodes of urinary tract infection, were
studied. All patients had evidence of urinary tract infection on or
shortly after their first visit to the Clinic, Following Investigation 
of the infection all responded to appropriate therapy and at the time of 
the present investigation were free of symptoms, had sterile urine, and 
were not taking regular antibacterial therapy. No patients were pregnant 
at the time of the study.
After an overnight fast, the patients were seen at the hospital and 
a standard glucose tolerance test was performed. A sample of venous 
blood was drawn on arrival to estimate fasting blood glucose level and
thereafter the patients were given 100 grams glucose diluted with 400 ml
water. Blood samples were taken for glucose estimations at 0, 30, 60,
90, 120 and 180 minutes after ingestion of the glucose. In addition, 
prior to the administration of the glucose, the patients were asked to 
provide a specimen of urine which was tested for glucose using both the 
Clinistix and Clinitest reactions (Ames Company). Further samples of
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urine were obtained at 60, 120 and 240 minutes, respectively.
Blood glucose estimations were performed on venous blood samples 
to which had been added a small amount of sodium flouride. Samples 
were assayed on an Auto Analyzer using the Hoffmann ferricyanide method 
(Hoffmann 1937). Estimations of blood urea, serum creatinine and packed 
cell volume using the microhaematocrit method were made on further aliquots 
of the initial blood sample.
All patients were informed of the reason for the test and their 
consent obtained.
After the glucose tolerance test was completed and the results 
available for study, patients were questioned regarding the presence or 
absence of a family history of diabetes mellitus,
RESULTS
Glucose tolerance tests were performed on 15 patients. The average 
age of the patients was 33.4 years (range 16 to 53 years); all were female; 
mean presenting blood urea levels (Hh^ S.E.) were 24 + 1*5 mg/lOO ml; mean 
presenting serum creatinine levels were 0.8 + 0.05 mg/100 ml and the 
mean packed cell volume was 35 + 0.5%. All patients had sterile urine 
at the time of the investigation and were taking neither antibacterial 
therapy nor any analgesic preparations which might interfere with the 
Clinitest reaction.
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Of the 15 patients, three (20%) had abnormalities detectable on 
intravenous pyelography (I.V.P.)— one had cortical scarring and all 
three had evidence of calyceal clubbing.
The results of the glucose tolerance test are shoxra in Table 5.1 
and Figure 5.1. In no case was there evidence of an abnormality in 
glucose handling. In particular, all patients had fasting blood sugar 
levels within normal limits and no patient showed evidence of either 
"diabetic" or "lag" curves. Glycosuria was not demonstrated in any 
patient.
No patient in this study had a family history of diabetes mellitus 
which was sufficient in severity to require therapy. However, one 
patient (a 34-year old mother of two children) reported that her maternal 
grandfather and her mother^s sister had both been said to have glycosuria 
by their general practitioners.
DISCUSSION
In fifteen patients with recurrent urinary tract infection, no case of 
latent or asymptomatic diabetes mellitus was detected using the standard 
glucose tolerance test. This result was not entirely unsuspected, since 
Monod (1942) showed that the growth rate of coliform bacilli in synthetic 
media is dependent on glucose concentrations only up to 25 mg/litre, while 
Fine (1965) recorded that the glucose concentration in the urine of normal 
subjects is well above this, being over 60 mg/litre. Moreover, Asscher 
et al (1968) reported that increasing the concentration of glucose in the
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urine from 28 mg/1 to 1 g/1 made a relatively small contribution to the 
total numbers of viable organisms growing in a culture medium of human 
urine. Thus even the presence of extremely high concentrations of glucose 
in the urine makes a minimal contribution to the number of organisms 
present in the urine once this becomes infected.
However, factors other than glycosuria may affect the prevalence of 
bacteriuria in diabetic patients. Hyperglycaemia can cause a reduction 
in leucocyte mobility (Brayton et al 1970) and leucocyte function itself 
may be impaired under those circumstances (Thornton 1971). These factors 
may separately or in combination lead to a reduction in host antibacterial 
defenses and so an increase in the prevalence of all infections including 
bacteriuria.
Nevertheless, the data presented provide no evidence that patients 
with recurrent urinary tract infection frequently suffer from latent 
diabetes mellitus.
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CHAPTERS
Analgesic Consumption and Renal Disease
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During the past twenty years, a large volume of literature has 
accumulated on the relationship between long-term analgesic consumption 
and impaired renal function. The topic has been the subject of two 
extensive review articles (Shelley 1967; Abel 1971), and has aroused 
considerable public interest and controversy. A critical question, as 
yet unanswered, concerns whether continuous analgesic ingestion per se 
leads to a progressive deterioration of renal function in all patients.
Unfortunately, most of the published studies on this subject have 
lacked suitable controls, and therefore their interpretation is open 
to question. Ifhere adequately controlled observations on hospitalised 
patients have been carried out, the existence of a cause and effect 
relationship has remained in some doubt (Sorensen 1966; Gault et al 
1968).
The present report describes a further investigation into the 
possible association between regular analgesic consumption and impaired 
renal function, using data collected by the Boston Collaborative Drug 
Surveillance Program (BGDSP).
METHODS
The BGDSP uses nurse monitors who are provided with standardised 
self-coding data sheets and are assigned to medical wards where they 
record data on consecutive admissions. The data include patient 
characteristics, discharge diagnoses, details of all drugs administered
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in hospital, and certain routine laboratory tests such as admission 
blood urea nitrogen (BUN) levels and urinalysis (Jick et al 1970),
For the last three years of the study, a history of all medications taken 
in the three months prior to admission to hospital has been obtained 
routinely. For each drug taken by the patient during this time, a 
record is made of the frequency and duration of its consumption.
A medication history was obtained from 7,017 patients. Of these,
331 (4.7%) were excluded because of unknown BUN levels on admission 
and a further 279 (4.0%) because of an unkno\fn frequency or duration 
of analgesic consumption. The remaining patients were divided into 
four groups:— Figure 6.1
Group A - Daily oral analgesic consumers.
Group B - Occasional (less than daily) analgesic consumers.
Group C “ Patients taking drugs other than analgesics.
Group D - Patients who denied taking any medication.
For each of these groups, frequency distributions were obtained for 
age, sex, survival, first discharge diagnosis, blood urea nitrogen levels 
on admission, présence of proteinuria, and abnormalities of the urine 
cell counts.
Finally, the records of all patients admitted to hospital because of 
an adverse drug reaction were scanned to determine the frequency with which 
analgesic preparations had been implicated in the development of impaired 
renal function.
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RESULTS
Patient Characteristics.
A total of 6,407 patients were reviewed. Their average age 
was 53 years, 36% were female, and 6.2% died while in the study. Four 
hundred and sixty-one patients (7.2%) were daily analgesic users (Group A); 
2,438 (38%) were occasional analgesic users (Group B); 3,215 (50.2%) used 
drugs other than analgesics (Group C); and 292 (4.6%) had taken no medications 
(Group D). The first recorded discharge diagnoses of these patients are 
shown in Table 6.1. Details of the ten commonest types of analgesics 
consumed are shown in Table 6.2.
Frequency of Analgesic Use.
(1) Relationship to Diagnosis (Table 6.3): A primary diagnosis of
renal disease was given in 234 out of the 6,407 patients (3.7%). The 
frequency of renal disease was 4,5% in daily analgeisc users, 3.8% in 
occasional analgesic users, 3.4% in users of other drugs, and 3.8% in 
patients taking no drugs. The frequency of renal disease in daily analgesic 
users was not significantly greater than that in occasional analgesic users 
(%2 = 0.44; p > 0.5) or in non-users (yj = 1.14; p > 0,2).
(2) Relationship to Renal Function: Admission BUN tevets (Table 6.4). 
The unadjusted mean admission BUN levels in Groups A to D were similar 
(19.3, 19.5, 23.4, and 18.8 mg/100 ml, respectively). Stratification by 
age, sex, and survival was carried out since there were small differences 
between the groups with respect to each of these factors. In addition,
the data were stratified by discharge diagnosis, since there was a greater
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proportion of patients with musculo-skeletal disorders among the daily 
users of analgesics (11.5%) than among the other groups (2.8%, 1.9%, 
and 1.4%, respectively). Within each stratum there were no significant 
differences in mean BUN levels between the four groups.
Urt-ne analysis. a record of urine protein concentration was available
for 6,052 patients (95%). Proteinuria was detected in 29.4% of those 
in Group A, 32.1% in Group B, 34.4% in Group C, and 41.1% in Group D.
Heavyj proteinuria (3-4+ albustix) was noted in 4.3%, 4.6%, and 7.6% of 
these groups, respectively (Table 6.5).
A record of the findings on microscopic examination of urine was 
available for 5,986 patients (92.5%). White cells were reported in 
21.1%, 16.7%, 21.4%, and 26.6% of Groups A to D, respectively. Red 
cells and/or casts were recorded in 3%, 3.7%, 4.1% and 4.8% of the 
Groups (Table 6.6). Thus, there were no statistically significant 
differences between the four groups with respect to either urine protein 
concentration or the findings on microscopic examination of the urine.
Duration of Analgesic Use.
(1) Daily Consumers: Of the 461 daily analgesic consumers, 259
(56.2%) admitted taking them for up to one year, 100 (21.7%) for periods 
of one to six years, and 102 (22.1%) for periods in excess of six years. 
These three groups were compared with respect to admission BUN levels 
and results of the urine analyses.
Admission BUN lei)el. The unadjusted mean admission BUN levels in the 
three groups were 18.9, 19.3, and 20,2 mg/100 ml, respectively (Table 6.7)
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Since there were differences between these groups with respect to age and 
sex, the data were stratified by these factors. . In each stratum the mean 
BUN levels for the three groups were similar.
Vvi/ne andtys'ts, A record of urine protein concentration was available
for 438 patients (95%). Proteinuria was detected in 28.5%, 28.7% and 32.6% 
and heavy proteinuria was reported in 4.8%, 3.2%, and 4.2% of the groups,
respectively (Table 6.8). Thus, there were no significant differences by
!
duration of daily analgesic consumption with respect to urine protein 
concentration.
A record of the findings on microscopic examination of urine was 
available for 432 patients (93.5%). White cells were reported in 16.2%, 
21.1%, and 33.7% of these groups, respectively (Table 6.9). Since there 
were differences between the groups with respect to age and sex, the data 
were stratified by these factors. The proportions of patients with white 
cells reported in their urine were similar in each stratum except in the 
case of females over the age of 60 years, in whom the proportions increased 
with increasing duration of analgesic use (x^ = 22.8; p < 0.01) (Table 6.10) 
Red cells and/or casts were reported in 2.8%, 4.4% and 2.1% of these groups, 
respectively. Thus, there were no statistically significant differences 
between the three groups with respect to urine protein concentration or 
the findings on microscopic examination of the urine except in the case 
of the urine white cell concentrations in females over the age of 60 years.
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(2) Occasional Consumers: Of the 2,438 occasional analgesic
consumers, 386 (15.8%) admitted taking them for up to one year, 315 
(12.9%) for periods of one to six years, and 1,737 (71.3%) for periods 
in excess of six years. These three groups were compared with respect 
to admission BUN levels and results of urine analysis.
Admission BUN level. The unadjusted mean admission BUN levels in these 
three groups were 20.4, 20.2, and 19.2 mg/100 ml respectively (Table 6.11) 
Since there were differences between these groups with respect to age and 
sex, the data were stratified by these factors. In each stratum the 
mean BUN levels for the three groups were similar.
Urine analysis. A record of urine protein concentration was available 
for 2,317 patients (95%). Proteinuria was detected in 32.1%, 30.4%, 
and 32.4%, and heavy proteinuria was reported in 5.7%, 4.4%, and 4.4%, 
respectively (Table 6.12).
A record of the findings on microscopic examination of urine was 
available for 2,288 patients (94%). lihite cells were reported in 14.8%, 
12.9%, and 17.7% of these groups respectively. Red cells and/or casts 
were reported in 3.6%, 4.6%, and 3.6% of these groups, respectively 
(Table 6.13). Thus, there were no significant differences by duration 
of occasional analgesic consumption with respect to urine protein con­
centration, or the findings on microscopic examination of the urine.
Effect of Missing Values.
From the original 7,017 patients, 331 were excluded because of un­
known BUN levels on admission (4.7%) and 279 were excluded because of
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unknown frequency or duration of analgesic consumption (4.0%). Thus,
8.7% of the original population were excluded from detailed analyses 
(Figure 6.1), To insure that the final conclusions of the investigation 
could not be influenced by these exclusions, the distribution of patients 
with unknown BUN values with respect to medication history was obtained 
and compared with that of the remaining patients (Table 6.14). There 
were no significant differences between these groups with respect to 
medication history.
In addition, the mean BUN level of patients excluded because of 
unknown details of analgesic consumption (20.7 ± 1.2 mg/100 ml) was 
compared to that of the remaining patients (19.5 ± 0.4 mg/100 ml). The 
BUN values from these two groups did not differ significantly (p > 0.2).
Admission due to Adverse Drug Reactions.
Of the 11,526 patients admitted to the monitored hospitals, 829 (7.2%) 
were admitted because of a suspected adverse drug reaction. In eight 
patients (0.07%) the admission was a result of renal disease attributed by 
the attending physicans to analgesic preparations. Of these eight patients, 
six had consumed preparations containing mixtures of aspirin and phenacetin, 
and two had taken aspirin-containing preparations. The mean age of these 
patients was 52 years, their mean admission BUN level was 98 mg/100 ml, and 
mean presenting hematocrit was 27%. Details of each individual are given 
in Table 6.15.
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DISCUSSION
Data on 6,407 consecutive medical patients admitted to hospital 
have been analysed to assess the relationship between regular analgesic 
ingestion and impaired renal function. A history of daily oral analgesic 
use was given by 461 patients (.7.2%),
The present data indicate that the frequency of renal damage as 
measured by a discharge diagnosis of renal disease, elevated presenting 
blood urea nitrogen levels, the presence of proteinuria, or abnormalities 
in the microscopic examination of the urine was not significantly higher 
among regular analgesic consumers, when compared with occasional analgesic 
consumers or patients who denied analgesic consumption. Furthermore, there 
was no evidence of a relationship between increasing duration of analgesic 
consumption and these indices of renal disease, except in the case of 
females over the age of 60 years. In such patients, there was a relation­
ship between increasing duration of daily analgesic consumption and the 
demonstration of white cells in the urine. However, in view of the' large 
number of comparisons made in the present analysis, it is possible that 
this finding —  the only positive one in the present investigation —  could 
have occurred by chance. Moreover, even if it did not, the possibility 
remains that the analgesics were taken by these patients for minor symptoms 
related to their urinary tract. The data provide no evidence of a causal 
association between analgesic consumption and the subsequent development 
of impaired renal function.
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While the data did not show a difference in the frequency of renal 
damage in patients taking salicylate-containing analgesics and those 
taking phenacetin-containing analgesics, the number of patients in the 
latter group was small, and therefore, it remains possible that such a 
difference could exist.
The result of the present study is consistent with data obtained by 
Sorensen (1966) who examined over 2,000 consecutive patients seen in a 
variety of hospitals in Copenhagen, and failed to show a difference in 
creatinine clearance between consumers and non-consumers of analgesic 
preparations.
By contrast, Dubach et al (1968) in a preliminary review of a large, 
prospective study of Swiss watch workers, reported that a history of 
urinary tract illness was more frequent in females who consumed analgesics 
regularly than in those who consumed them occasionally or not at all.
They further showed that females with metabolites of phenacetin in their 
urine at the time of the study had a greater prevalence of bacteriuria, 
hematuria, proteinuria, and elevated serum creatinine levels than those 
who were free of such metabolites. No such relationships were observed 
in males, raising the possibility that the analgesics were taken to 
relieve mild symptoms of urinary tract disorders rather than producing 
them. Although the data reported by Dubach et al were of a cross-sectional 
nature, this study continues and it is likely that these workers will be 
able to report upon the incidence of renal impairment and urinary tract 
illness both among analgesic consumers and among controls in the future.
8 8
Possible explanations for the different results found by many 
other workers (see review by Abel) are firstly, a failure to take into 
account the effects of age on any postulated association between prolonged 
analgesic intake and impairment of renal function; secondly, absence of 
a control population not consuming analgesics; and thirdly, differences 
in the types of analgesics available as over-the-counter preparations.
A further possibility which could account for a relationship between 
analgesic consumption and renal disease is that there is a small group of 
patients at particular risk of developing renal impairment following exposure 
to oral analgesics. In support of this, Prescott (1965) observed that only 
a fraction of normal adults showed evidence of nephrotoxicity as determined 
by renal tubular cell excretion following acute administration of phenacetin. 
The present data do not provide evidence for or against this hypothesis, 
and indeed, are consistent with the possibility that a small proportion of 
long-term analgesic consumers develop impaired renal function as a result 
of this habit. In fact, in the monitored wards eight patients (0.07% of 
admissions) had renal disease attributed by the attending physicians to 
long-term analgesic use.
In conclusion, whatever the true relationship between analgesic con­
sumption and renal impairment may be, this study of a large series of 
hospitalised patients provides no evidence of gradual deterioration in 
renal function with increasing duration of analgesic consumption.
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CHAPTER 7
Adverse Reaction Rates to
Commonly Administered Antibiotics
91
INTRODUCTION
As already described ( p p ^ ' 0 ) ,  the Boston Collaborative Drug 
Surveillance Program (BCDSP) prospectively collects data on drug exposure, 
adverse reactions, drug efficacy, etc., on consecutive admissions to medical 
wards in three countries. The participating hospitals are Massachusetts 
General Hospital, Boston Veterans Administration Hospital, Boston City 
Hospital, Peter Bent Brigham Hospital, and Lemuel Shattuck Hospital in 
Boston, Massachusetts; the Roger Williams Hospital at Brown University, 
Providence, Rhode Island; St. Joseph's and Westminster Hospitals in 
London, Ontario, Canada; and Hadassah Hospital in Jerusalem, Israel.
The data are collected by nurse monitors who review all patients 
admitted to their wards in the above hospitals. Following review and 
editing procedures, the data are then placed on magnetic tape files for 
random access at a later date.
For the present purpose, data pertaining to a group of antibiotics 
were reviewed to give information on the relative frequencies with 
which each drug was administered in the monitored wards, the rates of 
adverse reactions occurring in patients receiving these antibiotics, and 
the frequencies of life-threatening adverse reactions to each antibiotic.
METHODS
The computer was programmed to give details of patients exposed to 
each antibiotic prescribed, the number who develop adverse reactions attri­
buted by attending physicians to these antibiotics, the hospital number
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of each patient developing a reaction, and the proportion who developed 
life-threatening adverse reactions. Thereafter, additional information 
was obtained by scrutinizing the patient's abbreviated record stored on 
microfilm in Boston or, when necessary, the full hospital record of a 
particular patient was obtained from the participating hospital.
RESULTS
Details of the number of patients exposed to the twenty antibacterial 
agents used most frequently in the monitored hospitals are given in Table 7.1, 
together with the frequency of adverse reactions to each drug and a note 
of the type of reaction encountered (Tables 7.1, 7.2).
V&nieiVUnsx Over 1,700 drug orders for the penicillins have been 
monitored, 590 patients receiving aqueous penicillin, 592 receiving 
procaine penicillin, 299 receiving penicillin G (ordered in this form 
rather than aqueous penicillin), and 237 receiving penicillin V. The 
adverse reaction rates to these preparations are low ranging from 
2,9 - 4,6% of patients exposed. Life-threatening adverse reactions 
occurred only rarely with these drugs. The major adverse events attributed 
to the penicillins are allergic reactions (skin rashes, urticaria, and 
pruritus) and complications of injection (usually, pain or haematomata).
In addition, two patients receiving high doses of penicillin G for the 
treatment of septicaemia and peritonitis developed convulsions (Case Reports 
7i and 7ii). Finally, one patient with pneumococcal pneumonia and 
congestive cardiac failure developed hyperkalemia following therapy with 
penicillin (Case Report 7iii).
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Semisynthetie Béni cil tins: The most commonly administered antibiotic
in this large series of patients is ampicillin which was given to 
1,322 of the 10,209 monitored patients (13%). The adverse reaction rate 
observed with this drug was 11.1% —  the predominant reaction being 
skin rash which accounted for 58% (85/147) of all observed reactions 
attributed to ampicillin. The major number of remaining reactions were 
either nausea and diarrhea (45 patients) or superinfection (12 patients),
The other commonly used semisynthetic penicillin is oxacillin 
which was given to 228 patients. The observed adverse reaction rate 
was 6.6%. The major adverse reactions occurring were convulsions which 
developed in two patients, one of whom also received penicillin G 
(Case Reports 7iv and 7v).
Cephalosporins: The preeminent cephalosporin in the United States is
cephalothin. Cephaloridine is rarely used and was only given to 69 
patients in the present series of whom 60 were treated in Israel 
(Hadassah Hospital, Jerusalem),
Of the 530 patients who received cephalothin, 64 (12,1%) developed 
an adverse reaction and of those half (32 patients) complained of 
injection complications (pain at injection site, haematomata, and/or 
transient phlebitis). In addition to skin rashes observed in ten patients, 
two others developed jaundice attributed to the drug and eight sustained 
clinically significant superinfections. Three patients developed impaired 
renal function following administration of cephalothin, usually in 
combination with other nephrotoxic drugs (2 received kanamycin and 1 
received polymixin B),
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Aminoglycosides: Over 630 drug orders were made for streptomycin,
kanamycin, and gentamycin —  the aminoglycosides given parenterally 
for the treatment of infection, and over 500 drug orders were made for 
neomycin and paromomycin —  the aminoglycosides given orally to sterilize 
the bowel (usually in patients with cirrhosis),
a) Streptomycin group. Observed adverse reaction rates varied 
from 3.6% for streptomycin to 14.3% for kanamycin. In particular, 
the low rate observed with streptomycin is noteworthy. Tfo patients 
developed psychosis while taking this drug along with isoniazid
for the treatment of tuberculosis. (It is, however, likely that 
the isoniazid was responsible for this adverse event rather than 
the streptomycin.) Tinnitus and deafness were observed in eight 
patients receiving drugs in this group.
Observed rises in blood urea nitrogen were attributed to 
kanamycin on 17 occasions —  50% of all adverse reactions to this 
drug (See Chapter 8). In addition, four patients developed a 
rise in BUN attributed to gentamycin (again, one half of all 
adverse reactions reported by the attending physicians as being 
related to this drug),
b) Neomycin group. Neomycin and paromomycin were given predominantly 
to patients with severe cirrhosis. The adverse reaction rate to 
neomycin was high (13.9%) —  the major reactions being related to
the alimentary tract. It is, however, interesting to note that 
in eight patients clinically significant rises in blood urea nitrogen
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were attributed to this drug. The adverse reaction rate for 
paromomycin was lower (8.4%) as were the numbers exposed to this 
drug.
Botymixins: Polymixin B and Polymixin E (Colistin) are used inter­
changeably in the monitored wards. The former was given to 63 patients 
and the latter to 65 patients. Since the adverse reaction rates to 
each drug were similar, the numbers were added giving an overall 
adverse reaction rate of 16.4%. The predominant events attributed to 
these drugs were rise in BUN (9 patients) and paraesthesiae (7 patients),
ChtoTamphenioot: This drug was given to 224 patients in the monitored
series. The observed adverse reaction rate was 9.8%. The commonest 
adverse reactions were bone marrow depression (7 patients) and alimentary 
upsets (7 patients). One individual developed jaundice shortly after 
commencing the drug, which was felt to be responsible for the jaundice 
by the attending physician.
Tetracyatine: Next to ampicillin, this is the most commonly prescribed
antibiotic in the monitored wards. The adverse reaction rate is 
relatively low at 6.4%. The major events attributed to this drug were 
alimentary upsets (nausea, vomiting, and diarrhea). In addition, seven 
patients developed a rise in BUN attributed to tetracycline (See Chapter 8) 
and one patient developed hypoprothrombinaemia when started on tetracycline 
during a period of long-term (stabilized) warfarin therapy.
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Erythromyoin: This drug was given to 253 patients of whom 24 (9.5%)
developed an adverse reaction —  the major one being diarrhea (16 patients)
Isoniazid: This, the most active tuberculostatic drug, was given to
361 patients in the series and was implicated in the development of 
adverse events in 16 patients (4.4%). Although this frequency seems 
low when compared to other drugs in the group, many patients were 
admitted to hospital while taking the drug, hence it can be assumed 
that the "true" adverse reaction rate is higher than that observed.
In support of this, the majority of the observed adverse reactions 
(10/16 “ 62%) were severe events which are commonly linked to prolonged 
high-dosage therapy. Psychosis and severe depression was observed in 
six patients, jaundice in three, and a widespread vasculitis in one 
individual.
Sutphonamides: Sulphisoxazole is the member of this group used most
frequently in the monitored wards.(298 patients), Adverse events were 
recorded in 5.4% of patients, the majority being alimentary upsets.
Of particular interest and importance is the development of petechial 
haemorrhages in three patients, none of whom had thrombocytopenia.
In all three cases the lesion gradually recovered on the withdrawal 
of the sulphonamide.
Urinary Antiseptics : These drugs were given to 133 patients. Adverse
reaction rates were 12% for nitrofurantoin (skin rashes, nausea, and 
vomiting) and 4% for nalidixic acid (nausea),
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DISCUSSION
The results presented above give adverse reaction rates for the 
20 most commonly used antibacterial agents in a group of over 10,000 
consecutive admissions to medical wards in the monitored hospitals.
Three aspects of this study are of particular relevance to the management 
of urinary tract infection.
Firstly, the adverse reaction rates to those drugs most commonly 
used to treat urinary tract infection - sulphonamides, nitrofurantoin, 
nalidixic acid, ampicillin and tetracycline are of major interest. The 
reported reaction rates varied from 4% with nalidixic acid (but note 
small numbers of patients exposed to this drug) to 11.1% with ampicillin. 
Although the drug of choice for a particular patient will depend upon 
many factors including the sensitivities of the infecting organism, the 
data presented will provide additional aid in coming to a final decision.
In particular the reports of rise in BUN levels after tetracycline ad­
ministration should, taken in conjunction with its bacteriostatic rather 
than bacteriocidal properties argue convincingly against its use in patients 
with even mild renal impairment (see Chapter 8). Moreover, the high 
frequency of rash among ampicillin recipients will be a factor against 
this drug's use when alternative, less toxic drugs are available.
Secondly, the frequency with which rise in BUN was attributed to 
an antibiotic is of considerable importance and will be separately 
analysed (Chapter 8 ). Despite the absence of full data on sequential 
serum creatinine levels, creatinine clearances etc., it must be con­
sidered likely that a high proportion of patients in the present study
with drug-attributed rise in BUN levels do in fact have considerable
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renal impairment. Drugs reported to cause this complication (the amino­
glycosides, tetracycline and cephalothin) should be carefully evaluated 
before being given to patients with urinary tract infection, particularly 
those with pre-existing impairment of renal function.
Other potential causes of significant deterioration in renal function 
in patients with borderline or actual renal impairment, are factors such 
as severe vomiting or diarrhoea. Drugs most frequently implicated in such 
complications were neomycin (10.7% of exposures), erythromycin (6.3%), and 
ampicillin, chloramphenicol and tetracycline (3,1% to 3,4% each). Although 
these observed rates refer only to the present series of monitored patients 
and are unadjusted for factors such as age, sex and admission diagnosis, 
they can be taken as giving some idea of the relative frequencies of such 
events in other populations receiving these drugs.
Thirdly, since patients with poor renal function due to chronic 
pyelonephritis may develop other types of infection (for example pneumonia, 
septicaemia, etc.), knowledge of the probability of a given adverse reaction 
is of considerable importance. In particular, the development of convulsions 
and hyperkalaemia following penicillin therapy is of major importance and has 
previously been recorded by other investigators (Weinstein et al 1964; New 
and Wells 1965).
One surprising finding is the relative rarity of clinically significant 
super-infection attributed to antibiotics. Such, a complication has been 
reported to occur in about 2.5% of courses of antibiotic therapy, whereas the 
figure observed in the present programme is 0.6% to 0.7%. For a detailed
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review of the factors which contribute to this complication see Weinstein 
et al (1954). These authors observed a superinfection rate of 2.19% 
in 3,095 patients given chemotherapy, and emphasised that the major pre­
disposing factors were age (patients aged less than three years had a 
three to four fold Increase in frequency of superinfection) and infections of 
the ear, particularly the middle ear. If such patients are excluded from the 
data, the prevalence of superinfection falls by a factor of three to four, 
coming closer to that reported in the present study.
Louria and Brayton (1963) reporting on the frequency of superinfection 
following penicillin therapy noted that the rate of this complication was 
proportional to the dose of antibiotic received. There was, however, no 
evidence of this in the group of patients with clinically significant 
superinfection in the present study. Finally, these authors noted that 
only a fraction of the bacteriologically detected cases were clinically 
apparent (the proportion being close to one third).
In conclusion, it must be emphasised that the data presented in this 
chapter are essentially uncontrolled data based on the opinions of the various 
attending physicians in charge of the monitored patients. It is likely that 
a (small) proportion of patients in the study may have developed, for example, 
diarrhoea which was attributed to ampicillin, yet the true cause was not 
the drug, but some other factor. Thus the observed adverse reaction rates 
may be somewhat higher than the "true" rates, because of the occurrence of 
events wrongly attributed to the drugs. Likewise, some events may have 
escaped the attention of the attending physician and hence will not appear
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in the present data. An example of this type of event would be a transient 
abnormality of liver function tests which was disregarded, unnoticed, or 
misinterpreted. For a discussion of the need for controls in drug monitoring 
programmes see Reidenberg and Lowenthal (1968). Despite this limitation, it 
is likely that the rates observed in this study are close to the "true"rates. 
Moreover since any errors are likely to be randomly distributed among the 
various drugs, no systematic bias results from the absence of suitable control 
data.
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CHAPTER 8
Tetracycline and Drug- attributed Rise in
Blood Urea Nitrogen Levels
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A routine computer scanning of the data derived from 10,209 con­
secutive admissions to medical wards monitored by the Boston Collaborative 
Drug Surveillance Program revealed that there was a strong association 
(p < 0,0001) between the adverse event "rise in blood urea nitrogen (BUN)" 
which had been attributed to any drug, and the administration of tetra­
cycline, Whereas 25 of the 147 patients in whom such a rise in BUN was 
reported received tetracycline, the drug itself was only implicated in 
seven instances. This prompted a detailed evaluation of the relationship 
between tetracycline and reported rises in BUN,
METHODS
For the evaluation of this relationship, data from the first monitored 
admission of any patient was considered except where a rise in BUN was only 
reported on a subsequent admission in which case data from only the later 
admission were used.
Patients receiving known nephrotoxic antibiotics were excluded from 
the analysis since any relationship between tetracycline and rise in BUN 
in such patients would probably be obscured by the other antibiotic. The 
drugs excluded were amphotericin, polymixin B, colistin, kanamycin, 
gentamycin, neomycin and paromomycin. A total of 780 patients received 
these drugs, of whom 58 (7.4%) had a recorded rise in BUN. (Included in 
this group of 58 patients were four recipients of tetracycline.)
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The analysis was further confined to diuretic recipients, since 
the vast majority of the remaining cases of reported rise in BUN 
(82/89 = 92%) also received diuretics. The diuretics regularly 
administered in the surveillance wards include chlorothiazide, hydro­
chlorothiazide, hendroflumethiazide, trichlormethiazide, chlorthalidone, 
mercaptomerin, mersalyl, frusemide, triamterene and ethacrynic acid.
Since these drugs were usually given in combination and since the number 
of patients with a rise in BUN was small for each specific drug, the 
diuretics were considered together in further analyses.
Finally, all patients for whom the admission BUN level was not 
recorded were excluded from the analysis (202 patients out of 2,158 - 
9.3%).
The remaining patients who were investigated further, were divided 
into three comparison groups:
Group T - patients receiving tetracycline
Group A - patients receiving any remaining antibiotic 
other than tetracycline
Group N - patients who received no antibiotic
The homogeneity of Group A was verified. All antibiotics in this 
group had similar frequencies of observed rises in BUN.
Factors explored as possibly providing an explanation of the observed 
association between tetracycline and rise in BUN included age, sex, 
admission BUN, survival, first discharge diagnosis in terms of the categories 
of cardiovascular, respiratory, hepatic, neoplastic and other conditions,
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and referring hospital. Frequency distributions of these variables were 
obtained for each of the three comparison groups and also for patients 
with and without a reported rise in BUN.
RESULTS
1. Screening Procedure
Data from 10,209 patients were analysed. A recorded rise in BUN attributed 
to any drug was noted in 147 (1.4%) of patients. Drugs given to patients who 
developed a rise in BUN, with a greater than expected frequency when compared 
to patients who did not have a recorded rise in BUN, are shown in Table 8.1.
2. Detailed Analysis
These were confined to patients who received diuretics and who did not 
receive nephrotoxic antibiotics (as defined in Methods). There were 1,957 
such patients. Their average age was 61 years ; 60% were male; 10.7% died 
while in the monitored wards; and 36,9% had an admission BUN greater than 
25 mg/100 ml. The first recorded discharge diagnosis was of cardiovascular 
disease in 957 patients; respiratory disease in 254 patients; hepatic disease 
in 166 patients; neoplastic disease in 163 patients; and other conditions in 
417 patients. The relationship of discharge diagnosis to treatment group is 
shown in Table 8.2.
Vdlidtty of Comparisons. The numbers of patients in groups T, A, and N were 
204, 596, and 1,137, respectively. The distributions of these groups by 
age and sex were similar and therefore these were not controlled in further 
analyses. In addition, the distribution of patients with rise in BUN and 
those without were similar with respect to hospital, survival and discharge
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diagnosis and so were not controlled further. However, there were 
differences between the comparison groups with regard to admission BUN 
(Table 8,3^and this factor was taken into account in evaluation of the 
relationship between tetracycline-diuretic receipt and recorded rise 
in BUN.
Tetraeyotine and Rise in BUN (Table 8, 4^Figure 8.1). The observed, 
unadjusted frequency of drug-attributed rise in BUN among diuretic 
recipients was 9.8% for Group T, 3.5% for Group A, and 3.4% for Group N.
These frequencies are not fully comparable in view of the difference 
between groups in terms of admission BUN. The subjects were thus 
stratified by admission BUN. There was a higher frequency of recorded 
rise in BUN in the tetracycline group in each stratum. Using the Mantel 
Haenszel technique (Mantel and Haenszel 1959) the differences between 
Group T and A, and separately between Groups T and N were found to be 
significant at p values of less than 0.001 and 0.0005, respectively.
The pooled estimates of relative risk were 3.0 (99% confidence limits .
1.2 - 7.3) and 2.8 (99% confidence limits 1.3 - 6.1), respectively.
The mean admission BUN level in patients in groups T, A, and N 
who had a reported rise in BUN was 34, 41, and 31 mg/100 ml, respectively, 
and in those with no reported rise in BUN was 27, 32, and 26 mg/100 ml
respectively (Table 8.3). The mean rise in patients with a recorded
rise in BUN was 28 mg/100 ml (range 6 - 7 7  mg/100 ml). The mean rises 
in groups T, A, and N were 34, 33, and 22 mg/100 ml, respectively (Table 8.5). 
In five of the 20 patients in group T serial creatinine levels were avail­
able and of these, four had a rise in creatinine recorded at the time of
the rise in BUN (Case Reports 8i, 8ii) .
1 0 6
DosSj Route and Time Relationships, There were no differences in the 
mean daily dose and route of administration of tetracycline between 
patients with reported rises in BUN and those without.
In 18 of the 20 cases of rise in BUN in association with tetracycline- 
diuretic exposure, tetracycline was administered within one week prior to 
the reported rise. In the remaining two instances, one patient received 
tetracycline eight weeks before and the other three weeks after the 
detected rise in BUN. These latter cases were not excluded from the 
analysis since it is likely that similar cases were to be found in the 
two comparison groups (A and N), In these groups, however, the fact that 
many drugs were involved in the rises in BUN, provided considerable 
difficulties in determining which one should be reviewed for the purpose of 
exclusions,
diagnoses. Of the 18 patients who received tetracycline and diuretics 
prior to the reported rise in BUN, 11 received the drug for treatment of 
respiratory infections and 7 for urinary tract infections. The major dis­
charge diagnosis in these patients was congestive cardiac failure - seven 
patients, chronic bronchitis - five patients, cirrhosis (alcoholic) - 
three patients, neoplasm (colon) - one patient, gastric ulcer - one patient, 
diabetes mellitus - one patient.
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DISCUSSION
Although several authors have drawn attention to the development of 
a rise in BUN following tetracycline therapy (Shils 1962, 1963; Lew and 
French 1966; Roth et al 1967; Perkash et al 1969; George and Evans 1971) 
this adverse event is not yet sufficiently well recognised (Eastwood et 
al 1970; Edwards et al 1970).
Shils (1962) treated patients with this drug under standardised 
conditions in a metabolic ward and concluded that it causes a negative 
nitrogen balance which he attributed to an inhibition of protein synthesis. 
Subsequently, he emphasized that this side-effect may be clinically more 
important in patients with renal failure, presumably because of a failure 
on the part of the kidney to handle the additional load of urea (Shils 1963). 
More recently, Korkeila (1971) has suggested that the tetracyclines should 
be avoided in patients receiving parenteral nutrition since the antianabolic 
effect of tetracycline interferes with effective use of the administered 
protein leading to further elevation of BUN levels. Whereas several of 
the above authors have concluded that the rise in BUN associated with 
tetracycline could be explained on the basis of an antianabolic effect alone, 
it has been noted that an additional toxic effect on the kidney could not be 
ruled out. (Shils 1963; Lew and French 1966; George and Evans 1971;
Polec et al 1971) Of additional interest, Kuzucu (1970) has reported the 
development of renal failure in five patients given tetracycline and methoxy- 
flurane concurrently. This drug is an anaesthetic agent which has been shown 
to have a marked diuretic effect in some individuals (Crandell and MacDonald 
1968).
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Finally, in contrast to tha above reports, tetracycline which has 
been improperly stored may form degradation products which themselves 
are strongly nephrotoxic, producing a marked lesion in the renal tubules 
(Gross 1963; Benitz and Diermeier 1964).
The present study of a large series of hospitalised medical patients 
is the first systematic evaluation and verification of the existence of 
an association between tetracycline therapy and clinically important rises 
in BUN level. When this drug was given in association with diuretics, 
the recorded freqeuncy of this event was threefold relative to patients 
receiving diuretics without tetracycline. The statistical significance of 
the difference between tetracycline recipients and those in the comparison 
groups was high and the association remained strong even when taking into 
account various patient characteristics by stratifying the results.
Although there was no apparent relationship between the rise in BUN 
and dose or route of administration of tetracycline, the time relationship 
between tetracycline exposure and rise in BUN is striking, in that 18 of 
the 20 patients received tetracycline within one week prior to the record 
of the rise.
While the evidence thus points to a causal relatidmship between the 
tetracycline therapy and the recorded rise in BUN, ther® remains the 
possibility that it results from physician bias. Had there been no prior 
suspicion of this association, this would pose no problems. However, as 
already indicated, there is within the literature evidemce pointing to this
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possibility and in five cases in the present study, tetracycline itself was 
implicated, along with diuretics, as a cause of the rise in BUN. Thus the 
observed association could at least in part be attributed to physican bias. 
However, on clinical grounds, it seems unlikely that such bias could fully 
explain the large differences observed between tetracycline recipients and 
those in comparison groups, particularly when the analyses were confined to 
diuretic recipients.
Because of the nature of the system of data collection, the observed 
frequencies of rise in.BUN in the three comparison groups are likely to 
be underestimates of the true frequencies since only those rises detected 
and deemed to be drug-related are recorded.
The mean rise in BUN in the current series was considerable 
(28 mg/100 ml) and of obvious clinical importance. It was frequently 
associated with overt symptoms such as nausea and vomiting, and in all 
cases prompted dis continuation of the suspicious drug(s) by the attending 
physician. It is likely, however, that the magnitude of this rise is an 
overestimate of that which would be found in a prospective survey of a group 
of tetracycline recipients since it can be assumed that a greater pro­
portion of large as opposed to small rises were detected by the monitoring 
system.
Patients in the tetracycline-diuretic group who developed a rise in BUN 
had admission levels of BUN which were higher than those who did not, suggesting 
that those with pre-existing renal impairment are more prone to develop this 
complication.
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Little information ia available from the monitoring system on the 
tendency of tetracycline to produce uremia in the absence of diuretics, 
because a search for this event is generally prompted by diuretic treat­
ment. In addition, the data from this study do not allow for speculation 
as to the etiology of the tetracycline-associated rise in BUN, particularly 
as the finding relates to patients who received other drugs (i.e., 
diuretics) which act on the kidney. However, the finding of a coincidental 
rise in creatinine levels in four of five cases in the tetracycline group 
where this information was available, suggests that at least in those cases 
deterioration in renal function was a factor in the observed rise. Moreover 
since the point of entry to the study was a drug-attributed rise in BUN, 
such factors as high protein intake and gastro-intestinal haemorrhage are 
automatically excluded. Of the remaining possible causes of elevation in 
BUN levels (Dossetor 1966), dehydration and renal impairment are the two 
major possibilities. Although the necessary details were not recorded in 
many instances, it is likely that deterioration in renal function was the 
major cause of the rise in BUN levels in 14 of the 18 patients in whom 
tetracycline therapy preceded the rise.
In conclusion, the data presented provide evidence that tetracycline 
therapy in patients with conditions which require diuretic therapy, is 
associated with an enhanced risk of developing clinically significant uremia, 
particularly in patients with an initially elevated BUN level. It therefore 
seems advisable to avoid tetracycline in these patients when alternative 
antibiotics can be administered.
STATISTICAL ANALYSES
The comparison of the frequency of recorded rises in BUN within
two subsets of groups T and A (those with presenting BUN levels below
2
and above 25 mg/lOO ml) is made by computing the pooled % value with 
one degree of freedom. Thus, using the terminology —
’^1
Cl di Cl + di
ai + Cl bi + di li­
the expected value for ai(Eai) = (S]_ + c%) (^ 1 bj)
“1
the variance of ai (Vap = ■81..+ (ci + d ^
ij(nin?(n, - 1)
[ a.d. - b.c. 9] (n-j - 1)
(a^ + c^ )(b^  ^+ d^)(a^ + b^) (c^ + d^ )
[|lai - ZE(ai)| - 1/2]^
2V(ai>
= [120 - 10.531 - 1/2]^
when comparing groups T and A
7.35
= 10.954
giving p < 0.001
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Similarly, when comparing groups T and N
X^' = [120 - 9.691 - 1/2]^
7.59
= 12.67
giving p <0.0004
In calculating the pooled estimates of relative risk from two 
fourfold tables, the formula used was
^1^1 ^  ^ 2^ 2
Pooled estimate of relative risk = ^2
^1 1^ b^c^
  +
ni n^
and so in comparing groups T and A
8 X 328 ^ 12 X 247
Pooled estimates of relative risk = — -----
5 X 104 ^ 80 X 16
445 ■ 355
= 2.98
and similarly in comparing groups T and N
8 X 770 12 X 348
Pooled estimates of relative risk = ___-------------------
104 X 20 ^ 80 X 19
902 459
= 2.84
To apply the 99% confidence limits around the pooled estimates of 
relative risk, the formula used was —
11 3
99% confidence limits = pooled estimate of ± |-2.58 x standard errorj
relative risk of the mean
The resulting confidence limits are not symmetrical about the 
relative risk since the standard error is of a logarithmic type. For 
a detailed discussion of the statistics involved in this chapter, see 
Armitage (1971).
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APPENDIX
In the course of investigating the relationship between tetracycline 
and recorded rise in BUN, patients receiving nephrotoxic drugs were ex­
cluded from the analyses since these would tend to obscure the effect of 
tetracycline. However, in view of the suggestion that diuretics may 
enhance the nephrotoxicity of various antibiotics (see Chapter 9.), these 
data were further explored to assess the relationship between nephrotoxic 
drugs, diuretic administration and recorded rises in BUN.
For the purpose of this analysis the data were stratified by diuretic 
usage, the diuretic drugs being those enumerated in METHODS. Whereas 
in general tetracycline administration does not lead to a regular search 
for elevation in BUN levels, such a search is likely to occur, follow­
ing the administration of nephrotoxic antibiotics. Thus while it is 
not possible to compare the frequency of rise in BUN amongst tetracycline 
recipients who did not receive diuretics with those who did, such a 
comparison is valid in the case of recipients of nephrotoxic antibiotics.
. A total of 780 patients received nephrotoxic drugs (METHODS) of 
whom 733 (94%) had a recorded admission BUN level available. The analyses 
were therefore restricted to these 733 individuals of whom 57 (7.8%) 
had a recorded rise in BUN. The frequency of recorded rises in BUN for 
each antibiotic in the group is given in Table 8.6,together with this 
data analysed by diuretic usage. In this table a patient is counted 
more than, once if he or she received more than one of these antibiotics.
In all cases the proportion of diuretic recipients who developed a rise 
in BUN was greater than the proportion of non-recipients who developed 
a rise.
Since neomycin and paromomycin are given in the monitored wards
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predominantly for the therapy of severe hepatic disease, a condition 
which is not infrequently associated with renal failure (Sherlock 1968 ), 
further analyses were confined to patients receiving only kanamycin, 
gentamycin, polymixin, colis tin, and/or amphotericin. There were 327 
such patients of whom 9.8% developed a rise in BUN (Table 8.7). The 
frequency of recorded rise in BUN was greater amongst diuretic recipients 
(16/110 = 14.5%) than amongst non-recipients (16/217 = 7.4%) although 
this difference does not reach the conventional levels of statistical 
significance (%^ = 3.48 p = 0.06).
In addition direct comparison of diuretic users with non-users 
within this set of antibiotic recipients is not valid without taking 
into account other variables such as age-, sex, hospital and survival.
A review of the data revealed that the distribution of these comparison 
groups by hospital and by sex were similar and hence these variables 
could be disregarded in further analyses. However, both age and 
survival were positive confounding factors - that is diuretic users were 
both somewhat older, had a poorer prognosis in terms of survival and 
had a higher proportion of recorded rises in BUN than did the non­
users. While the effect of these variables on the final result could 
be taken into account using the Mantel-Haenszel proceedure as 
described previously, this was not done since the association was in­
sufficiently strong to warrant further pursuit.
It is concluded that, on the evidence available at present, the 
clinical relevance of a potential interaction between nephrotoxic anti­
biotics and diuretics has not been proven within the data of the Boston 
Collaborative Drug Surveillance Program. The evidence, however, is suggestive 
of such an effect, and it is likely that, with accumulation of more data, this 
interaction may be demonstrated in the future.
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CHAPTER 9
Effect of Frusemide on An tib io t ic - induced Renal Damage
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In a recent study of factors involved in the pathogenesis of acute 
renal failure in man, it was noted that of forty consecutive patients 
treated for this condition in a renal unit, seventeen had received 
cephaloridine in the few days preceding the onset of the condition 
(Lawson et al 1970). Other antibiotics had been given much less frequently 
(five had received tetracycline, three ampicillin, and one kanamycin). In
addition, fifteen of these seventeen patients had also been given diuretics
!
concurrently with the antibiotic, an observation which raised the possi­
bility of an interaction between these drugs leading to the development 
of acute renal damage. The present study was designed to investigate 
the possibility that the administration of antibiotics and diuretics 
to patients with mild transitory renal impairment after surgery, de­
hydration or trauma, might result in frank acute renal failure.
This report describes a series of animal experiments in which transitory 
renal impairment was induced with glycerol, and the effect of various 
combinations of antibiotics and a diuretic on renal function and histology 
was studied.
METHODS
Female rats aged between eight and 12 weeks and weighing between 100 
and 350 grams were used for the experiments. All received a commercial 
diet free of antibiotics and were given unlimited access to fluids during
20
the course of the experiment. Groups of animals were lightly 
anaesthetised using chloroform. Normal saline, glycerol B. P. diluted 
with normal saline, antibiotics or frusemide were injected subcutaneously 
either singly or in various combinations. Where appropriate, blood was 
taken at 90 minutes for assay of serum antibiotic levels. This was 
obtained from a ventricle after a brief chloroform anaesthetic.
The animals were sacrifised at 48 hours and blood was taken for 
urea estimation. The kidneys were removed and submitted for pathological 
examination under code. The tissues were fixed in 10% formo1-saline, 
embedded in paraffin and sections stained with haematoxylin and eosin. 
Each kidney was assigned to one of three histopathological sub-groups:
1. Normal kidneys. (Figure 9.1)
2. Focal proximal tubular necrosis, in which there was 
evidence of patchy areas of proximal tubular cell necrosis 
and regeneration, with mitotic activity occurring in more 
than five separate areas of one cut surface of the kidney. 
(Figure 9.2)
3. Diffuse proximal tubular necrosis, in which the lesions 
were more widespread and more severe than in Category 2.
(Figure 9.3)
Serum concentrations of antibiotic were determined by a diffusion 
technique with serial dilutions of serum where necessary (Humphrey and
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Lightbown 1952), Assays of cephaloridine, cephalothin, and kanamycin 
were performed using bacillus subtilis as test organism and those of 
colistin using a sensitive strain of bordetella bronchiseptica.
The experiments were carried out on a single strain of rat except 
where noted.
RESULTS
Control animals injected with normal saline in volumes of one ml 
and 4 ml showed no evidence of renal damage 48 hours after the injection. 
Similarly, frusemide in doses of 50 and 150 mg/kg produced no changes in 
renal histology, or elevation of the blood urea above 40 mg/100 ml. By 
trial and error, a dose of glycerol (2 ml/kg) was obtained which consis­
tently produced patchy focal acute tubular damage in about 50% of the 
animals studied. When a group of eight animals was given glycerol 2 ml/kg 
in combination with frusemide 50 mg/kg the effect was similar to that 
observed with glycerol alone.
Nephrotoxicity of cephaloridine alone. Table 9.1 shows the effect of 
various doses of cephaloridine on renal histology and function. With 
cephaloridine doses ranging from 250 mg/kg to 1 g/kg, mean blood urea 
levels in these groups did not differ, although there was a positive 
association between the dose of drug given and the number of rats sus­
taining focal acute tubular necrosis (regression coefficient 0.33 ± 0.09: 
p < 0.01)— Snedecor and Cochrane (1967).
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Nephrotoxicity of cephaloridine with frusemide or glycerol. Groups of 
rats given cephaloridine in a dose of 500 rag/kg plus frusemide 50 mg/kg 
did not exhibit increased nephrotoxicity when compared with rats given 
cephaloridine alone. Coincidental administration of cephaloridine 
(500 mg/kg) and glycerol (2 ml/kg) did not produce significant elevation 
of blood urea levels at 48 hours, nor did the combination lead to more 
severe pathological changes than those observed with glycerol alone.
Thus there was no evidence of an interaction between cephaloridine and
either frusemide or glycerol alone. Mean blood levels of cephaloridine 
at 90 minutes after injection in these animals were similar to those 
observed in animals given cephaloridine (500 mg/kg) alone.
Nephrotoxicity of cephaloridine^ glycerol and frusemide. The effect of 
administering various doses of cephaloridine to animals also receiving 
glycerol (2 ml/kg) and frusemide (50 mg/kg) is shown in Table 9.2. This
experiment was performed on two different strains of rat. In both strains
the proportion of animals sustaining renal damage (irrespective of 
severity) was positively associated with the dose of cephaloridine 
injected— in the case of strain A the regression coefficient was 0.18 + 0.04 
(p < 0.001), and with strain B, the regression coefficient was 0.27 +. 0.05 
(p < 0.0001). There were no statistically significant differences between 
these two slopes (p > 0.05) or between these slopes and the previously 
observed regression lines for cephaloridine alone (p > 0.05).
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Nephrotoxicity of cephalothin. The effect of substituting cephalothin 
for cephaloridine is shown in Table 9.3. These experiments were per­
formed on animals of strain B. Cephalothin alone produced minor 
pathological changes but no elevation of blood urea in a group of rats 
given the drug in a dose of 1500 mg/kg. However, the addition of 
glycerol (2 ml/kg) and frusemide (50 mg/kg) produced marked elevation 
of blood urea in groups of animals given cephalothin in doses of 500 mg, 
1,000 mg and 1,500 mg/kg. The proportions of animals showing histological 
evidence of renal damage was positively associated with cephalothin dosage 
(regression coefficient 0.42 + 0.09: p < 0.001). t'Jhen this coefficient 
was compared with that calculated from the data on rats in strain B who 
received cephaloridine with glycerol and frusemide (0.27 + 0.05) there 
was no statistically significant difference between the coefficients 
(p > 0.2). Rats receiving cephalothin in a dose of 1 g/kg together 
with frusemide and glycerol sustained extensive tubular necrosis at 
mean serum cephalothin levels of 113 yg/ml (range 73 - 132 yg/ml), close 
to that obtained in routine clinical practice.
Nephrotoxicity of colistin sulphomethate. The results of-a similar 
study using colistin sulphomethate as the antibiotic are shown in Table 9.4 
In a dose of 8 mg/kg this drug did not produce biochemical or histological 
evidence of nephrotoxicity, either alone or in combination with glycerol 
and frusemide. However, when colistin was given in a dose of 24 mg/kg, 
with glycerol and frusemide, the majority of animals developed extensive 
tubular necrosis. Since this occurred at dosage and serum antibiotic 
levels which were considerably higher than those attained in clinical 
practice, further experiments were not undertaken with this drug.
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Nephrotoxicity of ’kanamycin. A study of the nephrotoxic effects of 
kanamycin alone and in combination with glycerol and frusemide again 
revealed increased damage when the drugs were given in combination 
(Table 9.5). However, the dose of kanamycin required to show this 
effect and the resulting serum kanamycin levels were much higher than 
those normally attained in practice.
DISCUSSION
Antibiotics and diuretics are regularly given together to patients 
who may at the time be suffering from renal impairment of either a 
temporary or a permanent nature. The clinical observation that a 
greater than expected number of patients suffering from acute renal 
failure after surgery or trauma had been exposed both to cephaloridine 
and diuretics led to the design of this experiment (Lawson et al 1970).
In an attempt to mimic the clinical situation of patients who had 
suffered mild transient renal impairment, small doses of glycerol were 
given to rats. The dose used was determined by trial and error and was 
enough to produce only mild and reversible pathological changes in the 
rat's kidneys. The cause of glycerol-induced acute renal failure was 
initially thought to be intravascular haemolysis (Carroll et al 1965; 
Oken et al 1966), but subsequently Thiel et al (1970) showed that saline 
loaded animals given glycerol do not develop acute renal failure despite 
having severe intramuscular haemolysis. In addition, Hayes et al (1970) 
showed that prior injection of glycerol protects animals against acute
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renal failure produced by a second injection of glycerol, a finding 
which is not compatible with intravascular haemolysis as a primary 
cause of renal failure. One possible explanation of these findings 
is that glycerol induces acute renal failure via the renin/angino tens ion 
system. Since Brown et al (1970) have implicated renin release as a 
possible factor in the development of acute renal failure in humans, 
it seemed appropriate to use glycerol-induced tubular damage as a
model of the clinical situation in the present studies.
l'
Cephaloridine is kno^m. to be nephrotoxic in animals and man (Atkinson 
et al 1966; Perkins et al 1968; Foord 1969). In rats one gram to 1.4 grams 
per kilogram body weight will produce proximal tubular necrosis in over 
half of the animals examined 48 hours after the injection (Currie 1967). 
Similar results were obtained in the present investigation. Tuano et 
al (1966) suggested that cephaloridine nephrotoxicity was a dose related 
condition, and Foord (1969) supported this view, stating that renal 
damage was rare in humans if the blood levels of antibiotic were main­
tained below 100 yg/ml. In rats, Dodds and Foord (1970) noted that 
frusemide had an enhancing effect upon the degree of renal damage caused 
by cephaloridine but the doses these workers used were similar to those 
required to produce renal damage in over half the rats injected with this 
substance alone (LD^Q = 1 - 1.4 g/kg). In the present experiments, 
significant renal damage was produced in rats given glycerol and frusemide 
together with a cephaloridine dose varying from one-twelfth to one-third 
of the kno\fn nephrotoxic dose for rats. The extent of damage inflicted 
when cephaloridine was given in a dose of 500 mg/kg was severe, as
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indicated by the extensive histological changes and the markedly 
elevated blood urea levels 48 hours after the challenge.
Cephalothin is thought to be less nephrotoxic than cephaloridine 
when given to animals in identical circumstances (Perkins et al 1968). 
However, Thobum and Fekety (1970) have reported cases of deterioration 
in renal function following treatment with cephalothin in combination 
with other potentially nephrotoxic antibiotics. The present experiments 
reveal that cephalothin, like cephaloridine, exhibits enhanced nephro­
toxicity in rats when combined with glycerol and frusemide. Although 
the dose of cephalothin required to produce extensive acute tubular 
necrosis was higher than with cephaloridine the damage was apparent 
at serum levels of cephalothin close to those obtained in routine 
therapeutics.
Colistin is a polypeptide antibiotic largely excreted in the 
urine and has a considerably prolonged half-life in patients with 
renal failure (Goodwin and Friedman 1968). It has been reported to 
cause a major but transitory fall in glomerular filtration rate which 
may revert to normal on stopping the drug (Brumfitt et al 1966, Price 
and Graham 1970). Vinnicombe and Stamey (1969) failed to demonstrate 
a nephrotoxic effect of colistin given intravenously to dogs. Although 
in the present experiment colistin was associated with increased 
nephrotoxicity in rats when combined with glycerol and frusemide, this 
occurred at serum levels many times greater than those achieved clinically.
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Similarly, with kanamycin, an antibiotic known to be ototoxic 
and nephrotoxic, enhanced nephrotoxicity was demonstrated when it 
was combined with frusemide, but only at serum kanamycin levels 
approximately four times higher than the recommended maximum in 
humans.
The present experiments indicate that in the rat suffering from 
transitory renal impairment caused by the injection of glycerol, the 
nephrotoxicity of four antibiotics (cephaloridine, cephalothin, 
colistin, and kanamycin) is enhanced by coincidental administration 
of frusemide. In the case of cephaloridine and to a lesser extent, 
cephalothin, this damage occurs at blood levels of antibiotic within 
or near the normal therapeutic range, whereas with colistin and 
kanamycin the effects occur at considerably higher blood levels.
It is possible, therefore, that an interaction between diuretics and 
antibiotics leading to renal damage is most likely to be detected 
among recipients of cephaloridine who have mild, preexisting renal 
disease.
The mechanism of the interaction has not yet been elucidated. 
However, one possible explanation is that the renin/angiotension 
mechanism is involved. Both glycerol and frusemide are known to 
stimulate renin release into the peripheral circulation. Were these 
antibiotics to do likewise, it is possible that the combined effect 
would be great enough to lead to the onset of acute renal failure.
12b
Another possible cause is that suggested by Stewart (1967) who noted 
that the peptide antibiotics, penicillin, cephalosporin and bacitracin 
tend to polymerise in solution. Such polymers of cephaloridine contain 
the allergenic fraction of the drug, and they may also be responsible 
for the nephrotoxicity, since when injected into suitable animals at 
low doses, they are associated with the development of more severe 
renal damage than a similar dose of the depolymerised fraction (Stewart
1968) and do so at blood levels which are considerably lower than those
I
obtained after injection of the depolymerised fraction. Injected 
cephaloridine is knoim. to concentrate in the proximal renal tubules 
within one hour of administration (Currie et al 1966; Silverblatt 1970).
If the concentration of this drug or its metabolites were increased in 
the proximal tubular cell by having water reabsorption into the cell 
inhibited, as for example, is knoïvn to occur with frusemide (Suzuki et 
al 1964), it is possible that polymerisation could take place in vivo 
in this cell. A third possible explanation is that the mild renal damage 
.induced by glycerol rendered the rats more sensitive to the natriuresis 
induced by frusemide, resulting in considerable reduction in the intra- 
vascular space.. This in turn could lead to significantly higher plasma 
(and later tissue) levels of the nephrotoxic antibiotics. In support of 
this hypothesis the plasma levels of both cephaloridine and cephalothin 
ninety minutes after the injections were somewhat higher in animals 
receiving glycerol and frusemide than in those not receiving these drugs. 
However, the differences in blood levels were not statistically significant 
and the time interval between the injections and this observed difference
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was small (90 minutes) suggesting that factors other than simple 
dehydration of the animals would be required to explain the findings.
Whatever the pathophysiology of these effects, the above experiments 
give added confidence to the clinical observation that the administration 
of cephalosporin antibiotics, particularly cephaloridine, in combination 
with frusemide may be dangerous in patients with even mildly impaired 
renal function.
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CHAPTER 10
Cephaloridine- induced Renal Damage;
Studies in  Rabbits
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Cephaloridine is known to be nephrotoxic both to man and to a 
wide range of animal species (Linsell et al 1967; Perkins et al 1968; 
Atkinson et al 1966a). This toxicity is related to the total dose 
administered at any single time, varies in magnitude from species to 
species, and is greatest in the rabbit (Currie 1967). Daily admin­
istration to rabbits of a subnephrotoxic dose of the drug over a 
prolonged period has been reported to be free of significant nephro­
toxic effect (Atkinson et al 1966b).
The sensitivity of a species to the nephrotoxicity of cephaloridine 
appears to be directly related to the extent of metabolism of the drug 
by that species. In the rabbit, Silverblatt et al (1970) showed that 
histological damage confined to the proximal tubule could be observed 
under the electron microscope within one to five hours of an injection 
of 200 mg/kg cephaloridine. In addition these workers noted the appear­
ance of membranous profiles in the proximal tubular cells of treated 
animals. The origin of these profiles was not fully determined, but in 
the opinion of the authors they could be either remnants of disrupted 
cell constituents or newly synthesised membranes such as endoplasmic 
reticulum.
Proliferation of smooth endoplasmic reticulum occurs in the liver 
cells of animals treated with barbiturates, DDT, alcohol and many other 
drugs (Conney 1967) and this effect is associated with increased activity 
of several groups of drug-metabolizing enzymes. The enzyme inducing
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effect of phenobarbitone also can be shown in tissues other than liver 
(Conney 1971) and has been clearly demonstrated in rabbit kidney (Uehleke 
and Greim 1968),
The present studies were designed to assess both the effect of 
phenobarbitone on the metabolism and nephrotoxicity of cephaloridine in 
rabbits^ and also the nephrotoxic effect of two doses of this drug separated 
by one week.
METHODS
Thirty female New Zealand white rabbits were used for the experiments. 
They weighed between 1.5 and 2.5 kg and had been reared in an antibiotic- 
free environment. During the course of the experiments they were given 
unlimited access to food and fluids.
At the onset, two animals were killed for control purposes. They 
were lightly anaesthetised using chloroform and then sacrifised by direct 
dislocation of the cervical spine. The kidneys were immediately removed, 
examined and fixed for histological examination.
Effect of repeated blood sampling on renal histology. Three animals were 
given an injection of 2 ml normal saline and serial blood samples (2 to 3 ml 
each time) were withdrawn from the marginal vein of the ear at regular inter­
vals up to five hours after the injection, A total of nine samples were 
taken during this time. This process was-repeated seven days later and the 
animals sacrifised 48 hours after the second injection of saline. The
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kidneys were removed and examined as described above. In addition, 
blood was taken at the time of death for subsequent estimation of 
serum creatinine levels.
Effect of a single dose of cephaloridine (Group S animals). Four 
animals were given intravenous cephaloridine (50 mg/kg) directly into 
the marginal vein of the ear. Two were sacrifised at 48 hours and 
two at 220 hours after the injection. The kidneys were examined as 
described previously. A further five animals were then given 100 mg/kg 
cephaloridine in the same manner, three being sacrifised at 48 hours and 
two at 220 hours.
Effect of two doses of cephaloridine (Group C animals). Four animals 
were given two doses of 50 mg/kg cephaloridine intravenously separated 
by seven days and were then sacrifised 48 hours after the last dose 
(giving the time from the initial dose to sacrifise of approximately 
220 hours). Later, a further group of four animals were given two 
doses of 100 mg/kg cephaloridine separated by seven days and sacrifised 
forty-eight hours after the last dose. In all cases blood was taken at 
the time of death for estimation of the serum creatinine levels.
Effect of phenobarbitone on cephaloridine metabolism and toxicity 
(Group P animals). The experiments outlined in the preceding paragraph 
were repeated with the addition that six hours after the initial dose of 
cephaloridine each animal was injected intraperitoneally with phenobarbitone 
in a dose of 15 mg/kg. This injection was repeated daily for six consecutive 
days.
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Pharmaoo'kinet'ic studies. These were performed on all animals receiving 
two injections of cephaloridine. During the studies the animals were 
kept in metabolic cages and all urine pased for the 24 hours after each 
injection was collected and assayed for antibacterial activity.
Immediately after each injection of cephaloridine and at regular 
intervals thereafter up to a maximum of five hours, blood was withdra;fn 
from the marginal vein of the opposite ear, allowed to clot and the 
serum separated. The serum was then frozen at -4^C until it was assayed 
for cephaloridine level by the method described by Humphrey and Lightbo\m 
(1952), as modified by Bennett et al (1966). All assays were performed in 
quadruplicate.
The results were analysed with the aid of a computer which was 
programmed to give the following information:
1. An equation for the regression line between the logarithm of 
the observed plasma concentration of cephaloridine and the time 
from injection. This was calculated by the method of least 
squares and from it the half-life of the drug in serum was 
calculated (t^/2)*
2. The hypothetical serum concentration at the time of injection (C^^) 
was calculated by extrapolating the regression line back to time 
zero.
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3, From this calculated serum concentration at time zero (G^q ) 
the volume of distribution of the drug in the animal (V^) was
estimated ;
V , = Dose given (in yg)
d CgQ (in yg/L)
litres
4. From the observed elimination rate constant (k -i = — - )
t 1/2
and the volume of distribution (V^) , the body 
clearance of the drug (Gig) could be calculated:
(Figure 10.1)
RESULTS
I. HISTOLOGICAL DATA
The appearance of normal rabbit kidney prepared under the conditions 
of this experiment is demonstrated in Figure 10.2. The histological appear­
ances of the kidneys removed from animals who sustained repeated vene­
punctures following a control injection of saline were within normal limits.
Effect of a single dose of cephaloridine (Group S). Histological examination 
of the kidneys of animals receiving a single injection of antibiotic revealed 
no consistent abnormalities in individuals sacrifised at 48 hours after in­
jection of 50 mg/kg or 100 mg/kg cephaloridine. In animals receiving the 
lower dose and killed at 220 hours, the appearances were again normal, 
whereas in those receiving the higher dose some dilatation of the distal
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convoluted tubules and collecting ducts was present. In one of the 
latter group there was also mild fatty degeneration of the proximal 
convoluted tubule with patchy calcium debris in the lumen of both 
proximal and distal tubules.
Effect of two doses of cephdtoridine. There were no significant 
differences between the histological appearances in the animals 
receiving phenobarbitone (Group P) and the controls (Group C).
Eight animals received 50 mg/kg cephaloridine on two separate 
occasions one week apart, and were killed 48 hours after the second 
injection. All animals showed evidence of mild proximal tubular damage 
with pyknosis of the nuclei and cloudy swelling of the cytoplasm. In 
addition, the majority of the animals had granular casts in the distal 
tubules and collecting ducts (Figure 10.3). Only one of these animals 
had calcification present in the tubular lumina.
Eight animals received 100 mg/kg cephaloridine on two occasions.
All showed proximal convoluted tubular damage to a varying degree, with 
cloudy swelling, loss of brush border and nuclear pyknosis prominent in 
five animals. In six of the eight there was evidence of widespread calci­
fied debris present in the tubular lumina particularly in the outer 
cortical segment of the kidney (Figures 10.4 and 10.5).
The mean serum creatinine level at death of animals receiving 50 mg/kg 
doses was 0.8 + 0.1 mg/100 ml and of those receiving 100 mg/kg 1.4 + 0.1 mg 
per 100 ml (t = 7.99, p < 0.001).
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II. PHARMACOKINETIC DATA
The mean half-life of cephaloridine after the initial injection was 
similar in the animals assigned to Group P and Group C, being 41.7 + 4.9 
minutes and 37.3 + 3 . 2  minutes, respectively. Following treatment with 
phenobarbitone of those animals assigned to Group P, the second serum 
half-life was again similar in the two groups being 44.3 + 7,6 minutes 
in Group P and 43.9 + 7.6 minutes in Group C (Tables 10.1 and 10.2).
The volume of distribution of cephaloridine in those animals assigned 
to Group C was similar after the first and second injections (669 + 62 ml 
and 640 + 75 ml, respectively). However, the mean volume of distribution 
of cephaloridine in the treated animals (Group P) was somewhat lower after 
the second injection (581 + 40 ml) than after the first one (732 + 6 3  ml) 
although the results were not statistically significant (t = 1.99;
0.1 > p > 0.05),
The body clearance of cephaloridine was similar after each injection 
of drug both in Group P animals (13.1 + 2 . 3  and 11.3 + 2.2 ml/minute, 
respectively) and in Group C animals (12.7 + 1 , 1  and 11.5 + 2,0 ml/minute, 
respectively) (Tables 10,1 and 10.2),
As an indication of the accuracy of the regression lines from which 
the values of half-life and volume of distribution of drug were calculated, 
the observed and "expected" values for serum levels of drug at specific 
points of time in two rabbits are shown in Tables 10.3 and 10.4. The 
"expected" values are those calculated from the regression line derived from 
the observed data.
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Urine cephaloridine concentration. Estimating the 24-hour urine 
volume and cephaloridine concentration proved difficult. The urine 
samples were occasionally contaminated with faeces and the assay 
plates from these samples were frequently overgrown with bacteria.
In addition, there was considerable variation in the 24-hour urine 
volumes collected. In view of this, several attempts were made to 
catheterise each animal 24 hours after the injection of antibiotic 
to ensure that no residual urine was left in the bladder. These 
attempts were uniformly unsuccessful. Thus the observed total 
urinary excretion of cephaloridine in 24 hours was highly variable 
between animals and little weight can be placed on its accuracy 
(Tables 10.5 and 10.6),
DISCUSSION
These experiments confirm that cephaloridine is nephrotoxic when 
given in relatively small doses to rabbits. The results are similar 
to those described by Atkinson et al (1966a) and Silverblatt et al 
(1970). In a dose of 100 mg/kg given intravenously there was evidence 
of mild renal damage in all animals, with one individual showing patchy 
calcified debris in the tubular lumina 220 hours after injection. The 
presence of this debris is definite evidence of previous necrosis in 
the upper part of that nephron.
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When two doses of 50 rag/kg were given one week apart, the animals 
all showed mild proximal tubular necrosis and this lesion was more 
marked when the dose of drug was increased to 100 mg/kg, when the majority 
of animals showed extensive calcified debris in the tubular lumina. These 
findings imply that the toxicity of cephaloridine is not purely a function 
of the dose received at any single point in time but rather that it may 
increase with repeated insults particularly of marginally subnephrotoxic 
doses. This finding is not fully in agreement with that of Atkinson et 
al (1966b) who failed to find evidence of increased toxicity of this drug 
when given in daily doses up to 50 mg/kg for periods of up to 56 days.
The causes of this discrepancy are not clear but one possible explanation 
is that the cephaloridine was given intravenously in the studies- reported 
here whereas it was given intramuscularly by Atkinson and his co-workers.
It is possible that the intravenous route allowed a higher concentration of 
drug to be released into the proximal tubular cells in a shorter period of
time than was the case with the intramuscular route. In addition, it has
been observed that the toxicity of cephaloridine is variable even at a given 
dose, at least in the rat (Boyd et al 1971).
The cause of cephaloridine-induced proximal tubular damage is at present
unclear and some of the possible factors have previously been discussed in 
Chapter 9. The finding of calcified debris in the tubular lumina particularly 
localised to the outer cortical compartment has also been reported by other 
workers (Atkinson et al 1966a; Currie 1967; Boyd et al 1971) and this is 
suggestive of a vascular contribution to the renal damage. However, the
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present studies demonstrate the lesion to be a predominantly proximal 
tubular one and since cephaloridine has been shown to localise in this 
area of the kidney even after a single pass through that organ (Currie 
et al 1966) it is difficult to avoid the conclusion that the drug itself 
or one of its metabolites is toxic to that cell.
The present experiments failed to reveal a significant effect of 
phenobarbitone either on the metabolism or toxicity of cephaloridine.
The finding of a somewhat lower volume of distribution of cephaloridine 
after treatment with phenobarbitone is likely to be due to a reduction 
in the animals’ circulating blood volume as a result of moderate dehydration 
caused by excessive sedation.
Phenobarbitone is known to cause enzyme induction both in the rabbit 
liver (Cram et al 1965) and kidney (Uehleke and Greim 1968). Moreover, it 
has also been s h o w  that enzyme induction can lead to increased toxicity 
of some compounds, particularly carbon tetrachloride (Brodie et al 1971). 
Phenobarbitone has been shown to influence the metabolism of another 
antibiotic - griseofulvin - both in rats and in man (Busfield et al 1963,
1964). For this reason it seemed possible that it might increase the rate 
of metabolism of cephaloridine and so account for the observations of Pryor 
et al (1967) and Curtis and Marshall (1970) that the half-life of cephaloridine 
decreased with duration of regular dialysis therapy in patients receiving this 
treatment. Unfortunately, this explanation does not seem to be correct and 
the cause of this effect of regular dialysis (be it direct or indirect via 
one of the accompanying by-products of dialysis) is currently unknow.
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CHAPTER 11
An tib io t ic  Therapy in  Patients with
End- stage Renal Failure
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Patients with chronic renal failure are at constant risk from 
infections. This is particularly the case in those who require regular 
dialysis treatment (R.D.T.). The commonest offending organisms are 
staphylococci (giving skin infections including those around arterio­
venous shunts), Escherichia coli (giving septicaemias) and a wide range 
of other gram-negative organisms. One particularly troublesome organism 
prevalent in the regular dialysis unit of the Western Infirmary, Glasgow, 
at the time of this investigation, was pseudomonas pyocyaneus.
While many antibiotics are available to treat infections in such 
patients, antibiotic therapy is not without its dangers in these individuals 
On the one hand, toxic side-effects may arise because of impaired excretion 
of the drug leading to raised serum levels; such toxic effects as deafness 
from kanamycin, encephalopathy from penicillin and neurotoxicity from 
COlistin are well knoxm and will be reviewed in Chapter 12. On the other 
hand, inadequate serum levels resulting in ineffective therapy may occur 
if dosage is inappropriately reduced because of renal impairment. In 
addition, the use of regular dialysis treatment introduces yet another 
variable into the use of antibiotics in these patients, since dialysis 
may lead to a temporary increase in the clearance of these drugs.
Because of the dangers of toxicity, some workers have suggested that 
potentially dangerous antibiotics should not be given to patients with 
severe renal impairment (Goodman and Gilman 1965). However, it would 
seem preferable to give the therapeutic agent of choice in such a dose
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as to maintain adequate serum levels without reaching toxic heights.
In practice this could mean monitoring serum antibiotic levels in all 
patients with renal impairment. Clearly, however, this is impractical 
for many hospitals and difficult to adopt routinely even in the largest 
institutes. Moreover since patients undergoing R.D.T. are at enhanced 
risk of developing Australia antigen positive hepatitis with all its 
attendant risks to staff and patient, it would seem advisable to minimise 
the distribution of blood from such individuals where possible.
As a result of the development of a R.D.T. unit in the Western 
Infirmary, this investigation into the use of several antibiotics in 
such patients was undertaken in 1967.
PATIENTS AND METHODS
The nine patients studied all had end-stage renal disease and were 
being maintained by twice-weekly haemodialysis using Kolff twin coil 
artificial kidneys with Baxter-Travenol Chron-a-coils. No patient had 
received an antibiotic in the two weeks prior to the studies. All were 
fully informed of the nature of the investigation and their consent was 
obtained.
Blood was withdrawn immediately prior to the intramuscular injection 
of a single dose of the drug under study, and thereafter, samples were 
taken serially up to 100 hours. All samples were allowed to clot before 
the serum was separated and stored at -20°C. In addition, in selected 
individuals urine samples were collected for 24 hours after the injection
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to determine the renal clearance of the antibiotic under study. The 
drugs chosen for study were streptomycin, kanamycin, carbenicillin, 
cloxacillin and colistin.
Antibiotic assays were performed using the methods described by 
Humphrey and Lightbown (1952) and Grove and Randall (1955). All assays 
were carried out in triplicate. The streptomycin serum levels were 
obtained using Bacillus subtilis as test organism and DIFCO Streptomycin 
assay agar. The kanamycin levels were assayed on similar agar using 
Bacillus subtilis NCIB 8054 as test organism. Carbenicillin levels were 
assayed as described by Knudsen et al (1967) using Pseudomonaspyocyaneus 
NCTG 10490 as test organism and Penassay seed agar No. 1. Assay of 
cloxacillin employed similar agar to the carbenicillin assay with 
Sarcina lutea NGTC 8340 as test organism. Finally, the colistin assay 
involved Bordetella bronchieseptica ATCC 4617 as test organism growing 
on polymixin seed agar.
RESULTS AND COMMENTS
Nine patients were studied of whom four were presumed to have chronic 
glomerulo-nephritis, one had severe acute glomerulo-nephritis, one systemic 
lupus erythematosus, one malignant hypertension, one obstructive uropathy 
with infection and one polycystic kidneys with infection. All had 
creatinine clearances below 3 ml per minute and urine volumes below 600 ml 
per day. Their ages ranged from 18 to 54 years, five were male and they 
weighed between 48 and 72 kg prior to dialysis.
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Streptomyoin. (Tables 11.1 and 11.2) Two patients were given strepto­
mycin in doses of 0.25 gram intramuscularly half an hour prior to 
haemodialysis. The peak serum levels attained at two hours were 14 and 
16 yg/ml and levels over 8 yg/ml were maintained only for 12 hours.
Three patients who received 0.5 gram intramuscularly preceeding 
dialysis had peak serum levels of 24, 26 and 26 yg/ml and maintained 
levels exceeding 8 yg/ml for over 72 hours.
Four patients each received a single dose of 0.5 gram intramuscularly 
after dialysis. Peak serum levels attained in these individuals were 
30 to 34 yg/ml and levels exceeding 8 yg/ml were maintained for over 
eighty hours.
Since streptomycin would normally be used only to treat infections 
with M. tuberculosis blood levels exceeding 8 yg/ml would be required 
over a prolonged period. For this reason, monitoring of serum anti­
biotic levels would be required. Nevertheless, the results indicate 
that for adult patients weighing between 48 and 66 kg, a single dose 
of 0.5 gram streptomycin given before dialysis will result in adequate 
serum levels for 72 hours. A similar dose given after dialysis is 
likely to be associated with blood levels exceeding 30 yg/ml in the 
initial period and so should be avoided,
Kancwryo'tn. (Tables 11.3 and 11.4) Five patients each received a single 
dose of 0.5 gram kanamycin intramuscularly half an hour before dialysis.
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The dose received varied from 7.7 to 10.4 mg/kg body weight. Peak serum 
levels attained lay between 24 and 28 yg/ml. Levels exceeding 8 yg/ml 
were maintained for periods up to 60 hours after injection in all cases 
and over 72 hours in some (Figure 11,1),
Four patients each received 0.5 gram intramuscularly after completion 
of dialysis. Peak serum levels ranged from 22 to 32 yg/ml and levels 
exceeded 8 yg/ml for over 72 hours in all patients (Figure 11.1).
Kanamycin is indicated largely in the therapy of infections caused 
by E. coli and Proteus organisms. The majority of the former are sensi­
tive to this drug at concentrations of 5 yg/ml and the latter at 8 yg/ml. 
The results indicate that for patients weighing between 49 and 65 kg, a 
single dose of 0.5 gram kanamycin given before dialysis will provide 
therapeutic levels in the serum for up to 72 hours in the majority of 
cases. A sdLmilar dose given after dialysis will give higher serum 
levels for a longer time at the risk of an initial potentially toxic 
serum level.
CoHstin. (Tables 11.5 and 11.6) Three patients each received a single 
100 mg dose of colistin intramuscularly before dialysis. Peak serum 
levels attained were between 3.6 and 4.6 pg/ml and levels over 3 yg/ml 
lasted for only eight to 12 hours after the injection. Because of the 
low serum levels attained, a further four patients were given a dose 
of 150 mg before dialysis. Peak -serum levels attained were 6.5 yg/ml 
to 7.5 yg/ml with levels exceeding 3 yg/ml for over 40 hours in all 
cases,
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Three patients received colistin 150 mg intramuscularly after 
dialysis. In all cases, peak serum levels were higher than when 
the drug was given before dialysis and levels over 3 yg/ml lasted 
up to fifty hours after the injection. The effect of dialysis on 
serum collstin levels was considerably less than with streptomycin 
or kanamycin (Figure 11.2),
Colistin may well be the drug of choice for treating an infection 
with pseudomonas pyocyaneus. The levels obtained with a dose of 100 mg 
were inadequate for this purpose. With a dose of 150 mg, higher, more 
sustained blood levels were obtained whether the drug was given before 
or after dialysis. The degree of retention of this drug was less than 
expected in view of the observation that it is excreted largely by the 
kidneys (Colley and Frankel 1963). Colistin levels over 5 yg/ml are 
bactericidal for 90% of pseudomonas strains and such levels can be 
attained by giving 150 mg each 24 hours, giving the dose before dialysis 
on that day.
Much higher levels can be attained by giving large doses intra­
venously but there have been reports of convulsions, coma, and 
respiratory arrest following such usage in uraemic patients (Greenberg 
and Sanford 1967).
Corhenioiltvn. (Tables 11.7 and 11.8) Four subjects received one gram 
intramuscularly half an hour before dialysis. Peak serum levels attained 
were 26 to 32 yg/ml and levels exceeding 12 yg/ml were maintained for 
twelve hours in all subjects (Figure 11.3).
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When a similar dose was given to three patients after dialysis, 
the peak levels measured were 46 to 54 yg/ml and levels over 12 yg/ml 
were recorded in all patients for up to 30 hours after injection.
Carbenicillin is bactericidal for 90% of Proteus species at levels 
above 12 pg/ml. Thus when given in one gram doses to adults whose 
weights ranged from 53 to 69 kg, levels over 12 pg/ml resulted for 
twelve hours if given before dialysis, and 30 hours if given after the 
procedure. In view of the relative safety of the drug (see Chapter 12) 
it would seem advisable to give it in a dose of one gram daily, giving 
the dose on dialysis days after the completion of dialysis.
Ctoxacitt'in, (Tables 11.9 and 11.10) Four patients were each given a 
single dose of cloxacillin— one gram intramuscularly— half an hour 
before dialysis commenced. Peak serum levels attained were 36 pg/ml 
to 42 yg/ml, with levels over 10 yg/ml being present for eight hours 
in all cases.
When a similar dose was given after dialysis, the peak serum levels 
were similar, but the duration of effective blood levels was increased 
to twelve hours (Figure 11.4).
The present study indicates that retention of cloxacillin is not 
marked in patients requiring R.D.T. Since 100% of penicillinase- 
producing staphylococci are destroyed at blood levels over 3 yg/ml, 
a single one gram dose given at the end of dialysis and repeated daily, 
will give sufficiently high blood levels for all such organisms.
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Vvvne ontibi-ot'to 'levels* A 24-hour sample of urine was collected from 
a selected patient who received the studied antibiotic after dialysis.
This sample was assayed for the specific antibiotic activity but in no 
case was such activity clearly demonstrated. This result indicates that 
the proportion of antibiotic removed by glomerular filtration in these 
patients was exceedingly small.
DISCUSSION
The results described above are limited because of the small numbers 
of patients available for study. Nevertheless, they indicate the blood 
levels of antibiotic which can be attained after a standard dose of drug 
is given to patients on R.D.T. Using this data, recommendations can be 
made concerning the dose of these drugs required by such individuals—
Table 11.11. These recommendations are similar to others subsequently 
published in the literature (for review see Chapter 12),
The present results differ from others mainly in the case of colistin. 
Curtis and Eastwood (1968) found considerable prolongation of colistin half- 
life in patients on R.D.T. However, these workers were giving larger doses 
of this drug intravenously and consequently were dealing with higher serum 
levels. In addition, they reported an increased rate of removal of the 
drug during dialysis— a feature which was not prominent in the present 
study. This may in part be explained on the basis of the higher serum 
levels and in part on differences in the artificial kidneys used, since
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these workers were treating patients with a two-layer Kill dialyser 
•using a cuprophane membrane which may well be more permeable than the 
cellophane one used in Baxter Chron-a-coils.
Finally, it should be emphasised that the data presented here reflect 
total serum concentrations of antibiotic present at the time of assay.
No attempt was made to measure the fraction of drug which was protein- 
bound. It is possible that renal failure could alter the protein 
binding of antibiotics— a possibility which has recently been demonstrated 
for the sulphonamides (Anton and Corey 1971) and for diphenylhydantoin 
and dernethylimipramine (Reidenberg et al 1971). Were this to be the 
case, then the blood levels reached in these patients could prove less 
effective at treating the target infection than similar levels in patients 
without renal impairment.
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CHAPTER ]2
An tib io t ic  Therapy in Renal Failure :
A Review
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The regulation of drug therapy in patients with renal disease is 
fraught with difficulties. Although it is well known that drugs' normally 
excreted by the kidneys will be retained in the body for longer than 
normal periods in patients with renal failure, the dose modifications 
necessary to obtain therapeutic, non-toxic levels of drug over the 
required time intervals are difficult to calculate. As a result of this, 
incorrect dosage is not infrequently given to such patients who are 
therefore at a greater than normal risk of developing both adverse 
reactions to drugs and an ineffective response to therapy, due on the 
one hand to relative overdosage and on the other to relative underdosage. 
Although the latter is more difficult to prove. Smith, Siedl and Cluff 
(1966) in one of the earliest efficient prospective drug monitoring 
systems developed in the United States, reported that adverse reactions 
to all drugs were two and a half times more frequent in patients with 
presenting blood urea nitrogen levels of over 40 mg per 100 ml, than in 
those with presenting levels below 20 mg per 100 ml. This work has 
subsequently been confirmed by a similar group working in Boston (H. Jick, 
personal communication, 1971). Moreover, in a study of 178 episodes of 
acute central nervous system disease occurring in 103 uraemic subjects, 
Richet, deNovales and Verroust (1970) noted that 61 (34%) were definitely 
or probably drug related. Clearly the effect of renal damage on a 
patient's.ability to effectively handle drugs is of immediate and practical 
importance. Particularly is this the case with antibiotics, the majority 
of which are excreted by the kidney to a variable extent.
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Although it has been appreciated for some time that reduction 
either in the dosage of drug given or in its frequency, is necessary 
to avoid side-effects in such patients, these reductions must be suf­
ficient to eliminate the hazards of drug accumulation, while permitting 
adequate dosage for therapeutic purposes. Furthermore, varying degrees 
of renal failure will demand different dose regimes and in those with 
virtually no renal function, the effect of dialysis on drug metabolism 
and elimination will further complicate the issue. Once therapy has 
started, other variables may assume importance. For example, effective 
therapy of a urinary tract infection may improve renal function with a 
subsequent increase in the patient's ability to handle the drug, resulting 
in a reduction in serum levels below those necessary to completely 
eradicate the initial infection. Conversely, renal damage may occur 
after administration of some antibiotics, leading to a cycle of events 
precipitating higher, more toxic blood levels of drug and so on.
Despite these hazards, antibiotic therapy is frequently required 
in patients with renal failure. Infection is a major cause of death in 
such patients. It may involve the urinary tract and result in deteriorating 
renal function, particularly in those with pre-existing renal disease 
(e.g. polycystic kidneys), or it may involve other systems such as lung 
or, in the case of regularly dialysed patients, an arterio-venous shunt 
site. For these reasons, it is clear that effective methods of calculating 
appropriate doses of antibiotics in patients with renal impairment must be 
developed. Although several workers had wrestled with this problem prior
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to 1965 (Humphrey, 1944; McDermott, 1947; Anderson and Brodersen, 1949), 
it was not until the studies of Kunin and Finland (1959a), that a more 
rational, practical approach to the problem was developed. Since 1960, 
many workers have studied the use of antibiotics in renal disease; how­
ever, concise information on the dosage of these drugs is frequently 
lacking. To understand the reasons for this requires some knowledge of 
the mechanisms involved in drug elimination from the body.
MECHANISMS OF DRUG EXCRETION
At normal therapeutic concentrations, most drugs are removed from 
the body at a rate dependent upon the quantity present in the body. This 
rate of removal is proportional to the plasma concentration of the drug 
once tissue equilibration has taken place. The simplest method of 
expressing the rate of drug elimination is by calculating the time re­
quired for plasma concentrations of drug to fall to half the peak, post 
tissue-equilibration level (the T^y2 the drug). Such a calculation 
is readily performed in the clinical setting and is the basis of much 
of the work done on antibiotic dosages in patients with renal failure. 
Unfortunately, it has several drawbacks, of which two are of practical 
importance: firstly, the T^y^ Pleasured after a single dose of drug is
frequently shorter than that measured after a multiple dosage schedule 
is interrupted to perform the calculation. This is due in part to a 
failure to obtain true blood-tissue equilibration during the period after 
the initial dose was given. Under these circumstances, the observed
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half-life will reflect both the "true" half-life together with the rate 
at which the drug leaves the plasma to enter the tissues during the 
period of equilibration (Martin, 1965). Secondly, the above technique 
tends to underestimate the true excretion rate of strongly protein bound 
drugs, since after administration of such a drug a large reservoir of bound 
drug will be present in the tissues. As unbound drug is eliminated from 
the plasma,, it will be replenished from this reservoir, resulting in an 
apparently low rate of fall in concentration of drug in the serum.
If a drug is excreted entirely by the kidney, it has been sho\m that the 
half-life depends.upon the rate at which the drug is removed from the 
plasma by the kidney and also upon its volume distribution (Goldstein et 
al, 1968).
Thus;
T = k X Distribution Volume
Renal Clearance
where k = constant (0.693)
This distribution volume is equal to the amount of drug present in the 
body divided by the concentration of drug present in the plasma. It 
therefore depends upon a large number of variables such as the degree of 
protein binding and lipid solubility of the drug, the extra-cellular fluid 
volume of the treated patient, and the concentration of plasma proteins 
in this subject. Since there is no evidence that the degree of lipid 
solubility or water solubility of a drug is altered in patients with 
renal disease as compared to those with normal renal function, the most
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important variables in this context are the extra cellular fluid volume, 
the extent of protein binding, and the plasma protein concentrations.
Thus dehydration will lower the distribution volume of most drugs and 
overhydration will increase it.
Similarly, patients with markedly low serum protein levels, especially 
serum albumin levels (e.g. those with severe nephrotic syndrome) may have 
higher serum levels of unbound drug per unit dose, than those with normal 
serum albumin levels (Rolinson, 1967). In addition, the affinity of plasma 
proteins for certain drugs may be altered by disease states; examples of 
this are the reduction in protein binding of sulphonamides in uremic 
patients (Anton, 1968; Anton and Corey, 1971) and of diphenylhydantoin 
in uremic serum (Reidenberg et al, 1971).
Thus it can be seen that a large number of factors may interact to 
affect the handling of a drug in patients with renal impairment. Moreover, 
such patients who require hospitalization are likely to be given many 
drugs in that admission. The average in-patient in a British hospital 
may receive from four to nine drugs during his admission (Hurwitz, 1969), 
a figure similar to that observed in Boston by Jick and his colleagues 
(1970). When only those patients admitted with blood urea nitrogen levels 
over 40 mg per 100 ml are considered, the average number of drugs received 
per admission rises to around 12 (Jick, personal communication) and hence 
the possibility of a therapeutically significant interaction between drugs 
is increased in such patients.
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In the remainder of this chapter, the indications, hazards, and 
dosage modifications necessary for the use of a wide variety of anti­
bacterial substances in patients with renal failure will be reviewed, 
paying particular attention to the various variables discussed above.
Additional accounts of this subject may be found in works by 
Kunin (1967), Finegold et al (1969), Bennett et al (1970), and 
Reidenberg (1971). For a detailed account of the possible consequences 
of altering dosage schedules either by reducing the administered dose 
or by prolonging the time interval between doses, see the excellent 
review article by O'Grady (1971).
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PENICILLIN
Penicillin is a remarkably non-toxic drug, a property which is 
shared to a lesser extent by the semi-synthetic penicillins. Eagle and 
Newman (1947)showed that the clearance of this drug by the kidney 
exceeded 500 ml/minute and noted that it accumulated in patients with 
renal failure. Given intramuscularly, penicillin G has a half life in 
normal subjects of about one hour rising to around 10 hours in the anuric 
subject (Kunin and Finland 1959b). Despite this, few cases of penicillin 
toxicity have been reported in patients with renal failure. Massive doses 
have been reported to cause neuromuscular excitability and convulsions (New 
and Wells 1965), but the evidence implicating penicillin is inconclusive, 
since the cases concerned all occurred in patients with previous renal 
dysfunction. It is conceivable that the excitability was caused not by 
the penicillin itself but rather by its accompanying cation. Twenty mega 
units of benzyl penicillin contain some 32-34 mEq potassium which, under 
rare circumstances, could if given intravenously, give rise to neurological 
problems. Baldwin et al (1968) reported seven cases of uraemia, fever, 
eosinophilia and infiltration of the renal interstitium with eosiniphils 
and mononuclear cells which occurred in patients given large doses of both 
penicillin and methicillin, however, these authors felt that the evidence 
against penicillin was not impressive (see later under methicillin).
Bloomer et al (1967) reported four cases of "penicillin-induced encephalopathy" 
in patients with severe renal failure. Here again, the doses of drug used
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were excessive even under conditions of normal renal function. It would 
appear therefore that within wide limits, penicillin can safely be given 
to those with renal failure, the only potential problem occurring in the 
anephric subject or in patients during regular dialysis, when large doses 
should be given slowly to avoid sudden increase in the concentration of 
the accompanying cation.
In patients with renal failure, therapeutic blood levels of penicillin 
may be obtained for most sensitive organisms by giving one million units 
of benzyl penicillin 12 hourly (Kunin and Finland 1959b). Since this drug 
is dialysable (Schreiner 1970), the dose should be given at the end of 
dialysis. If the drug is required in high doses, for example in the 
treatment of subacute bacterial endocarditis, the dose given should be 
regulated by blood level estimations of both penicillin and its accompanying 
cation and relating the former to the kno^m minimum inhibitory concentration 
of the organism.
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SEMI-SYNTHETIC PENICILLINS
AmpldU'in* The most widely used of the semi-synthetic penicillins, 
at least in the United Kingdom and the United States, ampicillin has a 
wide spectrum of antibacterial activity (Goodman and Gilman 1970). It is 
highly effective against most strains of E. coli and some of Proteus 
species, although less effective than penicillin against sensitive strains 
of gram-positive cocci. The half life of this drug in normal individuals 
is about 1.8 hours, increasing to 18 hours in patients with creatinine 
clearance levels below 4 ml/minute (Kunin and Finkleberg 1970). The main 
adverse reaction occurring with ampicillin is skin rash. In a large series 
of consecutive hospitalised patients receiving ampicillin, rash occurred 
with a frequency of 9.5% compared to a frequency in those not receiving 
ampicillin of 1.8%, thus the risk attributable to ampicillin was 7.7%
(Shapiro et al 1969). Although no comment upon dosage of drug received by 
their patients was made in the published report, there was no evidence that 
rash appeared more frequently either in patients with impaired renal 
function as manifested by a presenting blood urea nitrogen level of over 
25 mg/100 ml, or in patients receiving a greater than normal dosage of 
two to three grams per day (Shapiro, personal communication). This finding 
is compatible with the postulated allergic basis of ampicillin-induced skin 
rash. Lee and Hill (1968) recorded an increased frequency of rash attribut­
able to ampicillin in a small series of patients with renal failure. However, 
it is possible that this apparent increase in frequency over those without 
renal impairment was due in part to better observation of the former patients 
together with a somewhat greater baseline frequency of rash in patients with 
renal failure.
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In serious infections in patients with severe renal impairment, 
therapy with ampicillin should be given in doses of up to 500 mg 
six hourly if required. Should rash be encountered, the usual course 
is a benign one, involving the patient in only minor discomfort.
Although such discomfort should obviously be avoided where possible, 
it is to be preferred to the more serious complications which may arise 
if a substitute, more toxic antibiotic is employed, Kunin and Finkleberg 
(1970) made the additional observation, that while ampicillin reached good 
concentration in the urine of patients with mild to moderate renal failure, 
it did not do so when the creatinine clearance fell below 5 ml/minute.
Thus ampicillin is likely to be ineffective against organisms causing 
urinary tract infection in such patients— a fact which may be of particular 
relevance to the early phase after cadaveric renal transplantation.
Since ampicillin is haemo-dialysable (Schreiner 1970) , dosage of the 
drug given to patients requiring dialysis, should be given at the end of 
this procedure. Normal dosage may be given to patients with renal failure 
requiring peritoneal dialysis, since the drug is not substantially cleared 
by this technique (Ruedy 1966).
CaTbeYVhQ'l'l'lvn* This drug is one of the newer semi-synthetic penicillins 
which is effective against many gram-negative organisms. Blood levels 
around 12 pg/ml are bactericidal for 90% of proteus species, and at this 
level, the drug is virtually non-toxic (Goodman and Gilman 1970). It has also 
been advocated for the treatment of pseudomonal infections when blood levels 
of 100 yg/ml are required ; however these levels are difficult to achieve in
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patients with normal renal function. Johny et al (1969) suggested that 
carbenicillin remains virtually non-toxic at such high serum levels, but 
Lurie et al (1970) and Waisbren et al (1971) reported the development of 
severe haemorrhagic diathesis in patients given high doses (up to 24 G/day), 
however, these patients were all suffering from renal failure and the 
association with carbenicillin may be coincidental.
Carbenicillin is retained in the body in renal failure and is 
fairly rapidly removed by haemodialysis (Schreiner 1970). In the treat­
ment of infection with sensitive organisms (M.I.C. < 12 yg/ml) one gram 
12 hourly will suffice in patients with creatinine clearances below 20 ml 
per minute. Those on regular dialysis therapy require doses of approximately 
one gram (14-15 mg/kg) daily the dose being given at the end of dialysis 
(see Chapter 11).
The high serum levels necessary to eradicate pseudomonal infections 
can be achieved in patients with renal failure with relative ease. Eastwood 
and Curtis (1968) suggest that patients with creatinine clearances below 
5 ml/minute require 2 G eight to 12 hourly to maintain serum levels around 
100 yg/ml with an increase in frequency of dosage to four hourly during 
dialysis. Such a policy is also advocated by Hoffman et al (1970) who 
demonstrated an increase in the half life of carbenicillin in the serum 
from the normal level of one hour to over 15 hours in severe oliguric 
renal failure.
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Meth'io'ttt'in. Methicillin was the first penicillin which was 
effective against penicillinase producing staphylococci. Its use is 
largely confined to the treatment of infection with staphylococci which 
are frequently the cause of shunt infections or of pneumonia in patients 
undergoing regular dialysis treatment. This drug is retained in patients 
with severe renal failure (Bulger et al 1967), who require a reduction in 
dosage usually attained by increasing the normal interval between doses 
from four to eight or 12 hours. Serum levels of methicillin are not 
significantly affected by either peritoneal or haemo-dialysis (Gilbert 
and Sanford 1970). Baldwin et al (1968) and Brauninger and Remington
(1968) described several patients who developed renal damage associated 
with allergic phenomena after administration of methicillin. While Baldwin 
and his co-workers suggested that this effect was dose-related, it is more 
likely that Brauninger and Remington are correct in implicating a hyper­
sensitivity response independent of administered dose. For this reason, 
methicillin should probably be avoided in patients with renal involvement 
in systemic collagenoses or following transplantation.
IsoxaBolyl Penio'itl'ins* Oxacillin, cloxacillin and dicloxacillin are 
all effective against penicillinase-producing staphylococci. They are given 
orally and are excreted in part by filtration by the glomeruli and secretion 
by the tubules (Marcy and Klein 1970). In the case of oxacillin, dosage 
reduction does not seem to be required when the drug is given to patients 
with renal failure (Bulger et al 1964), whereas with cloxacillin and dicloxa­
cillin a reduction in dosage has been recommended (McCloskey and Hayes 1967,
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Williams, et al 1967), When given to patients on regular dialysis treat­
ment, one gram cloxacillin daily will maintain serum levels over 5 yg/ml 
for 24 hours— the dose being given after the procedure on dialysis days 
(see Chapter 11 ). This serum level should be sufficient to eradicate 
most sensitive strains of penicillinase-producing staphylococci 
(M.I.C. < 3 yg/ml).
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CEPHALOSPORINS
Several cephalosporin antibiotics have come into general use since 
their initial discovery by Brotzu in 1948. In the United Kingdom, 
cephaloridine has been the most widely used drug, with cephalothin and 
cephalexin becoming available more recently. These drugs all have a 
wide antibacterial spectrum, being bactericidal to. many gram-positive 
and gram-negative organisms. Their main clinical use is against 
penicillinase-producing staphylococci, but they are also effective 
aginst Clostridia, streptococci, and a variety of gram-negative organisms, 
including E. coli. (Muggleton and O'Callaghan 1967). Cephaloridine and 
cephalothin must be given by parenteral route, but cephalexin can be 
administered orally.
Cephdlovtdi-ne. Within six hours of an intramuscular injection, 75% of 
cephaloridine is excreted in the urine, and this excretion is unaffected 
by the coincidental administration of Probenicid (Naumann 1967). Most of a 
single intramuscular dose is excreted within 24 hours by glomerular 
filtration. The half life of cephaloridine in the serum of normal subjects 
is 94 minutes. This is prolonged to three to four hours when the creatinine 
clearance falls below 40 ml/minute. With a creatinine clearance of 5 ml 
per minute the serum half life of cephaloridine is 20 to 24 hours. Urine 
concentrations of cephaloridine fall from over 1000 yg/ml at creatinine 
clearances of 70 ml/minute to under 80 yg/ml at creatinine clearances of 
less than 10 ml/min. (Pryor et al 1967). These authors also observed
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a progressive decline in the half life of this drug in the serum of an 
anephric patient, from an initial value of 21.5 hours to one of 8.2 hours 
after a period of several months of regular dialysis treatment. This 
observation was confirmed by Curtis and Marshall (1970) who noted an 
inverse relationship between the serum half life and the duration of 
regular dialysis therapy. The reason for these observations is not 
clear, but it is possible that the observed increase in the half life 
of cephaloridine is due to an enzyme induction effect of barbiturates 
which are frequently given to these patients.
Cephaloridine resembles penicillin and methicillin with respect 
to its retention in the body in chronic renal failure since a significant 
portion of it may be inactivated by non-renal mechanisms (Kunin and 
Atuk 1966). For patients on regular dialysis treatment, Curtis and 
Marshall recommended a dose of one gram cephaloridine intravenously 
daily, increased to six-hourly during dialysis if the drug is given 
for staphylococcal infections. In the treatment of gram-negative 
infections in patients on regular dialysis, they recommend a dose of 
one gram 12-hourly intravenously, increased to one gram, four-hourly, 
intravenously during dialysis. They suggest that the drug be given 
slowly, dissolved in 20 ml of saline.
While the use of cephaloridine in patients with no significant 
residual renal function is probably safe, there is some evidence to 
suggest that its use in patients with renal impairment not yet requiring 
dialysis is potentially dangerous. Perkins et al (1968) showed that the 
drug was nephrotoxic in,rabbits and monkeys when given in high doses.
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Foord (1969), summarizing the evidence for nephrotoxicity of cephaloridine, 
concluded that serum levels over 100 yg/ml should be avoided. He noted 
also that in the 36 cases of acute renal failure in which cephaloridine 
was a suspected cause, two thirds of the patients were known to have 
impaired renal function at the beginning of treatment. Finally, he 
observed that in several of these patients cephaloridine had been given 
coincidentally with diuretics, particularly furosemide. The studies 
reported in Chapter 9 suggest that in the presence of minor degrees 
of renal damage, cephaloridine may produce severe acute tubular necrosis 
at serum levels which are below the suggested nephrotoxic level, at least 
in animals. This side effect of cephaloridine is enhanced by the 
coincidental administration of frusemide, and until further information 
is available, it may be advisable to avoid the use of this drug in 
patients with renal impairment where alternative therapy is possible.
CephaZothvn, Cephalothin is normally excreted rapidly in the urine 
but in chronic renal failure it is metabolized in the liver, so that the 
normal half life in the serum of 0.85 hours is extended only to 2.9 hours 
in the anuric patient (Kunin and Atuk 1966). Dose modifications are 
therefore probably not required in patients with renal failure. There 
is at present no evidence available that cephalothin is nephrotoxic in 
man. Perkins et al (1968) failed to demonstrate a nephrotoxic effect in 
rabbits and monkeys. It would appear, therefore, that cephalothin is 
preferable to cephaloridine in patients with chronic renal failure, 
although its spectrum of antibacterial activity is not quite as wide 
as that of cephaloridine.
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Cephalexin* Cephalexin, the orally administered cephalosporin, 
has an antibacterial spectrum similar to cephaloridine, and is likely to 
be effective against most organisms found in the urinary tract, except 
pseudomonads. The antibiotic is rapidly cleared from the body by 
glomerular filtration, and 95% of an oral dose can be recovered from 
the urine in normal patients within six hours. The half life of 
cephalexin in the serum is prolonged from one hour in normal subjects 
to approximately 20 to 30 hours in the anephric patient (Kabins et al 
1970; Lindquist 1970). Serum levels achieved after a single oral dose 
become slightly higher as the creatinine clearance decreases, but at 
all levels of renal function the minimum level of cephalexin in the 
urine exceeded 32 yg/ml between four and 18 hours after the oral dose.
At lower levels of creatinine clearance only approximately 60% of the 
ingested dose was recoverable in the urine, suggesting an extra-renal 
route of disposal. The serum half life of cephalexin is reduced to 
four to six hours during dialysis (Bailey et al 1970). Neither those 
workers nor Gower and Dash (1969) noted any evidence of deterioration 
in renal function during cephalexin therapy, but Galbraith and Pilsworth
(1969) reported a fall in creatinine clearance in five out of 14 patients 
given this drug. Until further experience has been gained with cephalexin 
it is probable that the dosage should be reduced as the glomerular 
filtration rate falls. The dose schedule suggested by Bailey et al
(1970) is to give 500 mg as a loading dose, repeated eight-hourly if
the creatinine clearance exceeds 50 ml/minute; 12 hourly if the creatinine
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clearance falls between 20 ml/minute and 50 ml/minute; and each day if 
the creatinine clearance is below 20 ml/minute. On dialysis days, an 
extra dose of 500 mg at the end of dialysis should be administered. 
Such doses of cephalexin will be adequate for most urinary tract 
infections, but should be approximately doubled for major systemic 
infections. A similar dosage schedule has been recommended by 
Lindquist et al (1970).
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STREPTOMYCIN
Although most commonly used in the treatment of tuberculosis, 
streptomycin is also effective against many gram-negative organisms.
It is given parenterally and the majority of each dose is excreted in 
the urine. Kunin and Finland (1959b) demonstrated that streptomycin 
accumulates in patients with renal failure, the half-life extending 
from a normal value of 2.4 hours to over 50 hours in the anuric subject. 
Streptomycin is cleared by glomerular filtration and is readily removed 
by haemodialysis (Edwards and Whyte 1959), Toxic effects are related to 
magnitude and duration of therapy and are rare if blood levels of the 
drug are kept below 25 yg/ml.
The major current use for this drug is in the therapy of tuberculosis, 
a not infrequent complication of chronic renal failure. During therapy 
streptomycin levels should be kept between 8 and 25 yg/ml (90% of strains 
of M, tuberculosis are sensitive at 8 yg/ml). To achieve this in patients 
with creatinine clearances below 10 ml/minute, Kunin and Finland (1959b) 
recommend a loading dose of 1 G followed by 0.5 G every two to three days. 
The dose should, however, be adjusted by frequent measurement of the blood 
level of drug to avoid dangerous accumulation.
In patients requiring regular dialysis treatment, safe, effective 
levels of streptomycin can be maintained by giving 10 mg/kg body weight 
at the end of each (twice-weekly) dialysis (see Chapter 11 ). Ogg et al 
(1968) described the treatment of tuberculosis in a patient on regular 
dialysis treatment. These workers gave similar doses to those recommended
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here, but noted mild vestibular damage after a total of 11 G strepto­
mycin were given in five weeks. Thus serial assays of serum strepto­
mycin levels are required to regulate such long-term therapy.
AddvtoncCl Therapy for Tuberautosds, Ogg et al recommended 
isoniazid in a dose of 3 mg/kg body weight per day together with 
pyridoxine 20 mg/day to prevent deficiency of this vitamin during therapy 
(Robson and Sullivan 1963), and para amino salicylic acid (PAS) in a dose 
of 6 G/day. While such regimes give a guide to therapy, long term treat­
ment of a chronic infection such as tuberculosis requires serial measure­
ment of antibiotic levels.
More recently, McGeachie et al (1970) studied the use of rifampicin 
in patients with renal failure. This drug is excreted mainly in the 
bile and so can be given in normal doses to patients with renal failure. 
Thus there is a strong case for using it as a primary agent in the 
therapy of tuberculosis complicating renal failure.
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KANAMYCIN
Kanamycin is an extremely effective drug in the treatment of gram- 
negative infections. Fekety et al (1962) demonstrated that 90% of 
E coli strains were sensitive to serum levels of 5 yg/ml and 80% of 
Proteus species to 8 yg/ml. However, the use of kanamycin in renal 
failure has been restricted because of its side effects— mainly oto­
toxicity and nephrotoxicity (Kunin and Finland 1959b).
This drug is stable in the body and is almost entirely excreted 
by the kidney. SgSrenen et al (1967) demonstrated a linear prolongation 
of the half life of this drug in the serum with falling creatinine 
clearance levels. Although toxic effects are usually recorded when 
serum levels exceed 25 pg/ml, there have been reports of such at lower 
blood levels (Toma and Main 1967). S^renen et al suggested a complex dose 
regime based on serum creatinine levels to predict the optimal non-toxic 
dose of the drug to give to those with renal failure. -However, elegant 
studies by Orme and Cutler (1959) gave more information on this drug’s 
behaviour in patients with renal failure. By measuring simultaneous 
renal clearances of creatinine, inulin, PAH and kanamycin in 34 subjects, 
they noted that kanamycin clearance approached that of inulin and suggested 
that the drug was distributed in the inulin space (i.e. extracellular 
water), Thus changes in extracellular fluid volume will make significant 
differences to the half life of kanamcyin; a reduction in extracellular
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fluid reducing the half life considerably when compared with the half 
life in an overhydrated patient with the same glomerular filtration 
rate. These workers suggested that the half life of kanamycin could 
be determined by the formula noted below:
T = 3.6 X body weight (kg)
1/2 (hours) c . (ml/mln)
creatinine
and recommended a dosage of 7 mg/kg body weight given at intervals of 
three times the half-life of kanamycin. Even this regime may require 
modification if gross overhydration or underhydration exists. While 
this work represents the most scientific approach to determining kana­
mycin dosage for those with renal failure who do not require regular 
dialysisit is probably still advisable to check efficacy and safety 
of the dose given by regular estimations of serum kanamycin levels. 
Nevertheless, when McCloskey and Becker (1970) investigated the reliabil­
ity of this method they found that in practise when the patients’ serum 
creatinine level was below 9 mg/100 ml the method was highly reliable, 
although it was less so when initial serum creatinine levels were 
over 9 mg/100 ml. The finding that 83% of kanamycin orders prescribed 
for 12 patients behaved as predicted is impressive evidence in favour 
of this method.
In those patients requiring regular dialysis, 0.5 g kanamycin given 
at the beginning of dialysis will avoid dangerous levels of drug yet 
attain therapeutic concentrations for up to 80 hours (Cry et al 1966; 
Chapter 11).
180
GENTAMYCIN
Gentamycin is effective against a wide range of gram-positive and 
gram-negative bacteria including pseudomonads, proteus species, and 
various staphylococci. Serum levels above 4.5 pg/ml are bactericidal 
for these organisms (Weinstein 1967), Like kanamycin, gentamycin produces 
vestibular damage if excessive blood levels are reached (Jao and Jackson 
1964) and it has been recommended that blood levels of greater than 10 pg/ml 
be avoided (Curtis et al 1967).
Gentamycin is excreted by glomerular filtration and there is a 
strong inverse correlation between serum half life and the glomerular 
filtration rate (Kunin 1968; Gingell and Watemforth 1968; Bergen et 
al 1971). For normal subjects, the mean daily dose of gentamycin is
2.4 mg/kg body weight. Gingell et al (1969) recommended modifications 
in the dose given to patients with varying degrees of renal failure, 
suggesting that, after an initial dose of 1 mg/kg body weight, subsequent, 
doses be determined by altering the interval between doses:
Dose and Frequency G.F.R. (ml/min) Serum Creatinine (mg/lQOml)
1 mg/kg 8 hrly > 5 0  <1.2
1 mg/kg 12 hrly 30-50 1.2-2
0.5 mg/kg 24 hrly 10-30 2-5
0.5 mg/kg 36 hrly 5-10 5-10
0.5 mg/kg 48 hrly < 5 10+
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As an alternative method of calculation McHenry et al (1971) 
noted that "for clinical purposes, the T^/2 gentamycin could be 
estimated by multiplying the value of the serum creatinine (mg/100 ml) 
by four." These authors recommended administering gentamycin in a 
dose of 1 mg/kg body weight at times equal to two half-lives.
Because of the considerable similarity between kanamycin and 
gentamycin, it is likely that variations in extracellular water will 
also influence the half-life of this drug and so estimations of serum 
levels will still be advisable during prolonged therapy.
In patients requiring regular dialysis treatment, satisfactory 
levels of gentamycin can be obtained by giving 1 mg/kg body weight at 
the end of each bwice-weekly dialysis (Curtis et al 1967).
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THE POLYMIXINS
CoZ'lst'ln (Folymix-in E), This drug is active against many gram- 
negative bacteriae, but its use is largely confined to the treatment of 
pseudomonal infections. It is bactericidal to 90% of pseudomonads at 
serum levels of 5 pg/ml— a level which is readily attained in normal 
subjects by giving doses of 5 mg/kg body weight per day (Goodman and 
Gilman 1970).
MacKay and Kaye (1964) studied the effect of impaired renal function 
on the serum levels of this drug and recommended a dose regime for those 
with renal impairment:
Dose (mg/kg body weight) Interval ^creatinine (ral/min)
2.5 12 hrs. normal
1.5 12 hrs. > 40
1.5 18-36 hrs. < 40
2.0 given only 0
once
Similar studies were performed by Goodwin and Friedman (1968).
Brumfitt et al (1966) recorded a fall in creatinine clearance lasting 
up to four weeks in patients with normal renal function given a single dose 
of colis tin. Ifhile such a fall may, under certain circumstances, be tolerable 
in patients with normal renal function, it could prove disastrous in those 
with even mild pre-existing renal impairment. This was confirmed by Price 
and Graham (1970) who reported that, in 14 patients given the high dose 
of 26 mega units per day for the therapy of severe klebsiella infection,
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all showed a considerable fall in creatinine clearance and several died 
as a result of this. At autopsy these patients showed evidence of acute 
tubular necrosis. Renal function gradually returned to normal following 
withdrawal of the colistin thus confirming the observations of Brumfitt 
and his co-workers.
In a recent comprehensive study of 288 consecutive patients receiving 
colistin in the Massachusetts General Hospital, Koch-Weser et al (1970) 
recorded an overall adverse reaction rate of 25,1%— that is, one in every 
four patients receiving the drug experienced unwanted effects as a result. 
While this figure is higher than that found within the Boston Collaborative 
Drug Surveillance Program (see page0^), the .techniques used and the 
patients studied are not comparable. Of the patients studied by Koch-Weser, 
twenty per cent developed adverse reactions involving the kidney. Thus it 
is clear that this drug is nephrotoxic— a finding which has been denied by 
some workers (Taylor and Allison, 1962; Goury-Laffont 1962). In addition 
to their description of the prevalence of adverse reactions to this drug, 
Koch-Weser and his co-workers noted that these reactions were more common 
in heavier patients and concluded that the administration of colistin in 
doses proportional to the patients’ weight resulted in relative overdose for 
heavy patients and relative underdose for light patients. Dosage calculation
based on the square root of the patient's weight:—
Daily Dose = 15 mg x /weight in lbs. 
was shown to be the most efficient method of adjusting the amount of drug
required, I'Thile this calculation was based on the data obtained for 
colistin recipients, it is likely to have a more general relevance to the
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topic of dose-weight relationships. As the rate of colistin excretion is 
a function of the glomerular filtration rate (MacKay and Kaye 1964) and 
as both the glomerular filtration rate and blood volume are more closely 
related to surface area (which is a function of /body weight) than to 
simple body weight, doses of drug which are related to surface area and 
the /body weight are more likely to be of general applicability. At the 
present, for patients with normal renal function, it would seem reasonable 
to adopt Koch—Weser’s dose criteria of:
Daily dose (rag) - 15/ift. (lb) or = 22/wt. (kg) .
l-There possible in patients with impaired renal function, the drug should 
be avoided.
In patients requiring regular dialysis treatment, Curtis and Eastwood 
(1968) consider the possible nephrotoxicity to be irrelevant and emphasise 
the value of this drug in treating pseudomonal infections. They suggest 
that a single dose of 2-3 mg/kg body weight given intravenously at the end 
of each twice-weekly dialysis will maintain therapeutically active blood 
levels in such patients. This regime is similar to that advocated in 
Chapter 11 ,. however, it should be noted that it does produce transient 
high serum levels of antibiotic and there have been reports of convulsions, 
coma and respiratory arrest when colistin is given in high doses to 
uraemic patients (Greenberg and Sanford 1967).
Fotym'Cxrin B. This drug is used under similar circumstances to 
colistin. Hoeprich (1970) has argued in favour of using it in preference 
to colistin, however, for all practical purposes, the two are interchange­
able. In particular, dosage reduction for patients with renal impairment 
is similar with both drugs.
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TETRACYCLINES
The tetracyclines are a group of broad-spectrum bacteriostatic 
antibiotics which show marked antagonism to concurrently administered 
penicillin. They may be given orally or parenterally, show a variable 
degree of protein binding and are excreted both in the urine and in the 
bile. The renal clearance of chlortetracycline is 35% of the creatinine 
clearance, while that of oxytetracycline is 85% of the creatinine clear­
ance. The principal toxic effects of the tetracyclines are hepatic damage 
which occurs particularly if the drug is given parenterally (Dowling and 
Lepper 1964) and a rise in blood urea nitrogen (see Chapter 8 )• Photo­
sensitivity has been recorded following demethylchlortetracydine therapy, 
as has persistent high fever and eosinophilia (Rasik and Thompson 1970).
Following a single intravenous dose of tetracycline Kunin et al (1959d) 
observed a relationship between creatinine clearance and the serum half 
life of the drug. In the anuric patient, the half life was approximately 
ten times the normal of 4.8 hours. In the case of chlortetracycline the 
serum half life is normal in patients with renal impairment. Thus, 
chlortetracycline in normal dosage would appear to be the tetracycline 
of choice in patients with renal impairment. However, in view of the 
evidence that the tetracyclines may cause a rise in blood urea nitrogen 
levels in a considerable proportion of those exposed, it would seem 
advisable to avoid these agents in patients with pre-existing renal 
disease.
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ERYTHROMYCIN
Erythromycin is effective against many gram-positive organisms when 
given orally, although the organisms frequently develop resistance within 
a short period of time. The half life of erythromycin in the serum of 
anuric patients is prolonged to four to six hours, compared to a normal 
value of 1.4 hours (Kunin and Finland 1959b), This drug is relatively 
non-toxic, providing that the lauryl sulphate salt of the propionic acid 
ester is avoided since this derivative may cause an allergic cholestatic 
hepatitis (Goodman and Gilman 19 70). With erythromycin stearate or 
lactobionate, no reduction in normal dosage is required for patients with 
renal failure, although data on the clearance of this drug is limited.
FUCIDIC ACID
This steroid antibiotic is bactericidal to most strains of staphylo­
cocci and is unaffected by penicillinase. Combined with penicillin, 
methicillin or perhaps tetracycline, it is particularly effective against 
gram-negative bacteriae, fungi and yeasts (Godtfredsen et al 1962;
Goodman and Gilman 1970).
It is excreted by the liver, is not removed by the kidney, and is not 
kno;m to be nephrotoxic. Since it is 97% protein bound, the drug is 
virtually unaffected by peritoneal or haemo-dialysis. No modification of 
dosage is required in patients with renal failure, before or during dialysis, 
although it has been suggested that gastrointestinal side effects may limit 
its oral use in patients with renal disease(Hobby eL al 1970).
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CHLORAMPHENICOL
Chloramphenicol is a bacteriostatic antibiotic which, at varying 
concentrations, is effective against some rickettsiae, many gram- 
negative organisms and some staphylococci and streptococci. It is 
rapidly absorbed when given orally, is approximately 60% protein bound 
and is excreted largely in the urine by glomerular filtration, where 
in normal individuals it attains a concentration of some 20 times that 
of the plasma levels. In patients with renal failure the concentration 
of active drug is little altered by falling creatinine clearance but the 
accumulation of inactive metabolites is inversely proportional to the 
glomerular filtration rate (Lindberg et al 1966), These metabolites are 
predominantly aryl amines and their derivatives which may be responsible 
for some of the toxic effects of chloramphenicol. They can be removed by 
dialysis with an efficiency of approximately half that of the removal of 
creatinine (Kunin et al 1959c). The most important adverse reaction to 
chloramphenicol is bone marrow depression which occurs with sufficient 
frequency to be considered a major reason for avoiding the drug where 
possible.
For this reason, it would seem advisable to prescribe other antibiotics 
to patients in renal failure, since the accumulation of potentially toxic 
metabolites may cause an increased frequency of adverse reactions under 
these circumstances. Tfhere the drug must be used, it should be given in 
normal doses for as short a time as possible.
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AMPHOTERICIN B
This antifungal antibiotic is effective against histoplasma, 
coccidiodes, Candida species and cryptococcus. Although these 
organisms only rarely occur as systemic pathogens in Great Britain, 
the increasing use of renal and other transplantation procedures has 
lead to an increased frequency of opportunistic fungal infections with 
organisms likely to be sensitive to amphotericin.
In the normal individual, after a loading dose of 1 mg/kg body weight, 
maintenance doses of 0.5 mg/kg body weight per day will give serum levels 
of amphotericin considerably in excess of the necessary fungicidal levels. 
Unfortunately, the most frequent major adverse reaction with this drug is 
marked renal impairment which may occur in over one third of those treated.
When given to normal individuals, amphotericin produces a wide variety of 
histopathological lesions in the kidney varying from glomerular proliferative 
changes to tubular degeneration associated with hypokalemia and renal tubular 
disorders (Douglas and Healy 1969), Utz et al (1964) reviewed the complications 
of amphotericin therapy and included hypersensitivity reactions, acute hepato­
cellular dysfunction, red cell aplasia aiid renal damage.
Bindschadler and Bennett (1969) investigated three patients with renal 
failure given amphotericin. They did not demonstrate a correlation between 
renal function and peak serum levels, nor did they demonstrate further 
deterioration in renal function or accumulation of the drug. Thus, despite 
the considerably toxicity of this drug, current evidence suggests that, if 
necessary, it may be given (in normal dosage) to patients with renal failure.
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ETHAiffiUTOL
This drug has its specific effect on mycobacteriae and on no other 
organisms. It is well absorbed when given orally and is excreted mainly 
by the kidneys. Its major toxic effect is that of a retrobulbar neuritis 
which results in decreased visual acuity and reduced visual fields.
Fortunately this complication is reversible on withdrawal of the drug 
(Leibold 1966). The half life of this drug in the serum of normal subjects 
is four hours and this extends to 7-1/4 hours in the nephrectomised individual. 
Thus some reduction in dosage is necessary in patients with renal failure 
although exact recommendations have not yet been published. Dume et al
(1971) recommended the following dosage schedules for patients requiring 
dialysis: 17.8 mg/kg per 24 hours during a 30-hour peritoneal dialysis;
23 mg/kg after an eight-hour haemo-dialysis; and 17.8 mg/kg per 24 hours 
during dialysis-free periods.
VANCOMYCIN
Vancomycin is a potent bactericidal agent used mainly in the treatment 
of severe staphylococcal infections, especially those due to strains resistant 
to other antibiotics. It is given systemically— usually intravenously— and 
is excreted predominantly in the urine. The half life of this.drug in 
normal individuals is around six hours and this is prolonged in renal impair­
ment (Lindholm and Murray 1966). Because of its considerable nephrotoxic 
and ototoxic properties, this drug should be avoided in those with renal 
impairment. Should it be required, serial blood levels are advisable. For 
anuric individuals, a dose of one gram intravenously may give persistent 
blood levels for ten days.
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NITROFURANTOIN
This drug is a urinary antiseptic, effective against many gram- 
negative and some gram-positive organisms. When given orally, about 40% 
can be recovered in the urine of normal subjects (Paul et al 1959). The 
recovery in those with renal impairment is proportional to the creatinine 
clearance (Sachs et al 1968). Goff, Schlegel and O ’Dell (1968) reported 
that blood levels of nitrofurantoin remained low after a dose of 100 mg 
six-hourly until the creatinine clearance fell below 14 ml/minute, when 
accumulation became obvious in the serum. There was an inverse relation­
ship between creatinine clearance and urinary excretion in the patients. 
Schreiner (1970) noted that the drug was dialysible.
Side effects of nitrofurantoin therapy are haemolysis, hypersensitivity 
reactions, alimentary upsets and severe polyneuropathy, occurring particularly 
in patients with renal impairment (Martin et al 1962), although Craven (1971) 
reported five patients with peripheral neuropathy attributed to nitrofurantoin 
who developed symptoms in the absence of elevated levels of blood urea 
nitrogen.
Since therapy with this drug is likely to prove ineffective in patients 
with reduced creatinine clearances, because inadequate drug levels can be 
attained in the urine and since there is a risk of polyneuropathy complicating 
the therapy, the drug should not be given to patients with renal impairment. 
This conclusion was also reached by Felts et al (1971), who additionally 
demonstrated minor reduction in nerve conduction velocities in three of nine 
patients with urinary tract infection and impaired renal function.
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NALIDIXIC ACID
This is an antibacterial substance excreted in the urine in con­
centrations which are sufficiently great to be bacteriostatic to many 
gram-negative organisms including E, coli, Klebsiella and proteus species, 
but excluding pseudomonas. Concentrations attained in body fluids other 
than the urine are insufficient to exert any antibacterial effect (Goodman 
and Gilman 1970). Given orally, this drug is relatively free of toxic 
effects. Its use in patients with renal failure has received little 
attention, however, Sachs et al (1968) reported 17 patients with creatinine 
clearances ranging from 8-121 ml/minute, who received nalidixic acid in 
doses of one gram six-hourly. They reported high urine concentrations 
even in patients with markedly diminished glomerular filtration rates.
This work has subsequently been confirmed by Adam and Dawbom (1971) who 
noted an increased absorption and clearance of the drug when given with 
sodium bicarbonate. It seems likely, therefore, that nalidixic acid is a 
useful agent for the treatment of urinary tract infections even in those 
with severe renal impairment, however, under those circumstances, it is 
frequently desirable to attempt therapy with a bactericidal agent at first 
and then maintain success with a drug such as nalidixic acid. Finally, 
the rapid development of bacterial resistance may limit its usefulness 
(Ronald et al 1966).
Although most frequently given orally, some workers have given it intra­
venously under experimental conditions (Zinsser et al 1970). As yet however, 
such a procedure has not gained widespread acceptance and therefore cannot 
be recommended for patients with renal impairment.
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SULPHONAMIDES
The sulphonamides are bacteriostatic agents effective against many 
gram-positive and gram-negative organisms and recently used principally 
in the treatment of urinary tract Infection. Their antibacterial 
activity is inhibited by the presence of blood, pus or tissue breakdown 
products. Although a wide range of toxic effects has been reported with 
sulphonamides, including crystals of drug or metabolite in the urine and 
hypersensitivity reaction leading to nephropathy (Abramowicz and Edelmann 
1968), these appear to be rare with the drugs currently in regular use 
(see Chapter 7 ; Koch-Weser et al 1971).
Sulphadimidine is a weak organic acid excreted by glomerular filtration, 
proximal tubular secretion, tubular reabsorption, and passive pH dependent 
non-ionic back diffusion. Williams et al (1968) studied the renal clearance 
of intravenously administered sodium sulphadimidine in normal and uraemic 
subjects. The clearance of this drug was found to be higher in patients 
with chronic renal failure than in normals, the mean clearance being
11.4 ml/minute in patients with renal impairment, and 6.3 ml/minute in normal 
subjects. There was no correlation between glomerular filtration rate and 
sulphadimidine clearance. Although in normal subjects the sulphadimidine 
clearance was related to urine pH this was not so in those with chronic renal 
failure. These authors concluded that sodium sulphadimidine was not retained 
in patients with chronic renal failure and that the urine levels achieved 
were adequate for the eradication of sulphonamide-sensitive organisms.
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With sulphamethizole on the other hand, the serum half life is 
considerably prolonged in patients with low glomerular filtration rates 
(Goff et al 1968). Nevertheless these workers recorded that even with 
glomerular filtration rates of 8 ml/minute this sulphonamide attains 
bacteriostatic concentrations in the urine, thus the evidence suggests 
that some sulphonamides, notably sulphadimidine, can be given in normal 
dosage to patients with even severe renal impairment. Moreover, Koch- 
Weser et al (1971) noted that in a large series of prespectively monitored 
patients, adverse reactions to the sulphonamides sulfisoxazole and sulfa- 
methazole, were infrequent, occurring in about 3.1-3.3% of the monitored 
patients. In this series no case of nephrotoxicity attributable to 
sulphonamides was observed.
Recently the sulphonamide-trimethoprim preparations have gained in 
popularity for the treatment of urinary tract infections.- These drugs 
are however dispensed in fixed dose combinations which is unfortunate 
since there are substantial differences between the sulphonamides and 
trimethoprim in terms of their handling by the kidney. In particular, 
while sulphamethoxazole is not retained in moderate renal impairment, 
trimethoprim clearance falls sharply with declining renal function 
(Sharpstone- 1969). Thus in such patients careful attention should be 
paid to possible adverse effects of trimethoprim on the bone marrow. Al­
though there are reports of haematological reactions to this combination, 
the frequency with which these occur is at present ill defined (for review 
see under Evaluation on New Drugs 1971). In addition, it has been noted
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that alimentary upsets are common when this drug is given to patients 
with renal impairment (see Chapter 4 ; McGeown 1970).
Finally because the concentration ratio of the two drugs in this 
combination vary with the glomerular filtration rate and with urine pH 
the effect of such variations on the efficacy of therapy is unknown.
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PERITONEAL DIALYSIS
Patients undergoing peritoneal dialysis frequently have infections 
requiring therapy with antibiotics. In addition, many physicians adopt 
the practice of adding small amounts of antibiotics to the infused 
dialysis fluid in the hope of minimsing infection within the peritoneal 
cavity. Greenberg and Sanford (1967) studied the behaviour of four 
antibiotics— tetracycline, chlorampehnico1, kanamycin and colistin— given 
to patients during peritoneal dialysis. Of these four, only kanamycin 
was removed by dialysis in amounts sufficiently great to require a change 
in the normal dosage regime for patients with renal failure. The authors 
recommended an initial loading dose of 0.5 grams kanamycin followed 
by 0.25 grams per day during dialysis. When these antibiotics were ad­
ministered in the dialysis solution, adequate therapeutic serum concentrations 
were obtained with all drugs, however, it was found that when tetracycline 
was administered in normal doses, it was readily absorbed and could attain 
potentially toxic serum levels if therapy was maintained during the entire 
dialysis.
In a similar study to that reported above. Buck and Cohen (1968) showed 
that cloxacillin, ampici11in, cephaloridine, kanamcyin and polymixin added 
to dialysis fluids all produced therapeutic serum levels during dialysis and 
for some hours thereafter. Only in the case of cloxacillin did the serum 
levels fall rapidly after the end of dialysis (half life 2.5 hours). Similarly, 
cephalothin, ampicillin, chloramphenicol and tetracycline in reduced dosage 
have been shown to produce therapeutic blood levels when administered directly 
in the peritoneal dialysis solution (Bulger et al 1964; Ruedy 1966).
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Thus it would seem possible to attain adequate serum and tissue 
levels of various antibiotics by adding these to the dialysis fluids 
during such a procedure. However, it seems likely that most physicians 
would prefer to administer antibiotics in the normal manner even during 
peritoneal dialysis, rather than to adopt the fluid as a medium for 
introducing these drugs. One possible exception to this is where there 
is evidence of pre-existing inflammation in the peritoneal cavity when 
it is possible that direct administration of the drug to the inflamed 
area may be of additional importance (Linton, personal communication).
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DISCUSSION
This review was undertaken in an endeavour to provide guidelines 
both on the choice of antibiotic and on the correct dosage of each 
antibiotic in patients with varying degrees of renal failure.
Analysis of the published work reveals considerable difficulties 
in attaining this aim since few of the studies are directly comparable 
in terms of the methods'used. The classical papers by Kunin and his 
colleagues (1959) are good models of the type of study required, and more 
recently the studies of Bailey et al (1970), Curtis and Eastwood (1968), 
and Orme and Cutler (1969) illustrate how the pharmacology of any new 
antibiotic should be investigated in relation to the degree of renal 
impairment and the effect of haemodialysis. The pattern of absorption, 
metabolism and excretion of each drug should be defined in the normal, 
and studies on patients with reduced renal function should include peak 
serum levels obtained, serum half-life, urine antibiotic levels, effect of 
dialysis, and the effect of renal failure on the fraction of drug bound to 
serum proteins, WThere the drug is ordinarily given orally, data on its 
absorption in such patients is also required.
Comparison of various dose regimes has also proven difficult, since 
some authors advocate reduced dosage at the normal frequency while others 
favour prolongation of the time between doses. Where possible, it would 
seem preferable to administer the drug at the regular time intervals in 
reduced dosage after an initial normal loading dose (O’Grady 1971).
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In addition, it should be observed that an extrapolation from calculations 
based on the administration of a drug by one route, cannot be made to 
other routes of administration of the same drug. It has been shown, for 
example, that in the diabetic patient, penicillin given intramuscularly 
is poorly absorbed (Lemer and Weinstein 1964)— such studies have, however, 
not been reported in patients with renal failure in various stages of 
hydration.
In an attempt to rationalise this field of study, Dettli (1970) has 
considered the various factors which contribute to the disposition of a 
drug in patients with renal failure, and has derived somewhat complex 
mathematical expressions for calculating the optimum dose frequency of a 
drug. However, his calculations are based on the assumption that the 
patient’s ability to handle a given drug does not vary from time to time, 
and that the metabolic pathways are not likely to change as a result of 
intervening factors such as other enzyme-inducing drugs. There is, however, 
already evidence that these assumptions cannot be made (Pryor et al 1967; 
Curtis and Marshall 1970). Nevertheless, this approach is of considerable 
theoretical interest and may prove to be clinically relevant in the near 
future, as indicated by the work of Mawer et al (1972).
At present, the factors which seem to be the most important in terms 
of assessing the effect of renal impairment on the handling of a given 
drug are summarised in Figure 12.1. in the case of most antibiotics, little 
work has been carried out either on the oral absorption of such drugs, or 
on alterations in their metabolism by the microsomal enzyme systems.
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Furthermore, with the exception of the sulphonamides (see Anton and 
Corey 1971), little work has been done on possible alterations in the 
degree of protein binding of antibacterial agents in renal failure. 
Nevertheless, that such alterations may be of considerable importance 
in the case of other drugs has been shown in the work of Reidenberg and 
colleagues (1971), who studied the effect of uraemia on protein-binding 
of diphenylhydantoin. The lower half of Figure 12.1 briefly outlines 
possible consequences of alterations in the protein binding of drugs.
This again emphasises the need for careful investigations into the role 
of protein binding of antibiotics in patients with renal failure.
Drug Interact-ions. Patients admitted to hospital with severe renal 
failure frequently require a prolonged period of hospitalisation resulting 
in the administration of a large number of pharmacologically active drugs. 
Thus the potential for drug interaction is unusually high in such patients. 
Since many individuals either have infections with several organisms at 
once or have infections with "resistant organisms," therapy with multiple 
antibiotics is not infrequent and so attention must be directed towards the 
compatibility of such drugs in terms of their effect on the target organisms 
In addition, however, certain problems are more likely to arise in patients 
with chronic renal failure than in those with other conditions. Because of 
the frequency of fluid and electrolyte problems in these patients, the 
administration of either parenteral fluids or of potent diuretics is a 
frequent occurrence. Recently evidence is accumulating on the effect of 
such preparations upon coincidental antibiotic therapy.
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When a patient with chronic renal failure is receiving fluids 
intravenously at the same time as he or she requires a parenteral 
antibiotic, it is tempting to inject the drug "intravenously" by 
injecting through the cuff of the venous line. ï'/hile such a practise 
is reasonable, it has recently become acceptable, particularly in the 
United States, to add the antibiotic directly to the bottle of infusion 
fluid. Such a practise has been advocated by Professor 0 ’Grady and his 
colleagues from St. Bartholomew’s Hospital in London, since this technique 
allows for easier calculation of the dosage of drug required to provide 
predetermined serum levels (O’Grady et al 1971). However, it has been 
emphasised that penicillin rapidly loses its antibacterial activity if 
added to solutions containing both sodium bicarbonate and sucrose or 
dextrose (Simberkoff et al 1970). Both ampicillin and methicillin are 
also affected by addition to dextrose-containing solutions (Lynn 1971). 
Finally, when solutions of kanamycin and methicillin are mixed, the 
methicillin loses most of its antibacterial activity within minutes 
(Lynn 1971). Thus, until more information is available on the stability 
of antibacterial agents in infusion fluids, it would seem best to avoid 
this method of administration.
Turning now to the problem of the effect on antibiotic therapy of 
other drugs administered contemporaneously with the antibiotics, several 
clinically significant interactions are of importance. Firstly, the tetra­
cyclines are inactivated when they form chelates with metallic ions. The 
ions most frequently involved are calcium, magnesium, and aluminium, and 
this interaction is of relevance only when tetracyclines are taken orally
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(Goldberg 1965). Since tetracyclines are bacteriostatic and have been 
incriminated as a cause of significant rise in blood urea nitrogen, 
they should be avoided in patients with renal failure, particularly if 
such patients require therapy with aluminium hydroxide or other drugs 
containing those ions mentioned above. Secondly, sodium bicarbonate 
given orally increases the absorption of nalidixic acid (Adam and 
Dawbom 1971) . The mechanism for this is unkno;m, but possibly it is 
one of altered intestinal pH. If this is so, it may be relevant to 
observe that Finland and his co-workers (1945) demonstrated enhanced 
blood levels of oral penicillin when comparing achlorhydric subjects 
with normal controls. If the gastric pH is an important factor in the 
absorption of orally administered antibiotics, then this alone will 
affect their handling in patients with renal failure. Thirdly, both 
frusemide and ethacrynic acid are known to produce ototoxicity under 
rare circumstances (Mathog and Klein 1969; Schwartz et al 1970). The 
aminoglycoside antibiotics have also been established as causing oto­
toxicity. It is therefore not surprising that claims of a possible 
potentiating effect of these drugs given together have been made (Mathog 
and Klein 1969; Johnson and Hamilton 1970). These claims have as yet 
remained unsubstantiated in any large body of data, however, the possibility 
of such an interaction should always be entertained, particularly if the 
diuretic is given intravenously, since it is thought that ototoxicity is 
greatest when this route is employed. Fourthly, it has recently been 
suggested that the nephrotoxicity of the cephalosporins is enhanced by 
coincidental diuretic therapy (Foord 1969; Lawson et al 1970). ^Ihile 
certain experimental animal work has been reported which confirms this
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possible interaction (Dodds and Foord 1970; Chapter 9 ) the observation 
awaits final confirmation in a large series of prospectively studied 
patients.
This review has emphasised that, while a large volume of work has 
been reported on the effects of renal impairment on the body*s handling 
of antibiotics, much more remains to be done. In particular, it can be 
concluded that for most of the common antibiotics modified dose regimes 
can be prescribed for short periods of time, however, the position is 
much less clear when long term antibiotic therapy may be required. 
Possible interactions among antibiotics or between antibiotics and other 
drugs have been recorded. This field requires a considerable increase 
in the effort directed towards it particularly in patients receiving 
large numbers of other drugs or who have varying degrees of renal impair­
ment (e.g. post-transplant patients or those in the diuretic phase of 
acute renal failure).
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The work described in this thesis was undertaken to elucidate 
certain aspects of the management of urinary tract infections. The 
early part of the thesis is concerned with assessing the role of 
screening tests in the identification of bacteriuria in the first tri­
mester of pregnancy. This is important since it has been claimed that 
virtually all pregnant patients who develop urinary tract infections 
(U.T.I.) in late pregnancy have asymptomatic bacteriuria in the first 
trimester. Were this to be the case, then U.T.I. in pregnancy could 
become a preventable disease. To test this hypothesis, a simple routine 
screening procedure was carried out on a large population of pregnant 
patients attending a local maternity hospital. As a result a group of 
patients with asymptomatic bacteriuria was detected. Long-term follow-up 
of all patients screened revealed that the proportion of those developing 
U.T.I, in late pregnancy who had an initially positive screening test was 
low (i.e., the screening test for bacteriuria was not a sensitive pre­
dictor of subsequent U.T.I. in pregnancy). This result called in question 
the value of a single test as a means of preventing subsequent U.T.I.
In view of the importance of this finding for practitioners, a further 
theoretical assessment of the value of such screening tests was undertaken 
using as a basis the published data on the subject. This review indicated 
that, even under optimal conditions, the sensitivity of the screening test 
is unlikely to exceed 50% —  a finding which suggests that it is highly 
inefficient as a means of drastically reducing the incidence of U.T.I. in 
pregnancy.
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Running contemporaneously with this study of screening tests in 
pregnancy, an assessment of the role of routinely screening the urine 
for cells and bacteria of all patients with symptoms of U.T.I. in 
general practise was performed. The patients came from two separate 
group practises in Glasgow. In the course of analysing the data, it 
was noted that the reported incidence of such symptoms was over twice 
as high in one practise than in the other. Several factors were felt 
to contribute to this finding. Firstly, the symptoms appeared to be 
commoner in patients of low social class. Secondly, the higher prevalence 
of symptoms occurred in the practise which serves an area of particularly 
low social class. Finally, the higher frequency of symptoms occurred in 
the practise solely run by female physicians— a factor which might lead 
to an increased frequency of reporting symptoms to the physician.
A review of the past history and present complaints of the patients
failed to reveal any factor or group of factors which could be used to
indicate whether the patients' urine was or was not sterile at the first
visit. In addition, the response to therapy was good irrespective of the
nature of the findings in the urine on presentation. Thus the study failed 
to provide evidence of the value of routinely screening the urine of all 
patients attending their practitioners with symptoms of U.T.I. The main 
benefit to accrue from the procedure was that those with a positive modi­
fied Addis count (as a reflection of the leucocyte excretion rate in the 
urine) and bacteriuria, had a higher recurrence rate than patients with­
out these features. Nevertheless repeated recurrences were rare— only 2.7% 
of patients being referred to hospital for further investigation.
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The result of long-term antibacterial therapy in 66 patients 
with established U.T.I. was then reviewed. All the patients had 
had recurrent U.T.I. with frequent demonstration of bacteriuria and 
failure to respond to short-term courses of therapy. A three-month 
course of sulphadimidine, ampicillin or nitrofurantoin was found to 
be effective in relieving symptoms and in sterilising the urine for 
a period of one year in 49% of patients. Those individuals with 
normal intravenous pyelograms fared better than those with abnormal 
ones. One half of the recurrences in the two years after therapy 
occurred within three months of stopping the drugs.
Several factors other than frank infection have been implicated 
in the development of U.T.I, For example, it has been suggested that 
long-term, high-dose analgesic consumption predisposes individuals to 
renal disease which then frequently becomes infected. Likewise, it 
has been suggested that diabetes mellitus predisposes patients to U.T.I. 
Certain aspects of these hypotheses were tested in two studies reported 
here. Firstly, using data collected by the Boston Collaborative Drug 
Surveillance Program (BCDSP), an investigation into the relationship 
between long-term analgesic intake, renal disease (as indicated by 
presenting blood urea nitrogen levels) was undertaken. This cross- 
sectional data failed to reveal a positive association between 
excessive analgesic intake and either renal disease or impaired renal 
function. Moreover, there was no evidence of a dose-response relation­
ship between regular intake of over-the-counter analgesic preparations
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and these, admittedly crude, parameters of renal disease. The data 
therefore suggest that if such a relationship exists, it is either a 
subtle one which rarely causes major renal disease or it occurs only 
in a sub-population of the large group of long-term analgesic users.
Secondly, an investigation was performed to test the hypothesis 
that recurrent U.T.I. might be associated with latent diabetes mellitus 
in a large proportion of cases. The data, however, indicate that such 
a relationship did not exist in a group of fifteen individuals with 
known established U.T.I, and suggest that latent diabetes mellitus is 
not a common predisposing factor in such individuals.
The latter half of the thesis is concerned with the hazards of 
antibiotic therapy in patients with urinary tract infection and renal 
impairment.
Using data collected by the BCDSP, two major investigations were 
carried out. Firstly, a simple overview of the reported adverse 
reaction rates to twenty commonly used antibacterial agents was under­
taken. Included in this data is a general indication of the frequency 
with which physicians attribute renal damage to these drugs. Secondly, 
a more detailed analysis of the association between tetracycline receipt 
and subsequent rise in blood urea nitrogen (BUN) was undertaken. This 
revealed that in patients receiving diuretics, there was a three-fold 
increase in the frequency of reported rises in BUN amongst tetracycline 
recipients when compared with recipients of any other drugs excluding
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the nephrotoxic antibiotics. As an addendum to this chapter, the data 
on nephrotoxic antibiotics was reviewed. This showed that the frequency 
of reported rises in BUN was greater amongst diuretic recipients than 
non-recipients, however, the number of patients involved was small and 
so no firm conclusions could be drawn, other than to suggest that the 
figures are compatible with the findings of animal experiments reported 
in the subsequent chapter.
The next two chapters deal with animal experiments designed to 
assess the nephrotoxic potential of cephaloridine. It has been suggested 
that this drug is nephrotoxic to man and to animals, that its toxicity 
depends on the dose received at any one time rather than on the cumulative 
dose received, that the half-life of the drug in anephric man varies 
according to the length of regular dialysis therapy and that its nephro­
toxicity is enhanced by coincidental diuretic administration. The studies 
reported here confirm that the drug is nephrotoxic to rabbits and to rats, 
but suggest that the total dose of drug given to rabbits is of some import­
ance in determining the degree of nephrotoxicity observed. In several 
animals subnephrotoxic doses of cephaloridine given on two occasions 
separated by one week gave definite evidence of renal damage. The half-
life of this drug given to a group of rabbits was found to be variable.
There was no evidence that phénobarbital enhanced the rate of metabolism
of this drug in rabbits. Finally, experiments on rats whose kidneys were
mildly damaged with glycerol indicated that the nephrotoxicity of 
cephaloridine was considerably enhanced by the simultaneous administration 
of the diuretic frusemide.
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These data, derived' from animal experiments, suggest that the 
cephalosporin antibiotic cephaloridine should be used with caution 
in patients with impaired renal function particularly when potent 
diuretics are also being administered.
A final group of experiments were performed on patients under­
going regular dialysis treatment. The rate of disappearance from the 
serum of five frequently used antibiotics was studied in such patients 
In each case, the drug was'studied both before and after dialysis 
procedures. On the basis of the findings, recommendations were made 
concerning the dosage of each drug required by regularly dialysed 
patients.
The thesis concludes with a detailed review of the place of 
antibiotic therapy in patients with renal failure. Each antibiotic 
is considered separately and the literature pertaining to its use in 
such individuals is critically evaluated.
p R O B M ®  Br THE m m m m r  of urinary tract infection
- Clinical Epidemiological and laboratory Studies -
by
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S U M M A R Y
The work described in this thesis was undertalcen to elucidate 
certain aspects of the management of urinary tract infections. The 
early part of the thesis is concerned with assessing the role of 
screening tests in the identification of bacteriuria in the first 
trimester of pregnancy. This Is important since it has been claimed 
that virtually all pregnant patients who develop urinary tract 
infections (U.T.I,) in late pregnancy have asymptomatic bacteriuria 
in the first trimester. To test this hypothesis a simple screening 
procedure v/as carried out on a large proportion of pregnant patients 
attending a local maternity hospital. As a result a group of 
patients with asymptomatic bacteriuria was detected. Long-term 
follow-up of all patients screened revealed that the proportion of 
those developing U.T.I, in late pregnancy and who had an initially 
positive screening test was low# This result called in question the 
value of a single test as a moans of preventing subsequent U.T.I. In 
view of the importance of this finding for practitioners a further 
theoretical assessment of the value of such screening tests was 
undertaken using as a basis the published data on the subject. This 
review indicated that even under optimal conditions the sensitivity 
of the screening test in predicting subsequent U.T.I, is low - a 
finding which suggests that it is Inefficient as a means of 
drastically reducing the incidence of U.T.I. in pregnancy.
An assessment of the role of routinely screening the urine of all 
patients with symptoms of U.T.I. in general practice was then 
undertalcen# The study failed to provide evidence of the value of
routinely screening the urine of all patients attending their 
practitioners with symptoms of U.T.I. The main benefit to accrue 
from this procedure was that those with a positive modified Addis 
count (as a reflection of the leucocyte excretion rate in the urine) 
ond bacteriuria had a highei? recurrence rate than patients without 
these features. Nevertheless repeated recurrences were r&u?e « only 
2.7/j patients being referred to the hospital for further investigation, 
The result of long-term anti-bacterial therapy on 66 patients 
with established tf.T.I. was then reviewed. All patients haxi had 
recurrent U.T.I. with frequent demonstrations of bacteriuria and 
failure to respond to short-term oo\a*ses of therapy. A three-month 
course of the indicated anti-bacterial agent was found to be 
effective in relieving symptoms and in sterilising the urine for a 
period of one year in 49/o of the patients. Patients with normal 
intrfivenouB pyelograms fared better than those with abnormal ones*
One half of tlie recurrences in the two years after therapy occurred 
within ttoee months of stopping the drugs*
Several factors other than frank infection have been implicated 
in the development of U.T.I. For example, it has been suggested 
that long-term high dosage analgesic consumption pre-disposes 
individuals to renal disease which then frequently becomes infected, 
likewise it has been suggested that diabetes raellitus pre-disposes 
patients to U.T.I. Certain aspects of these hypotheses were tested 
in two studies reported here! firstly using data collected by the 
Boston Collaborative Drug Surveillmice Programme (B.C.B.C.P.) 
investigation into the relationship between long-term analgesic intolce
and renal disease was undertalcen. This cross-sectional data failed 
to reveal a positive association between excessive analgesic intaJce 
and either renal disease or impaired renal function. Moreover there 
was no evidence of a dose-response relationsMp in patients regularly 
consuming •over-the-counter* mmlgesic preparations and these, 
admittedly crude, porsmeters of renal disease. The data therefore 
suggests that if such a relationship exists it is either a subtle one 
which r^irely causes major renal disease or it occurs only in a 
sub-population of the large group of long-term analgesic users,
Secondly an investigation vqb performed to test the hypothesis that 
patients who succumb to U.T.I* might frequently suffer from latent 
diabetes mellitus* The data however indicates that such a 
relationship did not exist in a group of 15 individuals with Imovm 
established U.T.I, and suggests that latent diabetes mellitus is not 
a common pro-disposing factor in such individuals.
The latter half of the thesis is conceired with the hazards of 
antibiotic therapy in patients with urinary tract infections and 
renal impairment.
Using data collected by the B.C.U.S.P. two major investigations 
were carried out: firstly a simple over-view of the reported adverse
reaction rates to tv/enty commonly used anti-bacterial agents was 
undertalcen. Secondly a more detailed analysis of the association between 
tetracycline administration and subsequent rise in blood urea nitrogen 
was undertaken* This revealed that in patients receiving diuretics, 
there was a three-fold increase in the frequency of reported rises 
in blood urea nitrogen when compared with recipients of all other
driigs excluding the neplirotoxic antibiotics. As an addendum to 
this chapter the data on neplirotoxic antibiotics v/as reviewed •
Unfortunately the number of patients involved was small and so no
firm conclusions could be drawn other than to suggest that the 
figures were compatible with the findings of animal experiments 
reported in the subsequent chapter#
The next two chapters deal with animal experiments designed to
assess the nephrotoxic potential with cephaloridine# It has been 
suggested that iiiis drug is nephrotoxic to animals and to man, that 
its toxicity depends on the dose received at any one time rather 
than on the oumuiative dose received, that the half-life of the 
drug in an anephric man varies according to the length of regular 
dialysis therapy and that its neplrrotoxicity is enhanced by 
coincidental diuretic administration# The studies reported here 
confirm that the drug is nephrotoxic to rabbits and to rats, but 
suggest that the total dose of drug given to rabbits is of some 
importance in determining the degree of neptirotoxicity observed. In 
several animals sub-nephrotoxic doses of cephaloridine given on two 
occasions separated by one week gave definite evidence of renal damage, 
The half-life of this drug given to a group of rabbits was found to 
be variable and there was no evidence that phenobarbitone enhanced the 
rate of metabolism of this drug in rabbits* Finally experiments on 
rats whose kidneys were mildly damaged with glycerol indicated that 
the nephrotoxicity of coxihaloridine was conside3?ably enhanced by the 
simultaneous admini s tr at ion of the diuretic, frusemide # The data
suggests that the cephalosporin antibiotic cephaloridine should 
be used with caution in patients with impaired renal function 
particularly when potent diuretics are also being administered*
The final g3?oup of experiments were performed on patients 
undergoing regu3.ar dialysis treatment. The 3?ate of disappeaarance 
from the senm of five frequently used antibiotics was studied in 
such patients. In each case the drug was studied both before and 
after dialysis procedures. On the basis of the findings 
reoommenda.tions were made concerning the dosage of each drug 
required by regularly dialysed patients*
The thesis concludes with a detailed review of the ple,ce of 
antibiotic therapy in patients with renal failure. Each antibiotic 
is considered separately and the literature pertaining to its use 
in such individuals is critically évaluéd*
TABLE 1,1
RELATIONSHIP OF URINARY TRACT INFECTION IN PREGNANCY 
TO RESULTS OF INITIAL SCREENING TEST
SCREENING FREQUENCY OF URINARY TRACT INFECTION
TEST DEFINED CLINICALLY BACTERIOLOGICALLY CONFIRMEI
BACTERIURIC 
(Group A)
15/54 = 27.7% 9/54 16.6%
DOUBTFUL 
(Group B)
9/89 - 10.1% 6/89 6.7%
NON-BACTERIURIC 
(Group C)
70/1017 = 6.9% 32/1017 3.1%
ALL GROUPS 94/1160 = 8.1% 47/1160 4.1%
TABLE 1.2
SENSITIVITY AND SPECIFICITY OF SCREENING TEST 
IN PREDICTING URINARY TRACT INFECTION (U.T.I.)
URINARY TRACT INFECTION
SCREENING
TEST
DEFINED CLINICALLY 
(94 Patients)
BACTERIOLOGICALLY CONFIRMED 
(47 Patients)
Sensitivity (%) 15.9 19.1
Specificity (%) 95.4 ‘ 91.3
TABLE ,1.3
RELATIONSHIPS OF HYPERTENSIVE DISORDERS OF PREGNANCY
TO RESULTS OF INITIAL 
(A) URINE '
SCREENING
CULTURE
TESTS
GROUP A GROUP B GROUP C
NUMBER PER CENT NUMBER PER CENT NUMBER PER CENT
Hypertension at 
first visit
15 27.8 16 18.0 162 15.9
Previous hypertension 
and/or pre-eclampsia
6 11.1 11 12.4 97 9.5
Hypertensive disorders 
of pregnancy
11 20.4 14 15.7 113 11.1
All patients 54 100.0 89 100.0 1017 100.0
Group A —  bacteriuric on screening test 
Group B —  doubtful on screening test 
Group C —  non-bacteriuric on screening test
TABLE 1.4
RELATIONSHIPS OF HYPERTENSIVE DISORDERS OF PREGNANCY 
TO RESULTS OF INITIAL SCREENING TESTS
(B) ADDIS COUNT
POSITIVE ADDIS COUNT NEGATIVE ADDIS COUNT
NUMBER PER CENT NUMBER PER CENT
Hypertension at 
first visit
14 15.5 139 16.0
Previous hypertension 
and/or pre-eclampsia
15 16.6 87 10.0
Hypertensive disorders 
of pregnancy
20 22.0 119 13.7
All patients 90 100.0 876 100.0
TABLE 1.5
RELATIONSHIP BETWEEN HISTORY OF URETHRAL CATHETERISATION 
AND BACTERIURIA ON SCREENING
GROUP A GROUP B GROUP C
URETHRAL
CATHETERISATION NUMBER PER CENT NUMBER PER CENT NUMBER PER CENT
Never 32 59.3 53 59.6 641 63.1
0 nee 16 29.6 28 31.5 261 25.6
Twice 5 9.2 6 6.7 70 6.9
Three times or more 1 1.8 2 2.2 45 4.4
Total 54 100.0 89 100.0 1017 100.0
Group A - bacteriuric 'on screening test 
Group B - doubtful on screening test 
Group C - non-bacteriuric on screening test
FIGURE 2.1
RELATIONSHIP OF SCREENING TEST TO SUBSEQUENT 
DEVELOPMENT OF URINARY TRACT INFECTION*
1000
Positive Screen 
46
AbacteriuricBacteriuric
No UTINo UTI
Negative Screen 
954
Bacteriuric
No UTI
Abacteriuric
906.3
UTI
9.0
No UTI 
897.3
Total number of patients developing UTI = 31.8
Numbers with UTI who had positive screen = 10.9
Numbers with UTI who had negative screen = 20,9
Frequency of UTI in those with positive screen = 23.7%
Frequency of UTI in those with negative screen = 2.0%
'assuming —  95% accuracy of screening test
4.6% with positive screening test
25% bacteriurics develop urinary tract Infection
1% non-bacteriurics develop urinary tract infection
TABLE 2.1
CALCULATED EFFICIENCY OF TESTS IN PREDICTING BACTERIURIA
Group Test
Accuracy
(%)
Sensitivity 
for Bacteriuria 
(%)
Specificity 
for Bacteriuria 
(%)
A 80 16.2 98.8
B 90 30.3 99.4
C 95 47.8 99.7
D 97.5 65.3 99.9
Figures calculated on basis of 4.6% positive tests.
TABLE 2.2 (continued)
Based on variations in frequencies with which bacteriuric and non- 
bacteriuric patients subsequently develop urinary tract infection 
during pregnancy.
Group A^ - A^ - screening test accuracy of 80%
Group B^ - Bg - screening test accuracy of 90%
Group - screening test accuracy of 95%
Group - screening test accuracy of 97.5%
TABLE 2.2
CALCULATED SENSITIVITIES AND SPECIFICITIES OF 
VARIOUS SCREENING TESTS FOR BACTERIURIA IN PREDICTING 
DEVELOPMENT OF URINARY TRACT INFECTION DURING PREGNANCY*
Group
%
Bact. 
-)-UTI
%
Non-
bact,
-^ UTI
%
Positive 
S creen 
^UTI
%
Negative
Screen
^-UTI
Sensitivity 
for UTI 
(%)
Specificity 
for UTI 
(%)
N 25 0.5 19.8 5.4 15.0 96.1
25 1.0 20.0 5.8 14.3 96.1
25 2.0 20.2 6.6 12.9 96.0
H 25 0.5 22.4 2.9 26.9 96.3
25 1.0 22.4 3.4 24.1 96.3
^3 25 2.0 22.4 4.3 20.1 96.2
25 0.5 23.7 1.7 40.0 96.4
C2 25 1.0 23.7 2.0 34.2 96.4
C3 25 2.0 23.9 3.1 26.6 96.3
h 25 0.5 24,3 1.1 51.6 96.4
D2 25 1.0 24.3 1.5 42.4 96.4
D3 25 2.0 24.3 2.6 31.4 96.3
33 0.5 32.4 1.3 54.2 96.8
D5 ■ 33 1.0 32.4 1.8 46.4 96.8
I»6 33 2.0 32.4 2.7 36.0 96.7
*see opposite page
FIGURE 2.2
RELATIONSHIP OF THE SENSITIVITY FOR DETECTION OF 
URINARY TRACT INFECTION TO THE ACCURACY OF THE SCREENING TEST
IN DETECTING BACTERIURIA
Test
Sensitivity! %) 
60-1
50“
40
30-
20-
10
/ x
Frequency of
• = 0-5%
Bacteriurics
X =
o =
10 %
2-0%
80 90 100
Screening Test Accuracy ( % )
FIGURE 3.1
STANDARD FORM USED BY NURSE AND GENERAL PRACTITIONER 
WHEN PATIENT ADMITTED TO STUDY
TRIAL NO.
NAME:
ADDRESS:
AGE: PARITY:
HUSBAND'S OCCUPATION:
SYMPTOMS: PYREXIA LOIN PAIN FREQUENCY DYSURIA NOCTURIA STRESS
Degree :
Comment :
PAST HISTORY: ENURESIS H'MOON CYSTITIS PREGNANCY CYSTITIS PREV.PYELONEPHRITIS
Frequency:
Comment :
URINE EXAMINATIONS: 
DATE:
Addis :
Bacteriology : 
Therapy Group:
COMMENTS :
/ / / / /  /
RECURRENCES :
SYMPTOMS :
Degree: 
Comment :
URINE EXAMINATIONS 
Date ;
Addis :
Bacteriology : 
Therapy Group :
REFERRAL TO HOSPITAL: YES/NO
/ / / / / /
TABLE 3.1
DISTRIBUTION OF PATIENTS BY REFERRING PRACTICE: 
FINDINGS ON URINE EXAMINATION AND THERAPY RECEIVED
GROUP A GROUP B GROUP C GROUP D ALL GROUPS
Practice R 
Practice S 
Total
45
26
71
(20.7%)
22
25
47
(13.7%)
29
15
44
(12.8%)
105
76
181
(52.8%)
201
142
343
(100%)
Therapy 1 
Therapy 2 
Therapy 3
27
24
20
13
15
19
14
15 
15
61
60
60
115
114
114
Group A “ Abnormal Addis; over 10^ organisms/ml urine. 
Group B - Normal Addis; over 10^ organisms/ml urine. 
Group C - Abnormal Addis; under 10^ organisms/ml urine, 
Group D - Normal Addis; ‘ under 10^ organisms/ml urine,
Therapy 1 - Sulphadimidine 4 g daily.
Therapy 2 - Ampicillin 2 g daily.
Therapy 3 - Sulphadimidine 4 g daily with option to change later,
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TABLE 3.3
COMPARISON OF ORGANISMS ISOLATED FROM PATIENTS 
BELONGING TO THE TWO PARTICIPATING PRACTICES
PRACTICE R PRACTICE S BOTH PRACTICES
ORGANISM NUMBER PER CENT NUMBER PER CENT NUMBER PER CENT
Escherioh-Ca aot-ù 47 70.0 29 57.0 76 64.0
Staph, atbus 8 12.0 12 23.4 20 17.0
Micrococcus spp. 6 9.0 8 15.7 14 12.0
Proteus mtrdbtt’ts 5 7.5 2 3.9 7 6.0
Pseudomonas 
aerugtnosa'
1 1.5 0 0 1 1.0
TABLE 3.4
COMPARISON OF RESULTS OF MODIFIED ADDIS COUNT PERFORMED 
ON EARLY- AND MID-STREAM SPECIMENS OF URINE
EARLY SPECIMEN MID-STREAM SPECIMEN
Addis positive* 27 23
Addis negative 48 52
Total 75 75
= 0.37 p > 0.5
1
*Addis positive if over 10 white blood cells per counted 
area of Neubauer counting chamber.
TABLE 3.5
EFFECT OF THERAPY
SULPHADIMIDINE 
(Therapy 1)
AMPICILLIN 
(Therapy 2)
SULPHADIMIDINE + OTHER 
(Therapy 3)
Number with recurrences 6 (5.2%) 15 (13,2%) 14 (12.3%)
Number with persistent 
symptoms at 14 days 14 (12.2%) 7 ( 6.3%) 16 (14.0%)
Number abnormal at 
14 days 12 (10.4%) 10 ( 8.8%) 10 ( 8.8%)
Total exposed 115 114 114
TABLE 3.6
RECURRENCE OF SYMPTOMS DURING STUDY PERIOD
GROUP A GROUP B GROUP C GROUP D ALL GROUPS
Numbers reviewed at 18 months 65 41 38 166 310
Numbers who reported recurrences 
to G.P. during study 15 4 3 13 35
(11.3%)
Numbers interviewed at 
12 months 29 17 12 79 137
Number who spontaneously 
reported recurrences 6 1 0 11 17
(12.4%)
Number who admitted recurrences 
on questioning 10 3 6 19 38
(27.7%)
Group A - Abnormal Addis; over 10^ organisms per ml urine.
Group B - Normal Addis; over 10 organisms per ml urine.
Group C - Abnormal Addis; under 10^ organisms per ml urine,
Group D - Normal Addis; under 10 organisms per ml urine,
CASE REPORT 31.
Patient : 25 year old unmarried female.
Comment ; Frequent urinary tract symptoms for three years since first 
intercourse (with married man). Considerable conflict with 
family concerning extra-marital intercourse.
Symptoms respond to sulphadimidine for seven days, but 
recur frequently especially after intercourse.
5
Urine examination reveals >10 organisms per ml of urine 
(E. coli) and positive modified Addis count.
Blood urea = 30 mg/100 ml.
Serum creatinine = 0 . 7  mg/100 ml.
Intravenous pyelography: normal.
Cystoscopy: acute bladder inflammation; no evidence of
tuberculosis.
Patient responded to three-month course of trimethoprim-
sulphonamide followed by nightly nitrofurantoin (50 mg).
CASE REPORT 3ii.
Patient ; 54 year old married female, para 1 + 1.
Comment : Frequent urinary tract symptoms for five years although no
history prior to that. No catheterisation during pregnancy, 
no operations, no analgesic abuse.
Symptoms respond to seven-day course of ampicillin but recur 
regularly.
Urine culture reveals >10^ organisms per ml of urine 
(E, coli) and positive modified Addis count.
Blood urea = 36 mg/100 ml.
Creatinine clearance = 75 ml/min.
Intravenous pyelography: normal.
Cystoscopy: normal. •
Patient responded to three-month course of trimethoprim-
sulphonamide.
CASE REPORT 3iii.
Patient : 47 year old married female, para 3 + 0.
Comment ; Intermittent symptoms of urinary tract infection since birth of 
last child (a breech presentation, requiring pudendal block 
anaesthesiae, forceps delivery and urethral catheterisation).
Symptoms respond to seven-day course of sulphadimidine, but 
recur.
Urine culture >10^ organisms per ml of urine (Staph, albus) and 
positive modified Addis count.
Blood urea = 34 mg/100 ml.
Serum creatinine 0.8 mg/100 ml.
Intravenous pyelography: clubbing of calyces in upper pole of
(R) kidney with some scarring over those calyces.
Patient responded to three-month course of trimethoprim-
sulphonamide for at least 18 months after course started.
CASE REPORT 3iv.
Patient : 28 year old married female, para 2 + 0.
Comment : Approximately three episodes of urinary tract symptomatology
per annum since catheterisation following birth of first 
child. No history of U.T.I. prior to childbirth.
Symptoms respond to short courses of ampicillin or sulphonamides.
Urine sterile and microscopic examination negative (on eight 
occasions).
Blood urea 20 mg/100 ml.
Intravenous pyelography: normal.
Cystoscopy: normal
Micturating cystogram: normal.
Patient continues to have intermittent symptoms despite long­
term nitrofurantoin therapy. Has been seen by many physicians 
all of whom observe the presence of marked "psychological over­
lay to symptoms." In support of this, symptoms became exacerbated 
when next-door neighbour (Case Report 3viii) required regular 
dialysis therapy.
CASE REPORT 3v.
Patient : 29 year old married Pakistani doctor of medicine, para 1 + 0.
Comment : Recurrent urinary tract symptomatology since birth of only 
child. No problems at delivery, not catheterised. Patient 
is bacteriologist and anxious about possibility of renal impair­
ment .
Urine examinations - persistently normal.
Blood urea - 23 rag/100 ml.
Creatinine clearance - 90 ml/min.
Intravenous pyelography - dilated minor calyces on right side. 
Cystoscopy - negative.
Patient continues to have symptoms despite several short courses 
and one long-term course of antibacterial therapy.
CASE REPORT 3vi.
Patient : 79 year old, extremely fit, married female, para 3 + 0.
Comment : Five-year history of recurrent episodes of frequency, dysuria,
nocturia and stress incontinence. Symptoms do not respond to 
courses of antibacterial therapy for more than two months.
Urine examination persistently shows >10^ E. coli per ml 
of urine with positive Addis counts.
Blood urea = 37 mg/100 ml.
Creatinine clearance: 64 ml/min.
Intravenous pyelography: normal.
Cystoscopy: evidence of chronic cystitis with increased
vascularity of bladder wall and coarse trabeculation.
Patient only responded to long-term trimethoprim-sulphonamide 
after frequent bladder irrigations with neomycin.
CASE REPORT 3vll.
Patient ; 33 year old married female, nulliparous.
Comment ; Three episodes of urinary tract symptomatology in five months, 
no previous problems. No analgesic abuse.
c
Urine examination >10 E. coli per ml of urine with positive 
Addis count.
On referral to hospital, found to have pancytopenia with 
haematocrit of 21% and leucocyte count of 2,000 per cu.mm. 
Peripheral blood film macrocytic RBG and bone marrow shows 
megaloblastic erythropoiesis.
Serum folate level < 1 yg/ml.
Serum Bq2 level 300 mg/ml.
Schilling test shows reduced absorption pattern not 
corrected by added intrinsic factor.
Glucose tolerance test - flat curve.
Faecal fat excretion abnormally high.
Reduced xylose tolerance.
Small bowel biopsy - flat mucosal pattern.
Excellent response to folic acid - reticulocyte count 35%.
No recurrence of urinary tract symptoms after therapy for 
malabsorption syndrome.
CASE REPORT 3vlii.
Patient : 37 year old married female, para 3 + 0 .
Comment : Four episodes of urinary tract symptomatology in last four
years. No previous history. No analgesic abuse. No regular 
drug therapy. On this occasion given ampicillin, but symptoms 
recurred. Urine culture and microscopy negative on four 
occasions. On examination in hospital, showed classical signs 
of rapidly progressive renal failure (over four week course). 
Had hypertension, oliguria, proteinuria, haematuria. 
Investigations revealed a positive anti-nuclear factor antibody 
(1/256), and I.E. cells in peripheral blood.
Renal biopsy showed widespread sclerosis of glomeruli ; patient 
failed to respond to steroids and was eventually taken on for 
regular dialysis therapy.
Currently, (four years later) is successfully being dialysed at 
home and is taking small dose of prednisone.
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TABLE 3.8
COMPARISON OF CALCULATED INCIDENCE RATES OF URINARY TRACT SYMPTOMS 
IN PATIENTS FROM TWO GENERAL PRACTICES
AGE RANGE 
(years)
INCIDENCE RATESt 
PRACTICE R
INCIDENCE RATES 
PRACTICE S
15 - 19 37.4 82.5
20 - 29 31.7 54.4
30 - 39 41.0 84.2
40 - 49 38.8 104.4
50 - 59* 36.2 94.3
60 - 69 37.4 —
70 + 20.9 -
All "ages 35.1 76.2
tDerived from observed frequency of U.T.I. over 18-month period of 
admission to study and expressed as incidence per 1000 patients at 
risk per annum.
*Range 50 - 55 years in Practice S,
TABLE 3.9
COMPARISON OF SOCIAL STATUS OF PATIENTS WITH URINARY TRACT SYMPTOMS 
WITH THAT OF THE GENERAL FEMALE POPULATION OF GLASGOW CITY
TAKEN FROM THE 1961 CENSUS*
PRACTICE R PRACTICE S GLASGOW CITY
SOCIAL CLASS** NUMBER PER CENT NUMBER PER CENT NUMBER PER CENT
1 + 2 18 8.9 12 8.4 2,157 12.0
3 103 51.3 70 49.2 9,488 53.0
4 38 18.8 31 21.8 4,532 25.3
5 29 14.2 20 14.2 1,619 9.0
Unknown 14 6.8 9 6.4 128 0.7
All classes 201 100.0 142 100.0 17,924 100.0
*Based on figures supplied by the Registrar General of Scotland.
**Based on husband’s occupation where possible.
Class 1 
Class 2 
Class 3 
Class 4 
Class 5
professional
intermediate
skilled
semi-skilled
unskilled
TABLE 4.1
PRESENTING DIAGNOSIS OF 66 PATIENTS 
INCLUDED IN INITIAL TRIAL
DIAGNOSIS NUMBER
Recurrent urinary tract infection 42
Analgesic abuse/urinary tract infection 12
Hypertension/urinary tract infection 4
Renal calculi 4
Prostatic obstruction 2
Paraplegia 2
TABLE 4.2
ORGANISMS ISOLATED FROM URINE OF 66 PATIENTS*
ORGANISM NUbffiER OF 
PATIENTS
PER CENT
Esohertoh'ia Coti 60 91
Proteus spp. 20 30
Klebsiellae 1 1.5
Streptoaoceus faecal-is 3 4.5
Pseudomonas pyooydneus 1 1.5
*19 patients had mixed infections.
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TABLE 4.4
RESULTS OF TRIAL OF THREE-MONTH COURSE OF 
TRIMETHOPRIM-SULPHAMETHOXAZOLE
GROUP E GROUP F
Numbers 15 15
Adverse reactions 2 6
Recurrence of infection* 5 4
*within six months of commencing therapy.
Group E - patients with normal I.V.P, 
Group F - patients with abnormal I.V.P
TABLE 5.1
BLOOD GLUCOSE VALUES OBTAINED DURING 
100 G GLUCOSE TOLERANCE TEST (15 PATIENTS)
PATIENT AGE BLOOD GLUCOSE LEVEL (mg/100 ml)
Fasting 30 min. 60 min. 90 min. 120 min. 180 min.
1 16 72 142 133 118 84 79
2 19 86 110 94 87 81 77
3 20 75 125 102 96 93 69
4 22 81 148 134 120 103 91
5 25 ' 77 129 117 98 90 85
6 27 76 110 82 76 69 59
7 29 80 98 110 108 102 78
8 34 91 154 141 131 114 96
9 34 79 136 101 96 93 69
10 39 80 110 97 89 83 73
11 40 71 132 110 94 89 77
12 46 81 137 133 101 87 79
13 48 69 120 111 97 85 72
14 48 72 119 116 96 90 84
15 53 85 135 129 120 114 93
Mean 33.4 78.3 127 114 101.8 91.8 78.7
S.E.M. 3.1 1.6 4.1 4.4 3.8 3.1 2.6
FIGURE 5.1
MEAN BLOOD GLUCOSE VALUES OBTAINED 
DURING 100 g GLUCOSE TOLERANCE TEST IN 15 PATIENTS
BLOOD GLUCOSE 
(mg/lOOmI)
140-1
lOOG
Glucose
120 -
100-
8 0 -
60
i
0 1 2 
TIME (hours)
FIGURE 6,1
DISTRIBUTION OF 7017 PATIENTS WITH RECORDED MEDICATION HISTORY
7017
iinîoio^ 'Tn analgesic 
frequency or duration
unknown BUN 
value
279 332
6407
100 (21,7%) 
102 (22,1%)
other drugs
3216
Analgesics
2899
1-6 years 
> 6 years
no drugs 
292
daily occasionally
461 2438
< 1 year 386 (15,8%)
315 (12.9%) 
1737 (71,3%)
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TABLE 6.2
ANALGESICS’m o s t FREQUENTLY CONSUMED BY MONITORED PATIENTS
Daily Analgesic 
Consumers 
(461 Patients)*
No. %
Occasional Analgesic 
Consumers 
(2,348 Patients)
No. %
Aspirin 210 45.5 1,221 50.1
Bufferin 58 12.6 351 14.4
Darvon Compound 42 9.1 79 3.2
Anacin 19 4.1 164 6.7
Tylenol 18 4.0 73 3.0
Exedrin 12 2.6 106 4.4
Compound Codeine 7 1.5 90 3.7
Aspirin-Phenacetin-Codeine 6 1.3 38 1.6
Codeine 5 1.1 17 0.7
Empirin 5 1.1 33 1.4
0 Patients may give a history of consumption of more than one analgesic.
* Of the 461 daily analgesic consumers, 114 (24.7%) consumed phenacetin- 
containing compounds, 307 (65.6%) consumed preparations containing 
salicylate without phenacetin, and 40 (8.7%) consumed preparations 
containing other drugs.
TABLE 6.3
RELATIONSHIP BETWEEN DISCHARGE DIAGNOSIS OF RENAL DISEASE 
AND HISTORY OF ANALGESIC INTAKE
DAILY OCCASIONAL OTHER NO
ANALGESICS ANALGESICS DRUGS DRUGS
Renal Disease 21 (4.5) 92 (3.8) 110 (3.4) 11 (3.8)
Other Disease 440 2,346 3,106 281
All 461 2,438 3,216 292
TABLE 6.4
PATIENT CHARACTERISTICS
DAILY OCCASIONAL OTHER NO
ANALGESICS ANALGESICS DRUGS DRUGS
Number of patients 461 2,438 3,216 292
Mean BUN (+ SEM) 
mg/100 ml
19.3 + 0 . 7 19.5 + 0.4 23.4 + 0.4 18.8 + 0 . 9
Mean Age (+ SEM) Years 53.3 + 0 . 8 4 9 . 3 + 0 . 3 56.5 + 0.3 52.5 + 1.2
Proportion Female (%) 38.0 37.7 35.6 25.3
Proportion Died (%) 4.5 4.2 8.0 5.8
TABLE 6.5
RELATIONSHIP BETWEEN MEDICATION HISTORY AND 
URINE PROTEIN CONCENTRATIONS*
V
DAILY
URINE ANALGESICS
PROTEIN Number Per Cent
OCCASIONAL 
ANALGESICS 
Number Per Cent
OTHER 
DRUGS 
Number Per Cent
NO 
DRUGS 
Number Per Cent
0
1 - 2, + 
3 - 4, +
309
110
19
70.6
25.1
4.3
1574
637
106
67.9
27.5
4.6
1983
847
192
65.6
28.0
6.4
162
92
21
58.9
33.5
7.6
All 438 100.0 2317 100.0 3022 100.0 275 100.0
*as measured by Albustlx (Ames Company).
'TABLE 6.6
RELATIONSHIP BEH'JEEN MEDICATION HISTORY AND 
MICROSCOPIC FINDINGS IN THE URINE
DAILY OCCASIONAL OTHER NO
URINE ANALGESICS ANALGESICS DRUGS DRUGS
FINDINGS Number Per Cent Number Per Cent Number Per Cent Number Per Cent
T^lte cells 91 21.1 380 16.7 640 21.4 72 26.6
Red cells/casts 13 3.0 85 3.7 124 4.1 13 4.8
Other 328 75.9 1823 79.6 2231 74.5 186 68.6
All 432 100.0 2288 100.0 2995 100.0 271 100.0
TABLE 6.7
CHARACTERISTICS OF DAILY ANALGESIC CONSUMERS
DURATION OF CONSUMPTION (YEARS)
i
< 1 1 - 6 6 +
1
Number of Patients 259 100 102
Mean BUN (+ SEM) 18.9 + 0.9 19.3 + 1.6 20.2 + 1.6
(mg/100 ml)
Mean Age (+ SEM) 49.7 + 1.1 56.7 + 1.7 59.2 + 1.5
(years)
Proportion Female (%) 32.8 43.0 46.1
TABLE 6.8
RELATIONSHIP OF URINE PROTEIN CONCENTRATION* TO DURATION 
OF DAILY ANALGESIC CONSUMPTION
DURATION OF CONSUMPTION (years)
URINE
PROTEIN NUMBER
< 1
PER CENT
1 —
NUMBER
6
PER CENT
6 +
NUMBER PER CENT
0 178 71.5 67 71.3 64 67.4
1 - 2, + 59 23.7 24 25.5 27 28.4
3 - 4, + 12 4.8 3 3.2 4 4.2
All 249 100.0 94 100.0 95 100.0
*measured by Albustix (Ames Company)
TABLE 5.9
RELATIONSHIP BETWEEN MICROSCOPIC FINDINGS IN URINE 
AND DAILY ANALGESIC CONSUMPTION
DURATION OF CONSUMPTION (years)
URINE < 1 1 — 6 6 +
FINDINGS NUMBER PER CENT NUMBER PER CENT NUMBER PER CENT
White cells 40 16.2 19 21.1 32 33.7
Red cells/casts 7 2.8 4 4.4 2 2.1
Other 200 81.0 67 74.5 61 64.2
Total 247 100.0 90 100.0 95 100,0
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TABLE 6.11
CHARACTERISTICS OF OCCASIONAL ANALGESIC CONSUMERS
DURATION OF CONSUMPTION (years)
< 1 1 - 6 6 +
Number of patients 386 315 1,737
Mean BUN (±SEM) 
(mg/100 ml)
20.4 ± 1.0 20.2 ± 1.1 19.2 ± 0.5
Mean age (± SEM) 
(years)
43.9 ± 2.3 43.8 ± 2.5 51.5 ± 1.2
Proportion female (%) 41.1 41.9 36.1
TABLE 6.12
RELATIONSHIP OF URINE PROTEIN CONCENTRATION* TO DURATION 
OF OCCASIONAL ANALGESIC CONSUMPTION
DURATION OF CONSUMPTION (years)
URINE < 1 1 - 6 6
PROTEIN NUMBER PER CENT NUMBER PER CENT NUMBER PER CENT
0 250 67.9 211 69.6 1113 67.6
1 - 2, + 97 26.4 79 26.0 461 28.0
3 - 4, + 21 5.7 13 4.4 72 4.4
All 368 100.0 303 100.0 1646 100.0
*measured by Albustix (Ames Company)
TABLE 6.13
RELATIONSHIP BETWEEN MICROSCOPIC FINDINGS IN URINE
AND OCCASIONAL ANALGESIC CONSUl-lPTION
DURATION OF CONSUMPTION (years)
URINE
< 1 1 - 6 6 +
FINDINGS NUMBER PER CENT NUMBER PER CENT NUMBER PER CENT
White cells 54 14.8 39 12.9 287 17.7
Red cells/casts 13 3.6 14 4.6 58 3.6
Other 298 81.6 249 82.5 1276 78.7
Total 365 100.0 302 100,0 1621 100.0
TABLE 6.14
COMPARISON OF MEDICATION HISTORY IN THOSE WITH AND WITHOUT 
RECORDED BLOOD UREA NITROGEN (BUN) LEVELS
MEDICATION
HISTORY
BUN 
NOT RECORDED
Number Per Cent
BUN
RECORDED
Number Per Cent
Dally analgesics 22 6.6 461 6.9
Occasional analgesics 144 43.5 2438 36.5
Analgesics (unknown 
frequency)
12 3.6 279 4.2
Other drugs 139 42.1 3216 48.0
No drugs 14 4.2 292 4.4
All 331 100.0 6686 100.0
= 7.159 p > 0.14
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CASE REPORT 71
Patient: 57 year old male with Hodgkin’s disease and staphylococcal
meningitis following septicemia.
Comment : Patient admitted to Lemuel Shattuck Hospital, Boston, with
marked nuchal rigidity and profound shock, was shown to have 
staphylococcal septicemia and meningitis. Initially responded 
to therapy with penicillin G potassium 5 mega units four hourly 
intravenously. Two days after therapy commenced, he developed 
marked convulsions following an injection of penicillin. This 
responded to an injection of phenobarbitone followed by a 
five-day course of diphenylhydantoin. Dosage of penicillin 
was reduced to 2 mega units four hourly with good effect.
Initial BUN level on admission was 29 mg/100 ml. and this 
rose to 87 mg/100 ml on day of convulsions. At the time 
of reducing penicillin dosage serum potassium level was 
5.2 m Eq/litre.
CASE REPORT 711
Patient: 54. year old female with mild alcoholic cirrhosis admitted with
peritonitis.
Comment ; Prior to admission, this patient had passed several melaena
stools. On admission to Lemuel Shattuck Hospital, a diagnosis 
of peritonitis was made, the etiology of which was uncertain, 
but the presence of a colonic carcinoma was questioned.
Presenting hematocrit was 29% and BUN level was 34 mg/100 ml.
Patient was transfused 3 units of blood and penicillin G 
commenced in a dose of 5 mega units four hourly I.V. After 
an initial satisfactory response, she developed marked convulsions. 
These subsided following appropriate therapy. Dosage of penicillin G 
was reduced and patient recovered, BUN level on day of convulsions 
was 48 mg/100 ml, and serum creatinine level 2.9 mg/100 ml.
CASE REPORT 7itl
Patient: 87 year old female with pneumococcal pneumonia and congestive
cardiac failure.
Comment: This patient was admitted to Peter Bent Brigham Hospital in
marked congestive cardiac failure with a right lower lobe 
consolidation. Presenting hematocrit was 39%, BUN level 
was 48 mg/100 ml, and serum potassium was 4.0 m Eq/litre.
She was given two days of therapy with penicillin G potassium 
one mega unit six hourly, and thereafter changed to 
penicillin V potassium 250 mg six hourly. After six days 
of penicillin therapy, her serum potassium level had risen 
to 6.4 m Eq/L, while BUN level remained at 45-50 mg/100 ml.
Hyperkalemia was attributed to penicillin V by the attending 
physician.
CASE REPORT 7iv
Patient: 21 year old female with rheumatoid arthritis, nephrotic syndrome
and bacterial endocarditis.
Comment : Admitted to Peter Bent Brigham Hospital with the above diagnosis,
this patient was gravely ill on arrival with BUN level of 
70 mg/lOO ml., serum albumin of 2.1 G/lOO ml. and pancytopenia. 
She was given pencillin G potassium in a dose of 1 mega unit 
four hourly I.V. and oxacillin 1 G four hourly I.V. After 
seven doses of these drugs, she experienced marked convulsions 
which required paraldehyde and diphenylhydantoin to relieve 
them. Patient was then treated with cephalothin and subse­
quently recovered.
(Despite the clinical resemblance to disseminated lupus 
erythematosis no anti-nuclear factor or L.E. cells were 
demonstrated and the diagnosis could not be fully substantiated.)
CASE REPORT 7v
Patient: 52 year old female with staphylococcal septicemia following
aspiration pneumonia secondary to amphetamine overdose.
Comment : On admission to Lemuel Shattuck Hospital, this patient was
profoundly shocked and required emergency resuscitation. 
Following the diagnosis of staphylococcal septicemia, she 
was given oxacillin 2 G I.V. and ampicillin 2.5 G I.V. 
four hourly. After three days, patient sustained a severe 
convulsion which responded to appropriate therapy. Thereafter, 
the doses of antibiotics were reduced and she gradually 
recovered, BUN level on the day of the convulsions was 
20 mg/100 ml. Convulsion was attributed to oxacillin by 
attending physician.
Table 8.1
Frequencies of’administration of noted drugs to patients 
who did and did not develop a recorded rise in B.U.N. 
(irrespective of drug implicated in the observed rise).
No Rise in BUN Rise in BUN
Drug Numbers Per Cent* Numb ers Per Cent*
Neomycin 375 3.7 18 12.2
Kanamycin 174 1.7 17 11.6
Colistin 57 0.6 8 5.4
Polymixin B 34 0.3 4 2.7
Gentamycin 99 1.0 6 4.1
Cephalothin 426 4.2 16 10.9
Tetracycline 571 5.7 25 17.0
Frusemide 1,042 10.4 62 42.2
Triamterene 23 0.2 7 4.8
Ethacrynic Acid 219 2.2 14 9.5
Chlo ro thiazide 375 3.7 16 10.9
Hydro chloro thiaz ide • 644 6.4 34 23.1
Spironolactone 508 5.0 46 31.3
All Patients 10,062 98.6t 147 1.4t
* Percentage calculated on basis of total number of patients in that group 
t This percentage calculated on basis of 10,209 patients in series.
Table 8.2
Distribution of First Discharge Diagnosis 
by Treatment Group
DIAGNOSTIC CATEGORY GROUP T ■ GROUP A GROUP N
Cardiovas cular 95 (46. 6) 259 (43.5) 603 (52.1)
Respiratory 56 (27. 4) 126 (21.1) 79 ( 6.8)
Hepatic 13 ( 6.3) 28 ( 4.7) 115 ( 9.9)
Neoplastic 17 ( 8.3) 59 ( 9.9) 86 ( 7.4)
Others 23 (11.2) - 124 (20.8) 274 (23.7)
All categories 204 596 1157
Bracketed figures give percentages.
Group T " Tetracycline recipients
Group A - Recipients of other antibiotics
Group N - Recipients of other drugs
Table 8.3
Mean Admission BUN Level in Relation to Reported Rise in BUN 
(expressed in mg/100 ml blood)
Patients with Patients without
Group Rise in BUN* Rise in BUN*
T 34 + 4 27 + 2
A 41 + 5 32 + 1
N 3 1 + 3 26 + 1
*Results expressed as mean + standard error of mean.
Group T “ tetracycline recipients
Group A - other antibiotics recipients
Group N - recipients of other drugs
Table 8.4
Frequency of Recorded Rise In BUN among Recipients 
of Diuretics: In Relation to Admission BUN Levels
Admission BUN 
Level (mg/100 ml) Group T Group A Group N
< 25 8/112 (7.1) 5/333 (1.5) 20/790 (2.5)
> 25 12/92 (13,0) 16/263 (6.1) 19/367 (5.2)
All levels 20/204 (9.8) 21/596 (3.5) 39/1157 (3.4)
Group T - tetracycline recipients 
Group A -* recipients of other antibiotics 
Group N - recipients of other drugs
Bracketed figures give percentage of patients with recorded rise in BUN.
Figure 8.1
Frequency of Recorded Rise in BUN 
among Recipients of Diuretics
/o of Patients 
with rise in BUN  
15-1
10 -
5 -
0 0  Patients with admission 
B U N < 2 5 m g  100ml
^  Patients with admission 
BUN > 2 5m g  100ml
I I
Group NGroup T Group A
Group T -  Tetracycline recipients 
Group A -  Recipients of other Antibiotics 
Group N  -  Recipients of other Drugs
Table 8.5
Mean Recorded Rise in BUN in Relation to Treatment Received
Group Rise in BUN Range of Rise
(mg/100 ml) (mg/100 ml)
T 34 + 5 10 - 77
A 33 + 3 12 - 82
N 22 + 2 6 - 7 5
All Groups 2 8 + 3 6 - 7 7
Group T - tetracycline recipients
Group A - recipients of other antibiotics
Group N - recipients of other drugs
CASE REPORT 81
Patient: 70 year old male with congestive cardiac failure and
respiratory infection.
Comment: Admitted to Boston City Hospital suffering from an exacerbation
of congestive cardiac failure associated with mild bronchitis.
He was treated with hydrochlorothiazide, digoxin and tetracycline, 
After admission his BUN level was noted to rise from an initial 
level of 34 mg/100 ml to a maximum of 98 mg/100 ml. This rise 
was accompanied by a small rise in serum creatinine level 
(2.5 - 3.0 mg/100 ml).
On stopping tetracycline therapy, the BUN and creatinine levels 
returned to their admission values. The diuretic was implicated 
by the attending physician as a cause of the rise in BUN.
B.U.N. Level
mg/100ml(*..... •)
100 n
80
60  —
4 0 -
20-
  O  O'
Hydrochlorothiazide ^Omg/day 
Tetracycline 2 G /d a y
Serum Creatinine
m g /l0 0 m l( o — o)
r 5 -0
Transferred for 
Convalescence
8
I 4 0
-3*0
-20
- 1 0
012
Days in Hospital (Boston City Hospital)
Case 8 i i - 61 yrs with Hepatic Cirrhosis and Urinary Tract Infection
Frusemide 40 mg /day______________B.U.N. Level 
mg/100ml(*'”"*) 
lOOn Tetracycline IG /day r S O
Nalidixic Acid 4G/doy Ampicillin IG ^gy
-4 -08 0 -
- 3 0
4 0 - 2 0
20- - 1*0
70 90503 010
Days in Hospital (Lemuel Shattuck Hospital, Boston)
CASE REPORT 8ii
Patient: 61 year old female with alcoholic cirrhosis and urinary tract
infection.
Comment: Admitted to Massachusetts General Hospital suffering from her first
episode of hepatic failure. On recovery was transferred for 
convalescence to Leumuel Shattuck Hospital (L.S.H.), where she 
was noticed to have symptoms of a urinary tract infection, which 
was initially treated with nalidixic acid. During her first month 
of convalescence, baseline BUN levels fluctuated around 20 mg/100 ml 
and creatinine levels around 1,0 mg/100 ml.
On the twentieth day after admission to L.S.H., she was started 
on diuretic therapy (frusemide 40 mg. per day) which was 
continued for 56 days.
BUN and creatinine levels remained constant until tetracycline 
therapy was commenced for a recurrence of urinary tract symptom - 
atology, whereupon both these levels rose, the former to a maximum 
of 82 mg/100 ml and the latter to 3.6 mg/100 ml.
When tetracycline therapy ceased (but diuretic therapy continued), 
the BUN and creatinine levels gradually returned to approximately 
their admission levels. During this recovery phase, a course of 
ampicillin was given without a further rise in BUN occurring.
The rise in BUN was attributed to frusemide by the attending 
physician.
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Table 8.7
Frequency of recorded rise in BUN among recipients of nephrotoxic drugs 
given for treatment of infection: with stratification by diuretic therapy
No Diuretics Diuretics Total
Rise in BUN 16 (7.4%) 16 (14.5%) 32 (9.8%)
No rise in BUN 201 94 295
Total 217 110 327
FIGURE 9.1
NORMAL RAT KIDNEY - STAINED WITH HAEMATOXYLIN AND EOSIN
(x350)
FIGURE 9.2
RAT KIDNEY SHOWING FOCAL PROXIMAL TUBULAR NECROSIS 
STAINED WITH HAEMATOXYLIN AND EOSIN 
(x350)
d
FIGURE 9.3
RAT KIDNEY SHOWING EXTENSIVE PROXIMAL TUBULAR NECROSIS 
STAINED WITH HAEMATOXYLIN AND EOSIN 
(xl45)
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FIGURE 10.1
CALCULATED PHARMACOKINETIC DATA
so
0.693
1/2 =
■el
time from injection
where
tl/2
^SO
Do
= cephalorldine concentration in serum
= half-life of cephalorldine in serum (calculated from 
observed regression line)
= original cephalorldine concentration in serum at time = zero - 
extrapolated from observed regression line
= original dose administered
= volume of distribution of drug
^el ~ elimination rate constant /0.693\
1 tl/2/
FIGURE 10.2
NORMAL RABBIT KIDNEY STAINED WITH 
HAEMATOXYLIN AND EOSIN (x5G0)
9
i t
FIGURE 10.3
RABBIT KIDNEY STAINED WITH .HEMATOXYLIN AND EOSIN 
AND SHOWING GRANULAR AND CELLULAR CASTS IN COLLECTING TUBULES
(x 350)
%
FIGURE 10.4
RABBIT KIDNEY STAINED WITH HAEMATOXYLIN AND EOSIN 
AND SHOWING WIDESPREAD CALCIFIED DEBRIS IN TUBULAR LUMINA 
PARTICULARLY IN OUTER CORTICAL SEGMENT OF KIDNEY
( x l 4 5 )
FIGURE 10.5
RABBIT KIDNEY STAINED WITH HAEMATOXYLIN AND EOSIN 
SHOWING GREATER DETAIL OF LESION SEEN IN FIGURE 10.4
(x 350)
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TABLE 10.3
■COMPARISON OF OBSERVED AND CALCULATED VALUES FOR 
SERUM CONCENTRATION OF CEPHALORIDINE IN RABBIT 24
t
FIRST STUDY^
L t
SECOND STUDY^ 
Cg L
5 149 145 5 88 94
10 136 131 10 89 87
20 94 107 15 84 80
30 90 88 36 63 57
81 31 32 58 34 ' 39
118 16 15 130 15 12
128 10 12 174 4.5 6
194 5 3 249 2.3 2
245 3.5 1
^Correlation coefficient (Cg v L) = 0,995 
^Correlation coefficient (Cg v L) = 0.994
Cg - serum concentration of cephalorldine at time t (pg/ml) 
t = time after cephalorldine injection (minutes)
L - least squares estimate of cephalorldine concentration
TABLE 10.4
,COMPARISON OF OBSERVED AND CALCULATED VALUES FOR 
SERUM CONCENTRATION OF CEPHALORIDINE IN RABBIT 20
t
FIRST STUDY^ 
..S-S L t
SECOND STUDY^ 
Cs L
5 462 387 8 562 515
11 336 345 16 451 446
2.7 212 253 27 311 366
47 158 173 60 208 202
89 79 77 138 52 - 50
155 34 22 194 21 18
232 12 5 250 6 7
^Correlation coefficient (Cg v L) = 0,977 
^Correlation coefficient (Cg v L) = 0.991
Cg = serum concentration of cephalorldine at time t (pg/ml) 
t = time after cephalorldine injection (minutes)
L = least squares estimate of cephalorldine concentration
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FIGURE 11.1
EFFECT OF KANAMYCIN GIVEN BEFORE AND AFTER DIALYSIS
TO PATIENT A
Patient A —41 y r. old CT, weighing 58kg.
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FIGURE 11.2
EFFECT OF GOLISTIN GIVEN BEFORE AND AFTER DIALYSIS
TO PATIENT F
Patient F — 19yr. old ( f ,  weighing 60  kg.
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X =  150 mg colistin given before haemodiaiysis
0  =  150 mg colistin given after haemodiaiysis
1 denotes periods of haemodiaiysis
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FIGURE 11.3
EFFECT OF CARSENICILLIN GIVEN BEFORE AND AFTER DIALYSIS
TO PATIENT B
Patient B — 44yr. old Cf, weighing 65 kg.
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0 =  IG carb en icillin  given after haem odia iysis  
I i denotes p eriods of h aem odiaiysis
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FIGURE 11.4
EFFECT OF CLOXACILLIN GIVEN BEFORE AND AFTER DIALYSIS
TO PATIENT V
Patient D —19yr.old Ç , weighing 53kg.
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X =  IG  cloxacillin given before haemodiaiysis
0  =  IG  cloxacillin given after haemodiaiysis
1 I denotes periods of haemodiaiysis
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FIGURE 12.1 
‘DRUG METABOLISM IN RENAL FAILURE
I oral absorption
REf^AL C
yx ^  t metabolic inactivation by microsomal
/  ^  ^  enzymes (mainly lipid soluble drugs)
IMPAIRMENT
I renal excretion
(mainly water soluble drugs)
i protein binding
(especially acidic drugs)
t unbound (active) fraction
t pharmacologic effect t volume of distributioni metabolic inactivation
mini­
mises
^ ^1/2 plasma t toxic effects 4 - plasma levels 
(bound and unbound)
